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ABSTRACT 
 
 
Serum phosphate has recently emerged as a cardiovascular risk factor in several 
populations, including patients with chronic kidney disease.  Much of the adverse 
cardiovascular risk profile seen in chronic kidney disease can be attributed to 
structural heart disease, which appears to be driven by an increase in arterial 
stiffness.  There is strong evidence linking phosphate to vascular calcification, which 
in turn causes arterial stiffening.  In the following studies, phosphate is shown to be 
an independent predictor of renal function decline in patients with stage 2–4 chronic 
kidney disease.  In addition, phosphate is shown to be independently associated with 
left ventricular mass, a predictor of cardiovascular morbidity and mortality.  In the 
final study, the cardiovascular effects of reducing phosphate exposure with 
sevelamer carbonate, an oral, non-calcium-based phosphate binder, are assessed in 
a randomised, double blind, placebo-controlled trial of 120 patients with stage 3 
chronic kidney disease.  Although no demonstrable effects were seen on arterial 
stiffness, left ventricular mass, or left ventricular function, adherence to study 
medication was low given the high pill burden.  Testing of this hypothesis may 
therefore require introduction of a therapy that effectively lowers phosphate exposure 
through a more acceptable dosing regimen.
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1 BACKGROUND: CHRONIC KIDNEY DISEASE AND INCREASED 
ARTERIAL STIFFNESS 
 
1.1 The Kidneys 
 
The kidneys are two retroperitoneal organs that lie within the paravertebral gutters.  
Each kidney receives blood from the renal arteries, each a branch of the abdominal 
aorta, and drains blood into the renal vein, which is connected to the inferior vena 
cava.  The functional unit of the kidney is the nephron, which facilitates the key 
removal of waste products of metabolism from the body.  This is achieved through 
the filtration of blood at the glomerulus, followed by selective reabsorption of water 
and electrolytes in the proximal tubule and concentration of the filtrate in the loop of 
Henle and collecting duct, which finally results in the formation of urine.  Urine is 
excreted via the ureters, which drain into the urinary bladder.  In conjunction with 
removal of waste products, the kidney has several important homeostatic functions 
including the regulation of electrolyte and fluid balance, maintenance of acid-base 
balance, and regulation of blood pressure.  This is partially mediated through renal 
production of the hormone renin by the juxtaglomerular apparatus, which regulates 
salt and water retention via the renin-angiotensin-aldosterone system (RAAS).  The 
kidney also produces the hormone erythropoietin and activates vitamin D via 1-α-
hydroxylation of the relatively inactive 25-hydroxyvitamin D (calcidiol) to produce 
1,25-dihydroxyvitamin D (calcitriol). 
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1.2 Chronic Kidney Disease 
 
Chronic kidney disease (CKD) is common, affecting 13% of the population of the 
developed world (Coresh et al., 2007).  Over the last decade the prevalence has 
risen, reflecting an increase in the prevalence of diabetes and hypertension, the two 
biggest causes of end stage kidney disease (ESKD) in Western society (Coresh et 
al., 2007).  Other leading causes of ESKD are shown in Table 1-1.  Chronic kidney 
disease is categorised in five stages (Table 1-2) according to glomerular filtration rate 
(GFR) and markers of renal damage.  The degree of renal dysfunction can be 
estimated using the Cockcroft-Gault formula (Cockcroft and Gault, 1976), which 
approximates creatinine clearance from age, weight and serum creatinine, the 4-
variable Modification of Diet in Renal Disease (MDRD) equation (Levey et al., 1999), 
or the recently-introduced chronic kidney disease epidemiology collaboration (CKD-
EPI) formula (Levey et al., 2009), both of which determine estimated GFR (eGFR) 
from age, race, gender and serum creatinine.  Although the MDRD equation has 
been extensively adopted, it has been criticised for underestimating true GFR at 
near-normal levels of kidney function (Stevens et al., 2007).  The CKD-EPI formula 
has been proposed as a more accurate alternative method for estimating true GFR, 
particularly at GFR >60 ml/min/1.73m2.  Determination of GFR using radionuclear 
isotopes remains the gold-standard technique. 
 
Examination of epidemiological data indicates that the number of patients with early 
stage CKD greatly exceeds those with ESKD requiring renal replacement therapy in 
the form of dialysis or renal transplantation.  In 2003 the prevalence of ESKD in the 
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US was only 0.2% compared to a prevalence of 10.8% for CKD stages 1–4 (Coresh 
et al., 2003). 
 
Cause Percentage 
Diabetes mellitus 43.8 
Hypertension 28.1 
Glomerulonephritis 6.5 
Cystic kidney disease 2.3 
Other urologic causes 1.4 
Other causes 12.7 
Unknown 5.2 
 
Table 1-1.  Causes of end stage kidney disease. 
Data are percentages.  2009 data taken from the US Renal Data System 2011 Annual Data Report: 
Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National 
Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda. 
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Stage Description GFR (ml/min/1.73m2) 
1 Kidney damage* with normal or increased GFR ≥90 
2 Kidney damage* with mildly decreased GFR 60–89 
3 Moderately decreased GFR 30–59 
4 Severely decreased GFR 15–29 
5 Kidney failure <15 or dialysis 
 
Table 1-2.  Stages of chronic kidney disease. 
*Evidence of functional or structural kidney abnormalities for ≥3 months. 
GFR, glomerular filtration rate. 
 
1.3 Chronic Kidney Disease and Cardiovascular Risk 
 
The epidemiological association between cardiovascular disease and CKD is well 
established, with several observational studies demonstrating an increased risk of 
cardiovascular disease in patients with CKD (Di Angelantonio et al., 2010; Go et al., 
2004; Kurth et al., 2009; McCullough et al., 2007; Van Biesen et al., 2007).  In a 
study of over 1.1 million adults in the United States who had serum creatinine 
measured between 1996 and 2000, there was an independent graded inverse 
association between the risk of death or cardiovascular disease and eGFR at levels 
of eGFR below 60 ml/min/1.73m2 (Go et al., 2004).  Similarly, in a pooled analysis of 
four community-based longitudinal studies that comprised 22634 patients, CKD 
(defined as GFR between 15 and 60 ml/min/1.73m2) was an independent risk factor 
for the composite outcome of myocardial infarction (MI), fatal coronary heart disease, 
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stroke and death (Weiner et al., 2004).  A recent meta-analysis of over 105,000 
patients from 14 studies indicated an increased risk of all-cause and cardiovascular 
mortality with eGFRs below 60 ml/min/1.73m2 (Matsushita et al., 2010); the hazard 
ratios increased with decreasing eGFR.  The level of eGFR at which the risk of 
mortality from cardiovascular disease begins to rise is unknown.  A longitudinal study 
of 8913 randomly selected, apparently healthy subjects followed up over a 10-year 
period suggested that increased cardiovascular mortality occurs even earlier at 
eGFR levels of <90 ml/min/1.73m2 independent of other risk factors; this is a level of 
renal function that is commonly regarded as being near-normal (Van Biesen et al., 
2007).  It is evident that patients with early stage CKD are far more likely to die from 
cardiovascular disease than progress to ESKD requiring dialysis or transplantation 
(Go et al., 2004; Keith et al., 2004).  Whilst patients with ESKD have a cardiovascular 
risk of between 10 and 100 times that of healthy controls, they represent only 0.2% of 
the general population; the burden of cardiovascular disease caused by early stage 
CKD, which represents over 10% of the population, is therefore much greater in 
public health terms. 
 
The pathophysiological mechanisms that underlie the increased risk of 
cardiovascular disease in CKD are not fully understood.  The increased 
cardiovascular risk cannot be explained by “traditional” risk factors alone, many of 
which (including cholesterol and obesity) are inversely associated with survival in 
CKD.  This phenomenon, which has been described as “reverse causality”, “reverse 
epidemiology” and “confounding by disease”, may reflect survival bias amongst the 
subset of CKD patients that reach ESKD (Baigent and Landray, 2007; Kalantar-
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Zadeh et al., 2003).  Although approximately 50% of all ESKD deaths are due to 
cardiovascular disease, data from the United States Renal Data System (USRDS) 
indicates only 13% of these are attributable to vasculo-occlusive atherosclerotic 
coronary disease (MI), with the majority being attributed to sudden cardiac death 
(SCD), arrhythmia and congestive heart failure (CHF) (Ganesh et al., 2001; U.S. 
Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney 
Disease and End-Stage Renal Disease in the United States", 2011).  Heart failure is 
a major cause of morbidity and mortality in CKD with incident rates 3–4 times higher 
than in non-CKD subjects (Foley et al., 2005; U.S. Renal Data System, USRDS 2011 
Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease 
in the United States", 2011).  Thus, it appears that structural heart disease, leading to 
CHF and SCD, rather than occlusive arterial disease, is the leading cause of 
cardiovascular mortality in CKD. 
 
Left ventricular systolic dysfunction affects 15% of incident dialysis patients and is an 
independent predictor of death in this population (Foley et al., 1995).  Our research 
group has previously demonstrated the presence of subclinical LV systolic 
dysfunction in early CKD.  In a study comparing 40 normotensive stage 2 and 3 non-
diabetic CKD patients free from cardiovascular disease with 30 healthy controls with 
normal kidney function, LV peak systolic longitudinal strain and strain rate (indicators 
of longitudinal tissue deformation and hence LV systolic function) measured using 
echocardiography were reduced in the CKD patients despite the presence of 
apparently “normal” LV function when assessed using conventional 
echocardiographic criteria such as LV ejection fraction and tissue Doppler imaging 
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(Edwards et al., 2008b).  Abnormalities in these subclinical markers of systolic 
dysfunction have been associated with adverse cardiovascular outcomes in late 
stage CKD (Rakhit et al., 2007). 
 
In contrast to LV systolic dysfunction, abnormalities in LV structure are evident in 
almost all patients commencing dialysis.  In a prospective study of 433 incident 
haemodialysis patients in whom echocardiography was performed at the time of 
initiation of dialysis, 74% had established LV hypertrophy (LVH) (Foley et al., 1995).  
Abnormalities in LV structure and diastolic function have also been demonstrated in 
subjects with early stage CKD.  In a cross-sectional observational study comparing 
echocardiographic findings of 117 normotensive patients with stage 2 and 3 non-
diabetic CKD to 40 healthy control subjects, patients with CKD had delayed 
ventricular relaxation and increased LV end diastolic stiffness and pressure 
(evidenced by elevated left atrial volumes) compared to controls (Edwards et al., 
2008a).  Furthermore, ventricular-arterial coupling was preserved, with an increase in 
arterial stiffness being demonstrated alongside the increase in LV stiffness.  In an 
echocardiographic study of 603 patients post-MI, the presence of renal impairment 
was associated with increased LV mass and larger LA volumes, indicative of 
underlying diastolic dysfunction (Verma et al., 2007).  It is therefore apparent that 
structural and functional heart disease occurs early in the course of CKD and may be 
an important driver of the adverse cardiovascular outcome observed in this 
population.  It is well established that the presence of LVH is associated with adverse 
cardiovascular outcomes in CKD (Boner et al., 2005; Weiner et al., 2005).  There is 
increasing evidence, however, that no such biological dichotomy exists, and that LV 
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mass analysed as a continuous variable has a graded relationship with 
cardiovascular risk (Schillaci et al., 2000).  These findings suggest that any therapies 
that are effective in slowing or preventing the development of heart disease should 
be initiated during the early stages of CKD, long before LVH has developed.  
Furthermore, such therapies may provide useful insights into understanding the 
pathophysiological mechanisms that promote the development of increased LV 
mass. 
 
Over the last decade evidence has emerged suggesting that the development of 
structural heart disease in CKD is driven by an underlying increase in arterial 
stiffness.  This is mediated by the process of arteriosclerosis, a disease of the arterial 
medial layer that is characterized by increased collagen content, medial calcification 
and hyperplasia and hypertrophy of vascular smooth muscle cells (VSMC) that 
culminates in arterial wall hypertrophy and increased arterial stiffening.  This differs 
from atherosclerosis, which is a disease of the arterial intima characterised by 
calcified fibro-atheromatous plaque formation and vascular occlusion (Schwarz et al., 
2000).  Although associations have been established between the degree of arterial 
stiffness and atheromatous plaque burden (van Popele et al., 2001), recent studies 
have failed to demonstrate a significant influence of traditional atherosclerotic risk 
factors on the development of arteriosclerosis (Cecelja and Chowienczyk, 2009), 
suggesting that alternative pathologies are driving this process.  Whilst endothelial 
dysfunction and intimal disease are known to contribute to arterial stiffening (Moody 
et al., 2012), the relationship between arteriosclerosis and atheromatous disease 
remains poorly understood; this is compounded by the fact that both pathological 
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processes are often present in any one individual.  Arterial stiffness is increased in 
the early stages of CKD when kidney function is only mildly impaired (Edwards et al., 
2008a; Wang et al., 2005), and cross-sectional studies have demonstrated 
increasing arterial stiffness at each advancing stage of CKD (Wang et al., 2005). 
 
1.4 The Clinical Importance of Increased Arterial Stiffness 
 
A major function of the aorta and large arteries is to buffer oscillatory changes in 
blood pressure (BP) that result from intermittent ventricular ejection.  The healthy 
elastic aorta acts as a reservoir throughout the cardiac cycle, expanding in systole to 
accommodate blood ejected by the left ventricle and recoiling in diastole to maintain 
diastolic pressure and facilitate coronary perfusion, which predominantly occurs in 
diastole.  This highly distensible system dampens the aortic pressure waveform and 
ensures that most organs and tissues receive near steady flow with no exposure to 
peak systolic pressures; this mechanism is so efficient that there is almost no drop in 
mean arterial pressure from the ascending aorta to the peripheral arteries (Avolio et 
al., 2009).  Loss of arterial distensibility results in a more rigid aorta that is less able 
to buffer the pulsatile ejection of the left ventricle, resulting in greater pressure 
augmentation in systole, higher pulse pressures and greater shear stress (Davies et 
al., 2008).  An often cited explanation for the elevated systolic pressure that 
accompanies an increase in arterial stiffness (Franklin et al., 1997) is the more rapid 
return of reflected waves of ventricular contraction from the distal vasculature.  
According to this hypothesis, in young, healthy, compliant arteries, reflected waves 
return to the ascending aorta in diastole, thus augmenting diastolic pressure and 
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coronary blood flow, whilst in aged stiffer arteries the reflected waves return earlier in 
systole, augmenting systolic and pulse pressures and increasing ventricular 
afterload.  Although an attractive concept, there is now abundant evidence, recently 
published as a meta-analysis, showing that reflected waves arrive in systole 
irrespective of age (Baksi et al., 2009).  These data, together with information 
available from techniques that separate reflected waves from reservoir pressure, 
strongly suggest that the “cushioning effect” or Windkessel model appears to be the 
more important physiological explanation (Wang et al., 2003).  Regardless of the 
underlying mechanism, as arterial stiffness increases, the myocardium, brain and 
kidneys are exposed to higher systolic pressures and greater pressure fluctuations 
resulting in myocardial hypertrophy and fibrosis, cerebral and renal microvascular 
damage and an increased risk of stroke and development or progression of renal 
impairment (Figure 1-1) (O'Rourke and Safar, 2005).  Furthermore, lower diastolic 
pressure reduces diastolic coronary perfusion and promotes subendocardial 
ischaemia and ventricular stiffening (London et al., 1996); it also places greater 
reliance on systolic coronary perfusion, conferring heightened vulnerability of the 
myocardium to any decline in systolic function (Saeki et al., 1995). 
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Figure 1-1.  Consequences of increased arterial stiffness. 
 
Cardiac function is physiologically matched with arterial function through ventricular-
arterial coupling to ensure maximum cardiac work and efficiency (Chen et al., 1998).  
As arterial stiffness increases, the left ventricle generates greater end-systolic 
pressures that enhance ventricular systolic wall stress and increase ventricular 
stiffness.  These compensatory adaptations maintain cardiac performance with 
enhanced contractility at rest, but at a price: cardiac reserve is reduced, diastolic 
function is impaired and the cardiovascular response to alterations in pressure and 
volume load is blunted leading to haemodynamic instability (Chen et al., 1998).  
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Myocardial oxygen consumption also increases, promoting subendocardial 
ischaemia (Watanabe et al., 1993).  Increased ventricular stiffening further impairs 
diastolic coronary perfusion through increased compression of the coronary 
microvasculature (Davies et al., 2006).  Whilst this is a common feature of advanced 
disease characterised by LVH, it is often present despite normal ventricular wall 
thickness (Chen et al., 1998).  Reduced proximal aortic distensibility is closely linked 
to indices of LV stiffness in CKD (Edwards et al., 2008a) and also correlates with 
reduced exercise capacity despite normal or enhanced LV systolic function (Hundley 
et al., 2001).  It has been suggested that increased arterial stiffness arising from early 
CKD may underlie many cases of heart failure with normal ejection fraction, 
otherwise known as diastolic heart failure (Edwards et al., 2008a).  Impaired renal 
function is a common finding in patients with diastolic heart failure (Rusinaru et al., 
2011), and it is possible that diastolic dysfunction may represent a cardiac 
manifestation of underlying CKD. 
 
Increased arterial stiffness, systolic pressure and pulse pressure are characteristic 
features of ageing in Western populations (Franklin et al., 2001) and are independent 
risk factors for mortality and development of CHF (Haider et al., 2003).  Increased 
arterial stiffness has been proven to be a powerful independent predictor of all-cause 
mortality and cardiovascular events in patients with ESKD (Blacher et al., 1999), 
hypertension (Boutouyrie et al., 2002; Laurent et al., 2001) and diabetes mellitus 
(Cruickshank et al., 2002) as well as in older adults (Meaume et al., 2001; Sutton-
Tyrrell et al., 2005) and the general population (Mattace-Raso et al., 2006; Willum-
Hansen et al., 2006).  A recent meta-analysis of 17 longitudinal studies that 
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measured aortic pulse wave velocity (PWV), an index of arterial stiffness, in 15877 
individuals from a variety of population groups demonstrated an adjusted increase in 
total cardiovascular events, cardiovascular mortality and all-cause mortality of 14%, 
15% and 15% for every 1 m/s increase in PWV respectively (Vlachopoulos et al., 
2010). 
 
1.5 Mechanisms of Arterial Stiffness in Chronic Kidney Disease 
 
1.5.1 Increasing Arterial Stiffness with Age 
The biomechanical properties of the arteries are largely dependent on the relative 
quantities of collagen and elastin, the main scaffolding proteins of the extracellular 
matrix (ECM).  Numerous studies have shown that the large arteries stiffen with age 
with overproduction of abnormal collagen fibres and relative loss of elastin from the 
ECM (Greenwald, 2007).  The elastin lamellae become sparser with signs of 
fragmentation and calcification, while collagen molecules progressively acquire 
cross-links.  A major unresolved question is whether these changes are truly time-
dependent or reflect cumulative exposure to the risk factors described below.  
Similarly, the possible effect of the age-related decline in GFR on arterial stiffness 
remains unknown.  Studies of populations living hunter-gatherer or subsistence 
farming lifestyles, such as the Bushmen of the Kalahari desert in Southern Africa, 
have shown such individuals to have low systolic blood pressures that do not rise 
with age (Kaminer and Lutz, 1960).  When members of such populations migrate to 
urban areas and adopt industrialised lifestyles together with Western diets, their 
systolic BP and pulse pressure begin to rise with ageing, suggesting exposure to 
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environmental factors may be more important than ageing itself (Cooper et al., 1997; 
He et al., 1991; Poulter et al., 1990). 
 
1.5.2 Alterations in the Extracellular Matrix 
Evidence of altered ECM structure in CKD comes from studies of subtotally 
nephrectomised rats in which aortic wall thickness was significantly greater than in 
controls (Amann et al., 1997).  Extracellular matrix volume was increased, elastic 
fibres were smaller and collagen “islands” were evident.  Vascular smooth muscle 
cells were larger and greater in number with ultrastructural changes suggesting 
increased secretory activity.  No studies have yet examined changes in arterial 
microstructure in human CKD, but the coronary arteries of CKD patients show 
increased medial thickness and lower luminal area than those of non-CKD controls 
(Schwarz et al., 2000). 
 
The mechanisms underlying these ECM changes in CKD are currently undetermined 
but matrix metalloproteinases (MMP) have been implicated.  These endopeptidase 
enzymes regulate the ECM and are produced by vascular and inflammatory cells.  
Increased MMP production enhances collagen and elastin turnover through 
enzymatic cross-link degradation (Jacob, 2003), causing unravelling and weakening 
of the ECM.  There are data supporting this mechanism in hypertensive patients 
(Yasmin et al., 2005) but also accumulating evidence of a role for MMP in the 
development of arterial stiffness in CKD, including the presence of increased 
vascular MMP activity in ESKD patients compared to healthy controls (Chung et al., 
2009), suggesting a possible area for future therapeutic intervention. 
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1.5.3 The Role of Advanced Glycation End Products 
Irreversible covalent cross-linking of collagen and elastin with carbohydrates or 
carbonyl compounds through non-enzymatic glycation results in the formation of 
advanced glycation end products (AGE) (Reiser et al., 1992).  Such post-synthetic 
glycation occurs in abundance in impaired glucose tolerance and diabetes mellitus 
and to a lesser extent with ageing, although it is unclear whether or not this is 
inevitable or a consequence of exposure to factors such as oxidative stress and 
inflammation (Konova et al., 2004).  Affected collagen is stiffer and less susceptible 
to slow hydrolytic degradation; glycation may also influence arterial stiffening through 
generation of reactive oxidant species and nitric oxide deactivation, promoting 
endothelial dysfunction (Bucala et al., 1991).  Hypertensives and older patients 
treated with AGE cross-link breakers demonstrate significant reductions in arterial 
stiffness and endothelial dysfunction (Kass et al., 2001; Zieman et al., 2007). 
 
Levels of circulating AGE correlate directly with serum creatinine in diabetic and non-
diabetic CKD (Makita et al., 1991; Schwedler et al., 2002).  Advanced glycation end 
products accumulate in ESKD as demonstrated by skin autofluorescence and are 
independently associated with increased arterial stiffness (Ueno et al., 2008) and 
mortality.  A weak association between skin autofluorescence and arterial stiffness, 
measured through determination of aortic PWV, has also been demonstrated in over 
1700 stage 3 CKD patients, although following adjustment for age, gender, 
haemoglobin and renal function, this relationship only persisted in diabetic patients 
(McIntyre et al., 2011).  Although there is some suggestion that AGE are implicated 
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in the development of arterial stiffness in CKD, this finding is not universal 
(Schwedler et al., 2002).  Further studies are required to determine whether dietary 
AGE restriction or the use of AGE cross-link breakers might be an effective method 
of reducing arterial stiffness in CKD. 
 
1.5.4 Endothelial Dysfunction 
Endothelial dysfunction, characterised by impaired endothelium-dependent 
vasodilator activity or enhanced endothelium-dependent vasoconstriction, is strongly 
associated with increased arterial stiffness in healthy individuals (McEniery et al., 
2006).  Numerous studies have confirmed the presence of endothelial dysfunction in 
ESKD (Luksha et al., 2011; van Guldener et al., 1998; van Guldener et al., 1997).  
Abnormal endothelial function has also been demonstrated in patients with non-
diabetic CKD (eGFR range 14–54 ml/min/1.73m2) compared to healthy controls 
(Thambyrajah et al., 2000), and has been implicated as a contributor to the increased 
cardiovascular risk in this population (Stam et al., 2006; Yilmaz et al., 2011).  
Although this may reflect relatively high levels of systemic inflammation, oxidative 
stress and the high prevalence of risk factors such as hypertension, reduced renal 
clearance of uraemic toxins such as asymmetrical dimethylarginine (ADMA), a 
product of protein turnover, may also contribute (Vallance et al., 1992).  
Asymmetrical dimethylarginine, together with its structural isomer symmetrical 
dimethylarginine, inhibits nitric oxide synthesis dose-dependently in vitro and 
increases basal vascular tone and BP in humans (Bode-Boger et al., 2006; Vallance 
et al., 1992).  High plasma ADMA concentrations are associated with, and predict 
progression of, increased carotid intima-media thickness (Zoccali et al., 2002a) and 
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are also linked to LVH (Zoccali et al., 2002b) in ESKD patients.  A recent study has 
also demonstrated the potential role of low vitamin D status as a contributor to 
endothelial dysfunction in older adults (Jablonski et al., 2011).  This is no doubt that 
any direct underlying relationship between CKD and endothelial dysfunction is 
potentially confounded by the presence of co-morbidities such as diabetes mellitus 
and hypertension, which themselves promote abnormal endothelial function; the 
study of kidney donors before and after uninephrectomy provides a unique 
opportunity to assess the effect of an acute drop in eGFR on endothelial function in 
the absence of these confounders (Moody et al., 2012). 
 
Endothelin peptides are synthesised by endothelial cells and are powerful 
vasoconstrictors acting on VSMC.  They are implicated in the pathogenesis of 
several cardiovascular conditions and the progression of CKD (Dhaun et al., 2006).  
Infusion of endothelin-1 in healthy humans to increase plasma levels to those seen in 
ESKD is associated with significant increases in PWV, central systolic pressure and 
pulse pressure (Vuurmans et al., 2003).  Short-term endothelin-A receptor 
antagonism in non-diabetic CKD was associated with reductions in proteinuria and 
arterial stiffness that appeared to be independent of BP-lowering (Dhaun et al., 
2009).  Their long-term effects on cardiovascular risk reduction in CKD are yet to be 
determined, but there is emerging evidence that endothelin receptor antagonists may 
be of value in treating resistant hypertension, perhaps by direct effects on arterial 
stiffness (Weber et al., 2009). 
 
 18 
Although it is accepted that endothelial dysfunction promotes arterial stiffening, a 
study of cultured endothelial cells in vitro suggests that stiff arteries themselves 
further reduce nitric oxide bioavailability through diminished expression of endothelial 
nitric oxide synthase (Peng et al., 2003); arterial stiffness may therefore be self-
perpetuating.  Novel agents such as ghrelin appear to improve endothelial 
dysfunction (Tesauro et al., 2009) and offer potentially promising avenues for further 
investigation in CKD. 
 
1.5.5 Chronic Inflammation 
Although commonly regarded as a risk factor for atheroma, a clear association 
between inflammation and arterial stiffness exists, as demonstrated by studies of 
conditions characterised by chronic systemic inflammation (Cachofeiro et al., 2008; 
Maki-Petaja et al., 2006) and by studies of inflammatory markers and arterial 
stiffness in the healthy population (Yasmin et al., 2004).  More specifically, aortic 
inflammation, as assessed using positron emission tomography imaging, has 
recently been shown to influence arterial stiffness (Joly et al., 2009).  The long-term 
use of immunosuppressive agents in inflammatory disorders is associated with a 
reduction in surrogate markers of cardiovascular risk (Choi et al., 2002) and such 
agents require further cautious investigation. 
 
Systemic inflammation and oxidative stress promote endothelial dysfunction by 
decreasing nitric oxide availability through reductions in nitric oxide synthase activity 
and an increase in production of peroxynitrite, a cytotoxic oxidant that leads to 
oxidation of low density lipoprotein and uncoupling of endothelial nitric oxide 
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synthase (Koppenol et al., 1992).  Pro-inflammatory cytokines also damage 
endothelial cells by increasing the release of acid sphingomyelinase, which 
depresses endothelial cell signalling and function.  Low glutathione levels further 
increase activation of  sphingomyelinase (Liu and Hannun, 1997).  Replenishment of 
glutathione using N-acetylcysteine, a cheap and well-tolerated food supplement, has 
been shown to improve endothelial function and cardiovascular outcomes in two 
small studies of patients with ESKD (Tepel et al., 2003; Wittstock et al., 2009), and 
further assessment of its potential in reducing arterial stiffness is warranted.  
Inflammatory degradation of ECM elastin has been shown to accelerate arterial 
calcification in animal CKD models (Aikawa et al., 2009), prompting potential 
exploration of the role of immunosuppression and selective inhibition of elastase 
enzymes as therapeutic interventions in arterial stiffness reduction. 
 
1.5.6 The Renin-Angiotensin-Aldosterone System 
Angiotensin II is a powerful vasoconstrictor but also promotes inflammation by 
stimulating VSMC to generate intracellular superoxides and inflammatory cytokines 
(Kranzhofer et al., 1999); furthermore, in vitro experiments demonstrate induction of 
vascular remodelling through VSMC hypertrophy and proliferation, increased 
collagen synthesis and increased production of MMP (Takagishi et al., 1995).  This 
ECM remodelling can be controlled by angiotensin converting enzyme inhibitors 
(ACEI) (Ahimastos et al., 2005).  Interestingly, ACEI and angiotensin II receptor 
blockers (ARB) also inhibit AGE formation in vitro dose-dependently, possibly by 
reducing generation of reactive oxygen species and reactive carbonyl compounds 
(Miyata et al., 2002).  In a rat model of cystic renal disease, which was associated 
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with increased aortic stiffness and aortic calcification when compared to control 
animals, treatment with the ACEI perindopril was associated with reduced arterial 
stiffening and calcification of the elastic media (Ng et al., 2011). 
 
Short- and long-term inhibition of the RAAS with ACEI and ARB is associated with 
reductions in arterial stiffness but is almost invariably accompanied by BP reduction 
(Ahimastos et al., 2005; Mitchell et al., 2007).  The relative importance of BP-
lowering is difficult to distinguish from the direct tissue effects outlined above.  In a 
longitudinal study of haemodialysis patients treated with ACEI, BP-lowering 
combined with decreased arterial stiffness was associated with reduced all-cause 
and cardiovascular mortality (Guerin et al., 2001).  Such mortality benefits were 
absent in subjects with unaltered arterial stiffness despite BP reduction, lending 
some support to the theory that RAAS inhibition reduces risk through a BP-
independent mechanism in ESKD. 
 
Aldosterone levels, which frequently remain elevated despite treatment with ACEI 
and ARB, are correlated with arterial stiffness in hypertensive men independently of 
BP (Blacher et al., 1997).  Aldosterone increases arterial stiffness independently of 
wall stress in subtotally nephrectomised rats given high-salt diets (Lacolley et al., 
2002) and these effects are inhibited by the mineralocorticoid receptor (MR) 
antagonist eplerenone.  Such MR activation is associated with endothelial 
dysfunction and activation of VSMC genes involved in vascular fibrosis, inflammation 
and calcification (Brown, 2008).  Aldosterone reduces endothelial nitric oxide by 
increasing nicotinamide adenine dinucleotide phosphate oxidase activity and 
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promoting formation of reactive oxygen species (Struthers and MacDonald, 2004).  
Additionally, aldosterone upregulates expression and sensitivity of vascular 
angiotensin receptors in rats (Ullian et al., 1992).  The MR antagonist spironolactone 
inhibits angiotensin II-mediated VSMC proliferation in vitro, reduces aortic and 
myocardial collagen accumulation (Lacolley et al., 2001) and reduces oxidative 
stress and endothelial dysfunction (Virdis et al., 2002).  In subtotally nephrectomised 
rats, spironolactone reduces proteinuria, arterial pressure and cardiac hypertrophy 
(Greene et al., 1996).  Another MR antagonist, eplerenone, was shown to improve 
endothelial function and reduce formation of reactive oxygen species in an animal 
model of diet-induced atherosclerosis (Rajagopalan et al., 2002).  These studies 
highlight the importance of aldosterone in the development of cardiovascular and 
renal injury in animal models of CKD. 
 
There are limited data demonstrating the influence of RAAS on arterial stiffness in 
human CKD.  A pilot study of 25 stage 2 and 3 CKD patients demonstrated that ARB 
treatment improved small artery compliance (Garg et al., 2005).  A recent study 
comparing monotherapy with either enalapril or candesartan against combined 
therapy with both enalapril and candesartan in patients with stage 3–4 CKD 
demonstrated additive reductions in BP with combined therapy, as well as significant 
reductions in arterial stiffness measured using PWV and augmentation index (AIx) 
(Frimodt-Moller et al., 2012).  The direct renin inhibitor aliskiren was shown to reduce 
ankle-brachial PWV over 12 weeks in a small cohort of Japanese patients, although 
this study did not include a control group (Kanaoka et al., 2012).  In a randomised 
placebo-controlled trial, the addition of spironolactone to ACEI or ARB therapy in 
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patients with stage 2 and 3 CKD significantly reduced arterial stiffness and LV mass, 
supporting the hypothesis that aldosterone is a major mediator of arterial stiffness 
and LVH in CKD (Edwards et al., 2009).  There was, however, a significant reduction 
in BP such that a BP-lowering effect on arterial stiffness could not be excluded.  
Follow-up studies of this patient group have also demonstrated improvements in 
echocardiographic parameters of systolic and diastolic function amongst those taking 
spironolactone (Edwards et al., 2010).  Larger studies are required to determine 
whether such treatment is associated with improved clinical outcomes. 
 
A meta-analysis of RAAS blockade with either ACEI or ARB in CKD revealed a 
significant reduction in cardiovascular outcomes and incidence of heart failure when 
compared to placebo, although no reduction in cardiovascular or all-cause mortality 
was noted (Balamuthusamy et al., 2008).  The mechanism by which this 
improvement in cardiovascular outcome arises is undetermined, but an assessment 
of arterial stiffness parameters in such patients may prove to be highly informative. 
 
1.5.7 Diet 
Observational studies highlight the importance of environmental factors such as high-
salt diets in the development of hypertension and arterial stiffness (Safar et al., 
2000).  Dietary sodium enhances age-related vascular changes by promoting VSMC 
hypertrophy and increased VSMC tone; it also increases collagen cross-linking and 
facilitates aldosterone-induced oxidative stress and inflammation (Safar et al., 2000).  
In the presence of aldosterone, small increases in plasma sodium concentration 
decrease nitric oxide release and increase endothelial cell stiffness in vitro 
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(Oberleithner et al., 2007).  Restricting dietary sodium in hypertensive patients 
effectively reduces arterial stiffness (Gates et al., 2004).  The Western diet is 
relatively rich in dietary oxidants, AGE and bioavailable phosphate (Ferro et al., 
2009).  These substances undergo renal metabolism or excretion and therefore 
accumulate in CKD.  The influence of dietary factors such as sodium, phosphate and 
pro-oxidant compounds on arterial structure and function in subjects with and without 
CKD is remarkably poorly understood and is a fertile area for future research. 
 
1.5.8 Vascular Calcification 
Vascular calcification is highly prevalent in CKD and ESKD and is closely linked with 
increased arterial stiffness.  Chronic kidney disease is characterised by deranged 
handling of phosphate and calcium, and phosphate has been identified as a key 
mediator of soft tissue calcification.  Before the mechanisms by which phosphate 
promotes vascular calcification are examined in detail, an overview of normal 
phosphate regulation and development of abnormal phosphate handling in CKD is 
given. 
 
1.6 Normal Phosphate Regulation 
 
Phosphorus has an essential role in many cellular functions, such as signal 
transduction and energy exchange, and helps to regulate enzyme and receptor 
activities.  It is also an important structural component of deoxyribonucleic acid 
(DNA) and cell membranes.  Most organic phosphorus is in the form of phosphate 
(PO4); over 80% of total body phosphorus is stored in bones and teeth as 
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hydroxyapatite (Ca10(PO4)6(OH)2), with the remainder being found in the intracellular 
compartment and in serum as phosphate anions (H2PO4– and HPO42–) (Tonelli et al., 
2010; Uribarri, 2007).  Serum phosphate represents <1% of total body phosphorus 
and is largely non-protein-bound; the normal laboratory range (0.8 mmol/l–1.8 
mmol/l) reflects inorganic phosphate content (Uribarri, 2007).  Although serum 
phosphate represents a small proportion of total body phosphorus, derangements in 
serum phosphate level can indicate the presence of significant underlying 
abnormalities in phosphate homeostasis.  Serum phosphate levels display a 
circadian rhythm, with the lowest levels (typically 1.1 ± 0.1 mmol/l) occurring late 
morning and the peak (1.5 ± 0.1 mmol/l) occurring shortly after midnight (Portale et 
al., 1987).  In health, phosphate levels are closely regulated and maintained within a 
normal physiological range through adjustments in gastrointestinal absorption, renal 
excretion and resorption or formation of bone (Hruska et al., 2008), with the skeleton 
acting as a phosphate reservoir.  Approximately 1000–1500 mg of phosphate is 
consumed in the Western diet per day (Tonelli et al., 2010).  Three-quarters of this is 
absorbed from the gastrointestinal tract along the entire length of the small intestine 
and the remainder is excreted in the faeces.  Despite a wide variation in the dietary 
intake of phosphate, total body phosphate levels are maintained within the 
physiological range by hormonal regulation.  Gastrointestinal phosphate absorption is 
both passive and active, involving paracellular diffusion along an electrochemical 
gradient or active transport via the sodium-phosphate co-transporter type 2b (NPT-
2b) located on enterocytes of the small intestine (Feild et al., 1999).  Active 
absorption of phosphate from the gastrointestinal tract via this co-transporter is 
stimulated by 1,25-dihydroxyvitamin D (Ramirez et al., 1986).  An estimated 300 mg 
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of phosphate undergoes resorption from bone into the blood pool each day, with an 
equal amount being deposited back into bone to maintain equilibrium.  The kidney is 
an important regulator of phosphate homeostasis, enabling removal of any excess 
phosphate in the urine.  Most phosphate in serum is filtered at the glomerulus, but 
approximately 85% is reabsorbed in the renal tubules via the sodium-phosphate co-
transporter 2a (NPT-2a) situated on cells of the proximal renal tubule; the remaining 
phosphate is excreted in the urine (Tenenhouse, 2007).  Phosphate reabsorption by 
NPT-2a is increased by hypophosphataemia, 1,25-dihydroxyvitamin D, volume 
depletion and chronic hypocalcaemia, and reduced by hyperphosphataemia, 
parathyroid hormone (PTH), phosphatonins such as fibroblast growth factor 23 (FGF-
23), volume expansion and chronic hypercalcaemia.  The importance of 
gastrointestinal NPT-2b was demonstrated in a recent study of heterozygote NPT-2b 
knockout mice (Ohi et al., 2011); these animals had hypophosphataemia and 
reduced urinary phosphate excretion compared to wild type mice, and expression of 
renal NPT-2a was increased. 
 
Two of the principal hormones that regulate renal phosphate handling are PTH, 
produced by the parathyroid glands, and FGF-23, a 251-amino acid that is secreted 
by osteocytes and osteoblasts in bone.  Secretion of PTH by the parathyroid glands 
increases in response to a phosphate load or hypocalcaemia.  Parathyroid hormone 
increases reabsorption of calcium by the kidney but also increases renal phosphate 
excretion.  It also stimulates 1-α-hydroxylase to increase activation of vitamin D, thus 
promoting gastrointestinal absorption of phosphate and calcium.  Production of FGF-
23 is stimulated by 1,25-dihydroxyxvitamin D and also increases in response to a 
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dietary phosphate load; this was first demonstrated in human dietary studies 
(Antoniucci et al., 2006; Burnett et al., 2006; Ferrari et al., 2005) and more recently in 
a larger cross-sectional study of 1261 health professionals (Gutierrez et al., 2011), 
although the underlying regulatory pathways are currently undetermined (Wolf, 
2012).  Serum phosphate levels are maintained within the normal range as both PTH 
and FGF-23 inhibit renal tubular expression of NPT-2a (Shimada et al., 2004), 
reducing phosphate reabsorption by the kidney and increasing urinary phosphate 
excretion.  FGF-23 also suppresses 1,25-dihydroxyvitamin D by inhibiting renal 
expression of the activating enzyme 1-α-hydroxylase and stimulating expression of 
the catabolic enzyme 24-hydroxylase, thereby reducing gastrointestinal phosphate 
absorption (Saito et al., 2003).  The tubular actions of FGF-23 are mediated via FGF 
receptors (mainly FGFR-1); the interaction between FGF-23 and FGFR-1 is 
facilitated by klotho, a transmembrane protein co-receptor that increases the binding 
affinity of FGF-23 (Urakawa et al., 2006).  Klotho null mice have a premature ageing 
phenotype characterised by osteopenia and vascular medial calcification, highlighting 
the importance of FGF-23 in the regulation of normal mineral homeostasis (Kuro-o et 
al., 1997). 
 
1.7 Abnormal Phosphate Metabolism in Chronic Kidney Disease 
 
Chronic kidney disease is the commonest cause of disordered phosphate 
metabolism.  Even small reductions in GFR result in disturbed calcium and 
phosphate handling, suggesting that the concept of humans being born with “surplus” 
renal function may be incorrect.  During the initial stages of CKD, increased 
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production of the phosphaturic hormone FGF-23, stimulated by increasing serum 
phosphate arising from reduced glomerular filtration and renal tubular degradation, 
acts as a potent stimulus that reduces reabsorption of phosphate from the proximal 
renal tubules via the co-transporter NPT-2a.  This compensatory response serves to 
maintain normal phosphate balance by increasing urinary phosphate excretion in the 
face of declining renal capacity to excrete phosphate; serum phosphate levels 
therefore remain within the normal laboratory range (Gutierrez et al., 2005).  
Increased FGF-23 also reduces renal 1,25-dihydroxyvitamin D production by 
reducing 1α-hydroxylase activity (Shimada et al., 2004), causing a decrease in 
gastrointestinal absorption of calcium and consequent hypocalcaemia, although 
phosphate absorption is largely unaffected (Ramirez et al., 1986).  Renal activation of 
vitamin D is also impaired as a consequence of parenchymal injury, but elevated 
serum phosphate levels also directly inhibit 1α-hydroxylase; both result in a reduction 
in active vitamin D production and therefore gastrointestinal calcium absorption.  
Hypocalcaemia and hyperphosphataemia stimulate release of PTH from the 
parathyroid glands; PTH inhibits reabsorption of phosphate in the proximal renal 
tubules by NPT-2a, thereby increasing the urinary fractional excretion of phosphate, 
but also increases resorption of calcium and phosphate from bone.  FGFR-1 
receptors are present in the parathyroid gland indicating that FGF-23 can also affect 
PTH production directly (Krajisnik et al., 2007).  Increases in FGF-23 levels precede 
the rise in serum phosphate and PTH and the decline in 1,25-dihydroxyvitamin D 
(Gutierrez et al., 2005; Isakova et al., 2011b); FGF-23 is therefore a sensitive marker 
of the presence of disordered mineral metabolism in CKD.  Evidence from animal 
models of CKD suggests that an increase in FGF-23 is the upstream trigger that 
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promotes a decrease in 1,25-dihydroxyvitamin D and a rise in PTH, as inhibition of 
FGF-23 is associated with high serum phosphate, normal 1,25-dihydroxyvitamin D 
levels and reduced urinary phosphate excretion (Hasegawa et al., 2010).  Expression 
of klotho, the FGF-23 co-receptor, declines progressively in CKD, mirroring the 
increase in FGF-23 production; CKD has been described as an FGF-23-resistant 
state (Koh et al., 2001; Kuro-o, 2011).  Phosphate levels begin to rise at levels of 
GFR <30 ml/min/1.73m2 (Craver et al., 2007; Hsu and Chertow, 2002; Levin et al., 
2007) as these compensatory mechanisms are overwhelmed and unable to reduce 
tubular phosphate reabsorption any further in the face of declining filtration rate.  A 
positive phosphate balance is established, with dietary phosphate intake exceeding 
urinary phosphate excretion.  Elevated serum phosphate levels further promote the 
release of FGF-23 and PTH; by the time ESKD is reached, hyperphosphataemia is 
an almost universal finding. 
 
In addition to changes in gastrointestinal phosphate absorption and renal phosphate 
excretion, these hormonal changes also result in resorption of calcium and 
phosphate from the skeleton.  At GFRs <60 ml/min/1.73m2, 75-100% of patients 
have evidence of renal bone disease (Elder, 2002).  The commonest form of bone 
disease observed in CKD is high-turnover hyperparathyroid bone disease; mixed 
osteodystrophy (characterised by high-turnover bone disease with defective 
mineralisation) and low-turnover adynamic bone disease occur less frequently (Elder, 
2002).  The term chronic kidney disease-mineral bone disorder (CKD-MBD) was 
introduced to describe the abnormalities of bone and mineral metabolism and the 
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presence of vascular and soft tissue calcification characterised by CKD (Moe et al., 
2007). 
 
1.7.1 Vitamin D and Parathyroid Hormone 
Increasing phosphate levels suppress endogenous vitamin D synthesis and increase 
PTH secretion.  Lower levels of vitamin D are powerfully associated with increased 
cardiovascular risk (Moe et al., 2007).  Hypovitaminosis D is also associated with 
increased arterial calcification (Watson et al., 1997), decreased cardiac contractility 
(Zittermann et al., 2003), upregulation of the renin-angiotensin axis, hypertension and 
LVH (Li, 2003; Xiang et al., 2005).  Vitamin D therapy, used in the treatment of bone 
mineral disorders related to CKD, is associated with reduced cardiovascular mortality 
in observational studies of ESKD (Shoji et al., 2004); this may be partly explained by 
reduced vascular calcification through suppressed cbfa1 synthesis (Drissi et al., 
2002).  Hyperparathyroidism, commonly present in advanced CKD, may also 
contribute to vascular calcification.  Parathyroid hormone receptors are present on 
VSMC and parathyroidectomy is associated with reduced calcium deposition 
(Rostand and Drueke, 1999).  Hyperparathyroidism is strongly associated with 
hypertension (Smith et al., 2000), increased arterial stiffness (Smith et al., 2000), 
LVH, cardiac fibrosis (Amann et al., 1994), impaired cardiac contractility (Rostand 
and Drueke, 1999), impaired endothelial function (Kosch et al., 2000) and 
cardiovascular mortality (Rostand and Drueke, 1999).  In spite of these associations, 
a recently published randomised controlled trial comparing the calcimimetic agent 
cinacalcet against placebo in 3883 haemodialysis patients with moderate to severe 
secondary hyperparathyroidism demonstrated no significant reduction in the primary 
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composite endpoint of death, myocardial infarction, hospitalisation for unstable 
angina, heart failure or peripheral vascular event after a median of 21 months of 
treatment, despite significant reductions in PTH levels (Chertow et al., 2012). 
 
1.7.2 Fibroblast Growth Factor-23 
Interest in FGF-23 has soared recently with several studies demonstrating an 
association between FGF-23 levels and cardiovascular outcome.  A relationship 
between FGF-23 levels and increased mortality has been demonstrated in 
haemodialysis patients (Gutierrez et al., 2008; Jean et al., 2009), in patients with 
stage 2–4 CKD (Isakova et al., 2011c; Kendrick et al., 2011) and in patients with 
prevalent coronary artery disease and normal renal function (Parker et al., 2010).  
There is also evidence linking FGF-23 with cardiovascular events in CKD patients 
(Kendrick et al., 2011; Seiler et al., 2010) and with LV systolic dysfunction and atrial 
fibrillation in patients with normal renal function (Seiler et al., 2011).  A putative 
mechanism underlying this relationship was suggested from cross-sectional studies 
in which FGF-23 was independently associated with increased LV mass and LVH 
(Gutierrez et al., 2009; Kirkpantur et al., 2011; Mirza et al., 2009b).  This observation 
was confirmed by Faul et al in 3070 CKD patients (Faul et al., 2011).  In a series of 
experiments the same investigators demonstrated that FGF-23 induces LVH both in 
vitro and in vivo, and that treatment with an FGF-23 antagonist attenuates the 
development of LVH in animal CKD models (Faul et al., 2011).  Furthermore, FGF-23 
has been linked to progression of renal dysfunction in a cohort of 177 patients with 
non-diabetic CKD (Fliser et al., 2007); this finding was corroborated in a prospective 
study of 3879 patients with stage 2–4 CKD, in which FGF-23 predicted progression 
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to ESKD (Isakova et al., 2011c).  Other studies have associated FGF-23 with 
endothelial dysfunction in the general population (Mirza et al., 2009a) and with 
endothelial dysfunction and vascular calcification in CKD patients (Desjardins et al., 
2012; Yilmaz et al., 2010). 
 
1.7.3 Phosphate in the Western Diet 
Daily dietary phosphate intake is highly variable and not only dependent on the type 
of food consumed but also in the way it is prepared (Cupisti et al., 2006).  Food rich 
in protein, such as milk, dairy products and meat, has a high content of naturally 
occurring bio-available phosphate.  This exists as organic cellular or protein 
constituents and is hydrolysed in the gastrointestinal tract to release inorganic 
phosphate, which is readily absorbed (Uribarri, 2007).  Although “primitive” diets 
based on grains and legumes often have high phosphate content, they provide little 
bioavailable phosphate as most of this occurs in the form of non-absorbable 
phytates.  Effectively these diets result in prolonged eating of foods with low 
phosphate content rather than the “binge-eating” of high phosphate foods associated 
with large increases in post-prandial serum phosphate levels, which are common in 
today’s fast-food society (Bell et al., 1977).  In a rat model of CKD-MBD, animals fed 
the equivalent of a Western diet rich in bioavailable phosphate had higher urinary 
phosphate excretion and higher FGF-23 levels compared to animals fed a grain-
based diet based on non-absorbable phytates (Moe et al., 2009).  These results were 
replicated in a controlled crossover dietary study of 9 patients with CKD and a mean 
eGFR of 32 ml/min/1.73m2 fed with meat and vegetarian diets; patients receiving the 
meat diets had higher serum phosphate and FGF-23 levels (Moe et al., 2011).  
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Similar findings were found in a controlled study of 16 healthy female subjects given 
five different diets over separate 24-hour sessions, in which urinary phosphate 
excretion was higher after a meat-rich diet compared to when whole grains or cheese 
was given (Karp et al., 2007).  Phosphate excretion also increased after dietary 
phosphate supplementation.  Post-prandial increases in serum phosphate seen 
following an acute phosphate load also appear to be associated with transient 
endothelial dysfunction (Shuto et al., 2009). 
 
The widespread use of inorganic phosphate-containing additives in the Western diet, 
such as phosphoric acid (E338) and sodium polyphosphates, used as an acidulate 
and preservative in many foods, including beer, cheese, jam, cured meats and cola 
soft drinks, has contributed to a significant increase in our daily phosphate intake 
(Calvo and Park, 1996; Uribarri and Calvo, 2003).  This is compounded by the lack of 
clear labelling of phosphate content on food packaging and in nutritional information.  
It is estimated that consumption of greater quantities of processed food could 
increase phosphate intake by up to 1000 mg/day (Bell et al., 1977).  Finally, the 
consumption of multivitamins and mineral supplements can also significantly 
increase daily phosphate intake (Uribarri, 2007).  In health the body is able to handle 
a high dietary phosphate load by increasing urinary phosphate excretion (Bell et al., 
1977; Karp et al., 2007), but in the setting of reduced glomerular filtration this 
compensatory mechanism is impaired and hyperphosphataemia rapidly ensues.  The 
potential impact of food additives on phosphate levels in ESKD was demonstrated in 
a randomised multicentre trial of 279 patients with hyperphosphataemia (Sullivan et 
al., 2009).  Patients randomised to receive dietary education regarding avoidance of 
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phosphate additives had a greater decline in serum phosphate levels after 3 months 
compared to those receiving standard care (0.6 mg/dl [0.19 mmol/l] greater decline, 
95% CI -1.0 to -0.1 mg/dl). 
 
Important experimental evidence demonstrating the effects of dietary phosphate on 
cardiovascular structure was provided in a comparison of subtotally nephrectomised 
rats receiving high and low phosphate diets.  In this rat model of CKD, rats fed the 
high phosphate diet had higher serum phosphate concentrations compared to rats 
receiving the low phosphate diet (Amann et al., 2003).  The phosphate rich rats also 
had more cardiac interstitial fibrosis and increased arterial wall thickness compared 
to rats fed the low phosphate diet.  Sham-operated controls demonstrated no 
evidence of cardiac fibrosis or arterial wall thickening, irrespective of the diet given.  
These observations indicate that structural cardiovascular disease develops in the 
setting of a phosphate-rich diet and CKD, which is highly prevalent in the Western 
world and which impairs phosphate excretion, resulting in hyperphosphataemia.  This 
mechanism in no way underestimates the contribution of a high sodium intake to the 
development of hypertension.  Indeed by reducing arterial distensibility with age, 
phosphate exposure may well exacerbate the effect of sodium loading. 
 
1.8 Phosphate, Vascular Calcification and Increased Arterial Stiffness 
 
The cell biology of vascular calcification is complex, but it is clear that phosphate 
plays a key role in this pathophysiological process.  Vascular calcification refers to 
deposition of calcium-phosphate mineral (hydroxyapatite) in cardiovascular tissues.  
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Long thought to be a passive process, there is now compelling evidence that arterial 
calcification is actively regulated, involving direct osteogenic gene activation together 
with suppression of calcification inhibitors.  Vascular smooth muscle cells and 
osteoblasts derive from a common mesenchymal precursor cell, and VSMC appear 
to retain their ability to mineralise.  Exposure of VSMC to high concentrations of 
intracellular calcium and phosphate in vitro results in their phenotypic switch to an 
osteogenic cell type with up-regulation of genes promoting matrix mineralisation and 
calcium deposition (Jono et al., 2000).  A calcium-phosphate precipitate forms in 
association with the ECM (Reynolds et al., 2004).  This osteogenic differentiation 
appears to be driven by upregulation of transcription factors such as core binding 
factor α1 (cbfa1), osteopontin, osterix and bone morphogenetic protein (bmp), which 
control expression of osteogenic proteins such as osteocalcin, osteonectin and 
alkaline phosphatase.  In the media of calcified arteries cbfa1 is highly expressed in 
association with osteopontin and type I collagen.  Upregulation of these transcription 
factors is observed in VSMC in vitro and in vivo, although mineralisation is only seen 
to occur after induction of hyperphosphataemia, which is prevalent in advanced CKD 
(Mathew et al., 2008).  The type 3 sodium-dependent phosphate co-transporter, Pit-
1, facilitates movement of inorganic phosphate into VSMC, which stimulates cbfa1 
expression dose-dependently (Jono et al., 2000).  Mineralisation of the ECM is 
completely inhibited by antagonism of Pit-1, suggesting that calcification is an active 
cellular process dependent on phosphate uptake (Reynolds et al., 2004).  This 
concept is supported by the finding that inhibition of phosphate uptake in Pit-1 
knockdown cells blocks the induction of the osteogenic transcription factors cbfa1 
and osteopontin (Li et al., 2006).  Phosphate also induces VSMC death and apoptotic 
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body release, associated with inflammation and calcification, as well as release of 
matrix vesicles from living cells (Reynolds et al., 2004).  These vesicles contain 
preformed hydroxyapatite and calcify intensively.  Osteogenic proteins are also 
expressed in VSMC following their exposure to uraemic serum in vitro (Chen et al., 
2002); this occurs independently of phosphate concentration, suggesting that the 
uraemic milieu, perhaps through oxidative stress, also directly induces vascular 
calcification. 
 
Loss of inhibitors of mineralisation such as fetuin A, osteoprotegerin and matrix G1a 
protein (MGP) is associated with progressive arterial and ectopic soft tissue 
calcification.  Levels of MGP are inversely correlated with severity of coronary artery 
calcification (Jono et al., 2004) and fetuin A levels have been shown to inversely 
correlate with aortic PWV IN ESKD (Kuzniar et al., 2008).  Fetuin A appears to 
decline in parallel with renal function (Cottone et al., 2010).  In a cross-sectional 
study of 312 patients with ESKD, fetuin A levels were lower than in healthy controls 
and were associated with increased cardiovascular and all-cause mortality (Ketteler 
et al., 2003).  A subsequent larger analysis of data from 822 non-diabetic patients 
with stage 3 and 4 CKD, however, demonstrated no such relationship with mortality 
(Ix et al., 2007).  The down-regulation of these inhibitors in vivo in ESKD may allow 
calcification to occur at relatively low phosphate concentrations, as suggested by the 
association of modestly elevated serum phosphate (still within the reference range) 
with a greater prevalence of coronary, aortic and valvular calcification independent of 
serum vitamin D and PTH levels in studies of CKD patients (Adeney et al., 2009). 
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Vascular medial calcification is prominent in CKD and plays an important role in the 
pathogenesis of arterial stiffness.  The extent of arterial calcification correlates with 
severity of arterial stiffness independent of age and BP in ESKD and early stage 
CKD (Guerin et al., 2000; Raggi et al., 2007; Toussaint et al., 2008), as well as in the 
general population (McEniery et al., 2009).  The presence of arterial calcification is a 
strong predictor of all cause and cardiovascular mortality in ESKD (Chiu et al., 2010; 
London et al., 2003).  In the prospective, longitudinal, multicentre observational 
Coronary Artery Risk Development In Young Adults (CARDIA) study of 3015 young 
adults with normal renal function followed up for 15 years, higher serum phosphate 
levels (>3.9 mg/dl; equivalent to >1.26 mmol/l) at baseline were associated with 
greater levels of coronary artery calcification at follow-up in multivariate analyses 
(Foley et al., 2009b).  Higher serum phosphate was also shown to be an independent 
predictor of development of coronary artery calcification over a 6-year period in a 
longitudinal study of community-dwelling adults (Tuttle and Short, 2009).  Higher 
serum phosphate levels have been reported amongst ESKD patients with coronary 
artery calcification in another cross-sectional study (Goodman et al., 2000).  There is 
weak evidence for a link between phosphate and arterial stiffness.  The studies 
reporting this association are small with some variability in association depending on 
the technique used to assess arterial stiffness.  In a cross-sectional study of 48 
patients with CKD and a GFR ranging from 17 to 55 ml/min/1.73m2, serum 
phosphate correlated with PWV (r=0.35, P=0.02) in univariate analysis; this 
association was not, however, significant in multivariable analyses (Toussaint et al., 
2008).  In another cross-sectional study of 1370 participants of the Multi-Ethnic Study 
of Atherosclerosis, of which 440 had CKD, subjects with phosphate levels >4 mg/dl 
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(>1.28 mmol/l) had a 4.6 times greater risk for a high ankle-brachial pressure index 
(ABPI, a measure of peripheral arterial stiffness) compared to those with phosphate 
levels <3 mg/dl (0.96 mmol/l) after multivariable adjustment, although an increase in 
pulse pressure or large and small arterial elasticity was not demonstrated (Ix et al., 
2009).  A cross-sectional analysis of 581 patients from the third National Health and 
Nutrition Examination Survey (NHANES III) also used ABPI as a measure of arterial 
stiffness to demonstrate an increasing proportion of patients with high ABPI across 
increasing quartiles of serum phosphate (Kendrick et al., 2010).  A more recent study 
of 42 patients with nephrotic syndrome demonstrated increasing age-adjusted PWV 
across tertiles of serum phosphate, although this was a retrospective analysis 
(Sexton et al., 2013). 
 
Arterial stiffness and calcification appear to be driven by the characteristic renal 
mineral bone disorder comprising hyperphosphataemia, hypocalcaemia and 
hyperparathyroidism together with reduced bone mineral density (BMD).  The 
presence of CKD-MBD is strongly linked with the extent of arterial calcification, a 
powerful predictor of mortality (Moe et al., 2007).  Several studies have shown that 
CKD-MBD is related to adverse outcomes in dialysis patients (Moe et al., 2007).  In 
the largest of these involving over 40,000 patients, the population attributable risk for 
disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of 
hyperphosphataemia (Block et al., 2004).  Many observational studies have reported 
an association between low BMD and cardiovascular morbidity and mortality in the 
general population (Kado et al., 2000; van der Klift et al., 2002; von der Recke et al., 
1999).  There is also an inverse relationship between bone mineral content and 
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vascular calcification and several longitudinal studies have shown that individuals 
with the greatest rate of bone loss demonstrate the fastest progression of vascular 
calcification (Hak et al., 2000; Kiel et al., 2001; Schulz et al., 2004). 
 
The results of the studies described above indicate that phosphate is intimately 
linked with the development of vascular calcification in CKD, which in turn may lead 
to increased arterial stiffness and adverse cardiovascular outcome.  The evidence 
implicating phosphate with increased arterial stiffness is, however, less convincing. 
 
1.9 Phosphate as a Cardiovascular Risk Factor 
 
Observational studies have shown serum phosphate to be an independent predictor 
of mortality in CKD (Kestenbaum et al., 2005) and ESKD patients (Block et al., 1998; 
Ganesh et al., 2001).  The first report to demonstrate an independent relationship 
between serum phosphate and adverse outcome was a cross-sectional study of 
haemodialysis patients (Block et al., 1998).  The adjusted risk of overall death for 
patients with a serum phosphate >6.5 mg/dl (2.1 mmol/l) was 1.27 times greater 
compared to those with serum phosphate levels between 2.4 and 6.5 mg/dl (0.77 and 
2.1 mmol/l).  A follow-up study of 12833 haemodialysis patients confirmed this 
relationship and also showed serum phosphate to be independently associated 
specifically with cardiovascular death (Ganesh et al., 2001).  Every 1 mg/dl (0.32 
mmol/l) increase in serum phosphate was associated with a 9% greater increase in 
risk of death from coronary artery disease and a 6% increased risk of SCD.  In a 
retrospective analysis of 3490 patients with pre-dialysis CKD, an adjusted survival 
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model estimated a 23% increase in the risk of death for every 1 mg/dl (0.32 mmol/l) 
increase in serum phosphate (Kestenbaum et al., 2005).  Furthermore, the adjusted 
hazard ratio for death rose to 1.9 in patients with serum phosphate >5 mg/dl (>1.6 
mmol/l) compared to those with serum phosphate <2.5 mg/dl (<0.8 mmol/l).  
Phosphate remained an independent predictor of mortality even when within the 
normal laboratory range.  The importance of phosphate as an independent predictor 
of mortality in CKD was recently confirmed in a meta-analysis of 47 cohort studies 
that included 327644 patients with early and late stage CKD (Palmer et al., 2011).  
The relative risk for all-cause mortality was 1.18 (95% confidence interval 1.12–1.25) 
for every 1 mg/dl (0.32 mmol/l) increase in serum phosphate.  Serum phosphate is 
also a predictor of mortality after renal transplantation (Connolly et al., 2009; 
Sampaio et al., 2011), with higher serum phosphate levels at time of transplantation 
being associated with an increased risk of all-cause mortality.  Furthermore, data 
from two longitudinal studies suggests higher phosphate levels measured at the time 
of transplantation or six to twelve months post-transplantation are associated with an 
increased risk of graft failure (Benavente et al., 2012; Sampaio et al., 2011). 
 
Although elevated serum phosphate, calcium and PTH and vitamin D deficiency are 
all associated with increased all-cause and cardiovascular mortality in CKD, a 
systematic review has indicated that the mortality risk for phosphate is greater than 
for these other parameters (Covic et al., 2009b) of CKD-MBD, highlighting the 
importance of phosphate as the key driver for adverse outcome in this population. 
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Serum phosphate levels within the reference range are also associated with 
cardiovascular morbidity and mortality in studies of the general population (Dhingra 
et al., 2007; Foley et al., 2008; Larsson et al., 2010; Tonelli et al., 2005).  In a 
prospective analysis of over 3300 Framingham Offspring study participants free of 
overt cardiovascular disease and CKD, higher serum phosphate levels were 
associated with an increased risk of cardiovascular disease (including heart attack, 
stroke, angina, peripheral vascular disease and heart failure) in a continuous graded 
relationship (Dhingra et al., 2007).  An association between higher levels of serum 
phosphate and the risk of death and future cardiovascular events, including 
development of heart failure and fatal or non-fatal MI, was demonstrated in 4127 
survivors of MI with normal kidney function in a post hoc analysis of participants of 
the Cholesterol And Recurrent Events (CARE) study (Tonelli et al., 2005).  A similar 
relationship between phosphate and cardiovascular mortality has been demonstrated 
in type II diabetics (Chonchol et al., 2009).  In the prospective, community-based 
Atherosclerosis Risk in Communities Study involving over 13,000 participants with 
normal renal function followed up for 13 years, serum phosphate was independently 
associated with an increased risk of all-cause mortality (adjusted hazard ratio 1.14 for 
every 0.5 mg/dl increase in serum phosphate) (Foley et al., 2008).  In another 
community study of over 2000 men with 30 years of follow-up, serum phosphate 
independently predicted all-cause and cardiovascular mortality (Larsson et al., 2010). 
 
In summary, there is a wealth of information from population studies linking 
phosphate to increased cardiovascular morbidity as well as cardiovascular and all 
cause mortality, both in the general population and in CKD.  In addition, data from in 
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vitro and small animal work demonstrate possible mechanisms through which 
phosphate may influence cardiovascular risk, including the promotion of vascular 
calcification or development of LVH mediated by FGF-23.  Hard evidence indicating 
that phosphate is the direct cause of adverse cardiovascular outcome is, however, 
lacking. 
 
1.10 Phosphate Binders in Chronic Kidney Disease 
 
The current management of bone-mineral disorder in CKD involves the use of dietary 
phosphate restriction in combination with oral phosphate binders to control 
hyperphosphataemia, together with administration of active vitamin D or vitamin D 
analogues to maintain normal PTH and calcium levels.  In advanced CKD dietary 
phosphate restriction alone is usually insufficient to control the hyperphosphataemia 
observed at these levels of renal dysfunction.  The use of oral phosphate binders is 
thus advocated by nephrologists to correct hyperphosphataemia in an attempt to 
prevent secondary hyperparathyroidism and CKD-MBD.  The KDIGO guidelines 
recommend the maintenance of normal serum phosphate levels through dietary 
restrictions and phosphate binders in stage 3–4 CKD (KDIGO clinical practice 
guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney 
Disease-Mineral and Bone Disorder (CKD-MBD), 2009). 
 
The calcium-based binders calcium carbonate and calcium acetate are the most 
commonly used phosphate binders worldwide and are effective at reducing serum 
phosphate in hyperphosphataemic patients (Qunibi et al., 2011).  Despite this proven 
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efficacy, and the strong evidence linking serum phosphate to adverse cardiovascular 
outcomes and mortality, there is a notable lack of randomised, placebo-controlled 
trials of phosphate-lowering therapy that demonstrate reductions in mortality or 
cardiovascular outcomes (KDIGO clinical practice guideline for the diagnosis, 
evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone 
Disorder (CKD-MBD), 2009).  Two observational studies have noted lower all-cause 
mortality rates amongst individuals receiving phosphate binder therapy in intention-
to-treat multivariate analyses and propensity score matching.  In an analysis of a 
prospectively studied cohort of 10044 incident haemodialysis patients that 
participated in the Accelerated Mortality of Renal Replacement (ARMORR) study, 
Isakova et al. demonstrated that treatment with phosphate binders was 
independently associated with reduced mortality at 1 year (Isakova et al., 2009).  A 
similar analysis performed in a historical cohort of 1188 men with non-dialysis-
dependent CKD and a mean eGFR of 38 ± 17 ml/min/1.73m2 also demonstrated a 
significantly reduced mortality amongst patients treated with phosphate binders 
(adjusted hazard ratio 0.61, P<0.001) (Kovesdy et al., 2010). 
 
Recently concerns have emerged regarding the use of calcium-based phosphate 
binders.  These agents cause calcium loading that may result in the promotion of soft 
tissue and vascular calcification.  Newer, non-calcium-based phosphate binders, 
such as sevelamer and lanthanum, have been introduced as alternative agents for 
reducing serum phosphate without contributing to total calcium load.  Sevelamer, 
initially released as sevelamer hydrochloride and available from 2009 as sevelamer 
carbonate following concerns regarding acidosis from the hydrochloride component 
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(Pai and Shepler, 2009), is a non-absorbed phosphate binding crosslinked polymer 
that is taken with meals to reduce the gastrointestinal absorption of phosphate.  The 
structure of sevelamer comprises multiple amines that interact with phosphate ions in 
the gut through covalent and ionic bonding, thus preventing gastrointestinal 
absorption.  Randomised studies and meta-analyses comparing treatment with 
sevelamer against calcium-based agents in haemodialysis patients suggest that 
sevelamer has slightly lower efficacy in reducing serum phosphate levels 
(Navaneethan et al., 2009; Suki et al., 2007), but this is not a consistent finding.  In a 
randomised, unblinded study comparing sevelamer with calcium-based binders in 
200 haemodialysis patients treated over 52 weeks, control of hyperphosphataemia 
was equivalent in both groups (Chertow et al., 2002).  The incidence of adverse 
effects relating to treatment appears to be slightly higher in patients receiving 
sevelamer treatment, but this is offset by the lower risk of hypercalcaemia (Suki et 
al., 2007).  Studies comparing the effects of sevelamer with calcium-based 
phosphate binders on progression of vascular calcification have been contradictory.  
One of the first randomised studies comparing sevelamer with calcium-based agents 
in ESKD indicated a significant increase in calcium score in the coronary arteries and 
aorta measured using electron beam tomography in the calcium-based phosphate 
binder group compared to the sevelamer group (Chertow et al., 2002).  A number of 
subsequent open-label studies have supported this finding.  In an open label study of 
114 haemodialysis patients, sevelamer was not associated with progression of 
coronary artery or aortic calcification when compared to calcium carbonate after 52 
weeks of treatment (Braun et al., 2004).  Another open-label randomised study of 42 
haemodialysis patients showed patients receiving sevelamer had less progression of 
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aortic calcification over 24 weeks compared to those randomised to receive calcium 
carbonate (Takei et al., 2008).  In incident dialysis patients with at least mild coronary 
artery calcification, use of calcium-based binders was associated with more rapid 
progression of calcification when compared to the use of sevelamer hydrochloride 
over an 18-month period (Block et al., 2005).  There is a suggestion from a small 
study of 15 haemodialysis patients that sevelamer reduces PWV, but this requires 
confirmation with larger studies (Takenaka and Suzuki, 2005).  Similar results for 
vascular calcification have been demonstrated with sevelamer in the pre-dialysis 
CKD population (Russo et al., 2007) and with lanthanum carbonate in ESKD 
(Toussaint et al., 2011).  In another open-label study, however, there was no 
significant difference in progression of vascular calcification between haemodialysis 
patients receiving sevelamer and those receiving calcium after 12 months (Qunibi et 
al., 2008).  Whether the use of sevelamer is associated with reduced mortality is also 
unclear, and studies to date have been underpowered for this endpoint.  A recently 
published open-label study of 212 patients with stage 3–4 CKD randomised to 
treatment with sevelamer or calcium carbonate demonstrated lower all-cause 
mortality amongst patients randomised to sevelamer (Di Iorio et al., 2012).  In a 
secondary analysis of 127 incident haemodialysis patients randomised to sevelamer 
or calcium-based binders over a median of 44 weeks, all-cause mortality was 
significantly lower amongst those receiving sevelamer (P=0.05).  These findings 
contrast with the results of an earlier larger, multicentre, open-label randomised trial 
of sevelamer and calcium-based binders in 2103 ESKD patients, in which treatment 
with sevelamer was not associated with lower mortality rates (Suki et al., 2007).  In a 
sub-group analysis of 927 patients aged over 65 years, however, a significantly lower 
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mortality rate was observed in the sevelamer group (hazard ratio 0.77, 95% CI 0.61–
0.96).  Meta-analyses have not shown any significant difference in mortality amongst 
haemodialysis patients receiving sevelamer and those receiving traditional calcium-
based binders (Jamal et al., 2009; Navaneethan et al., 2009; Tonelli et al., 2007). 
 
Lanthanum carbonate is an alternative non-calcium-based phosphate binder that 
appears as efficacious as calcium carbonate in reducing serum phosphate levels in 
ESKD but with a much lower incidence of hypercalcaemia (Finn, 2006; Hutchison et 
al., 2005).  There are limited data available regarding effects of lanthanum on 
vascular calcification or cardiovascular and all-cause mortality, and follow-up safety 
data are limited to two years (Hutchison et al., 2005; Toussaint et al., 2011).  Two 
small studies have evaluated the short-term effects of lanthanum on FGF-23 levels in 
humans with conflicting results (Gonzalez-Parra et al., 2011; Isakova et al., 2011a).  
Findings from studies using sevelamer have been more encouraging, with evidence 
of a decrease in FGF-23 levels during the first 6–8 weeks of therapy (Oliveira et al., 
2010; Yilmaz et al., 2012).  These results require verification in larger blinded 
randomised studies with longer periods of follow-up. 
 
1.11 The Hypothesis 
 
In summary, CKD is characterised by alterations in phosphate handling, with reduced 
urinary phosphate excretion causing an increase in secretion of FGF-23 and PTH 
and reduction in levels of 1,25-dihydroxyvitamin D.  These compensatory 
mechanisms result in resorption of calcium and phosphate from bones, and the 
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characteristic CKD-MBD.  It is postulated that excess circulating phosphate is 
deposited within soft tissues such as the vasculature.  Phosphate is an active 
promoter of calcification at the cellular level and induces the osteogenic 
transformation of VSMC and the subsequent deposition of mineral within the 
extracellular matrix.  The resulting calcification of the vascular media is associated 
with increased arterial stiffness, which is an independent predictor of mortality in 
CKD.  Stiffening of the aorta increases afterload of the left ventricle, resulting in 
structural changes, such as increased LV mass, and functional changes such as 
impaired relaxation and diastolic dysfunction, both of which are predictors of adverse 
cardiovascular outcome. 
 
The results of studies determining the effects of lowering phosphate exposure on 
markers of vascular calcification and parameters of arterial stiffness may have 
profound implications for the management of cardiovascular risk in the CKD 
population.  Reducing phosphate exposure may be achieved through either dietary 
modification or through pharmacological means.  Modification of dietary behaviour as 
part of a large randomised trial is a notoriously difficult undertaking and will invariably 
have multiple effects on both micro- and macronutrients.  Observational studies of 
diet, such as vegetarian versus omnivorous diets, particularly between two different 
populations, are full of potential confounders, perhaps most notably fat and salt 
intake, and any associations between diet and outcomes do not necessarily reflect a 
common pathway (Flegal, 1999).  Furthermore, compliance with a modified diet 
outside of a controlled environment over the time period necessary for such 
modifications to be associated with detectable changes in arterial stiffness, LV mass 
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or LV function is likely to be poor.  Possible alternative treatments to reduce 
phosphate exposure include the use of niacin and related compounds, which inhibit 
active gut phosphate absorption.  There are some concerns, however, with respect to 
long-term efficacy, tolerability and safety (Berns, 2008); niacin has since been 
withdrawn from the market following safety concerns.  Hyperphosphataemia in CKD 
is currently treated with oral phosphate binding agents.  Although efficacious at 
reducing serum phosphate in advanced CKD, currently available phosphate binders 
have to be taken with meals and all have adverse effects (Tonelli et al., 2010).  The 
relatively recent introduction of non-calcium-containing phosphate binders following 
concerns regarding calcium-loading provides a possible vehicle for testing the above 
hypothesis without fears of increasing vascular calcification and thus promoting 
arterial stiffening.  Indeed, lowering serum phosphate with newer, non-calcium-
containing agents such as sevelamer carbonate may attenuate the progression of 
arterial calcification and arterial stiffening when compared with the traditional 
calcium-based phosphate binders (Takenaka and Suzuki, 2005). 
 
It is hypothesised that treatment of patients with stage 3 CKD with the non-calcium-
based oral phosphate binder, sevelamer carbonate, will limit exposure of the 
vasculature to phosphate and thus attenuate the progression of arterial stiffness, 
reduce the development of systolic hypertension, reduce LV mass and reduce 
diastolic dysfunction (Ferro et al., 2009). 
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2 TECHNIQUES 
 
The following chapter describes the common methods used in the forthcoming 
studies. 
 
2.1 Cardiovascular Magnetic Resonance Imaging 
 
2.1.1 Ventricular Mass, Volumes and Function 
Cardiovascular magnetic resonance imaging was performed using a 1.5-T Siemens 
Symphony scanner (Siemens, Erlangen, Germany; Figure 2-1) with subjects 
introduced headfirst into the scanner in the supine position (Figure 2-2).  Serial 
contiguous short axis cines were piloted from the vertical long axis and horizontal 
long axis images of the left and right ventricles (ECG R wave-gated with 
retrospective triggering, steady-state free precession imaging [True-FISP]; temporal 
resolution 40-50 ms, repetition time 3.2 ms, echo time 1.6 ms, flip angle 60o, slice 
thickness 7 mm with 3 mm gap) in accordance with previously validated 
methodologies (Maceira et al., 2006).  Images were acquired in held end-expiration.  
Analysis was performed offline (Argus Software, Siemens, Erlangen, Germany) by a 
single blinded observer for the assessment of ventricular volumes (end-diastolic, 
end-systolic and stroke volumes), function (ejection fraction) and LV mass (Maceira 
et al., 2006; Myerson et al., 2002).  The outline of the LV myocardium was traced by 
drawing around the epicardium and endocardium at end-diastolic and end-systolic 
frames for each short axis cine.  The most basal slice was determined by the 
presence of a complete ring of myocardium at end-diastole.  Verification of LV stroke 
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volume was performed in two ways: i) by tracing around the endocardium of the right 
ventricle at end-diastole and end-systole for each short axis cine to determine right 
ventricular stroke volume; and ii) by assessing aortic forward flow at the level of the 
pulmonary artery.  Left ventricular measurements were accepted if LV stroke volume 
was within 10 ml of right ventricular stroke volume and aortic forward flow.  As a 
second internal measure of quality control, LV mass was accepted if end-diastolic 
and end-systolic masses were within 10% of each other. 
 
 
 
Figure 2-1.  Siemens Symphony magnetic resonance scanner. 
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Figure 2-2.  Subjects were introduced into the magnetic resonance scanner headfirst in a supine 
position. 
 
Left ventricular mass was indexed to body surface area, which was calculated using 
the Mosteller formula (BSA in m2)=√(weight in kg x height in cm)/3600) (Mosteller, 
1987).  Left ventricular hypertrophy was defined as an LV mass index greater than 
age and gender corrected limits according to previously published recommendations 
(Maceira et al., 2006). 
 
2.1.2 Aortic Distensibility 
For the determination of thoracic aortic distensibility steady-state free precession 
(True-FISP), R-wave gated, retrospectively triggered, sagittal-oblique cine sequences 
were undertaken in held end-expiration with the following parameters: temporal 
resolution 50-60 ms, echo time 2.2 ms, flip angle 60°, field of view 300 mm and slice 
thickness of 5 mm (Figure 2-3).  Transverse slices were then acquired at the level of 
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the pulmonary artery (Figure 2-4) to examine the ascending and proximal descending 
aorta and the level of the diaphragm to assess the distal descending aorta.  Aortic 
distensibility (x10-3 mmHg-1) was calculated through measurement of cardiac cycle-
dependent changes in aortic area after accounting for brachial pulse pressure and 
resting vessel cross-sectional area using a previously validated formula (Groenink et 
al., 1998): 
 
 
 
where Δ Aortic Area  =  (Maximum Aortic Area – Minimum Aortic Area) and Pulse 
Pressure was the average of three brachial pulse pressure measurements performed 
synchronously with a non-ferromagnetic cuff in the non-dominant arm at the time of 
CMR image acquisition.  Area measurements were performed offline in triplicate at 
all three aortic levels using CMR Tools software (Imperial College, London, UK).  
Cardiac magnetic resonance-derived aortic distensibility allows accurate non-
invasive determination of aortic stiffness with high reproducibility (Forbat et al., 1995) 
that closely correlates with the current gold-standard of carotid-femoral PWV 
described in section 2.2 (Nelson et al., 2009).  Furthermore, CMR has the added 
advantage of enabling direct evaluation of regional stiffness at different aortic 
locations at high spatial and temporal resolution.  As measurements of aortic 
distensibility are dependent on distending pressure (McEniery et al., 2007) all values 
were adjusted for mean arterial pressure.  This adjustment was performed by 
carrying out linear regression of the two variables of aortic distensibility and mean 
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arterial pressure to determine unstandardised residual values.  These values were 
then added to the mean aortic distensibility to determine adjusted aortic distensibility. 
 
 
 
Figure 2-3.  Oblique sagittal slice of the thoracic aorta acquired with cardiovascular magnetic 
resonance imaging. 
Transverse lines indicate position of slices for determination of ascending, proximal descending and 
distal descending aortic distensibility. 
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Figure 2-4.  Transverse slice through the aorta at the level of the pulmonary artery. 
Cross-sectional areas for the ascending and proximal descending aorta have been determined. 
 
2.1.3 Reproducibility 
Interstudy reproducibility of LV mass and aortic distensibility measurements was 
determined by repeating CMR on the same day in 12 randomly selected subjects 
(10% of the overall cohort recruited for the subsequent randomised study described 
in section 5).  Both scans were then analysed by the same observer.  Intraobserver 
variability of LV mass and aortic distensibility was assessed through repeat analysis 
of 12 randomly selected scans by the same observer.  Both sets of results were 
analysed using an intraclass correlation coefficient for variability with a two-way 
random effects model. 
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The overall reliability of interstudy measurements of LV mass index was good with an 
intraclass correlation coefficient of 0.918 (95% CI 0.742–0.976, P<0.0005).  
Intraobserver reproducibility for LV mass was also high with an intraclass correlation 
coefficient of 0.992 (95% CI 0.981–0.997, P<0.0005). 
 
2.2 Assessment of Arterial Stiffness 
 
Several non-invasive methods for determination of local or regional aortic stiffness 
are available (Laurent et al., 2006).  Determination of carotid-femoral PWV along the 
aorto-iliac pathway is considered the simplest, most reproducible non-invasive 
method for the direct assessment of regional arterial stiffness.  This particular 
measure of arterial stiffness has been used in a number of epidemiological studies 
demonstrating the value of aortic stiffness in predicting future cardiovascular events 
and is considered the current “gold-standard” technique. 
 
There are many different devices available for the determination of PWV (DeLoach 
and Townsend, 2008).  The SphygmoCor system (AtCor Medical, Sydney, Australia) 
uses a high-fidelity micromanometer (SPC-301, Millar Instruments, Texas, USA) and 
the technique of applanation tonometry to sequentially record carotid (proximal) and 
femoral (distal) waveforms transcutaeneously; this system has been validated for the 
assessment of aortic stiffness against invasive measurements of central aortic 
pressure (Laurent et al., 2006; Pauca et al., 2001).  In the studies described in 
subsequent chapters, PWV and PWA were performed using the technique of 
applanation tonometry and a SphygmoCor device (AtCor Medical, Sydney) (Laurent 
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et al., 2006).  Measurements were performed in the morning following an overnight 
fast and subjects were advised to avoid consumption of caffeine or alcohol in the 12 
hours preceding the study.  Applanation tonometry was performed in a quiet room 
following 15 minutes of supine rest using a high-fidelity micromanometer (SPC-301, 
Millar Instruments, Texas; Figure 2-5).  Measurements were obtained in held 
expiration where necessary to optimise trace quality.  All measurements were made 
in triplicate and mean values used in analysis. 
 
 
 
Figure 2-5.  The technique of applanation tonometry using a high-fidelity micromanometer. 
 
2.2.1 Pulse Wave Velocity 
Carotid-femoral PWV was calculated by measuring the distance between the carotid 
and femoral arteries and dividing this by the transit time (the time delay between the 
occurrence of each waveform).  The distance between the two recording sites was 
approximated through measurement of the surface distance in metres using a 
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standard tape measure.  This has been previously performed in three ways: i) 
measurement of the total distance between carotid artery and femoral artery; ii) 
measurement of the total distance then subtracting the distance from the carotid 
artery to the sternal notch; and iii) measuring the distance from the sternal notch to 
the femoral artery and subtracting the distance from the carotid artery to the sternal 
notch (Van Bortel et al., 2002).  In all the studies described in subsequent chapters 
the distance calculation employed was measurement of the total distance between 
carotid and femoral artery with subtraction of the distance from the carotid artery to 
sternal notch. 
 
The transit time was calculated using the foot-to-foot method, which determines the 
time difference between the onset of the pulse wave at the carotid and femoral 
measuring sites.  The foot of the pulse wave was defined as the onset of the steep 
rise of the pulse wave at end diastole.  Carotid and femoral arterial waveforms were 
sequentially recorded using the micromanometer whilst an ECG was simultaneously 
obtained (Figure 2-6).  The transit time was calculated by determining the onset of 
the pulse wave from the R wave of the ECG; the time between the R wave and 
carotid (proximal) pulse was subtracted from the time between the R wave and 
femoral (distal) pulse to derive the transit time.  Carotid-femoral PWV was then 
calculated in metres per second using the formula: 
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This method is reproducible in both healthy subjects and in patients with renal 
impairment (intraobserver variability of 0.07±1.17 m/s and interobserver variability of 
-0.30±1.25 for a typical mean of 8.15 ± 3.01 m/s) (Wilkinson et al., 1998; Wimmer et 
al., 2007). 
 
 
 
Figure 2-6.  Output from pulse wave velocity. 
 
Aortic PWV is BP dependent so values were adjusted for mean arterial pressure as 
described elsewhere (Ford et al., 2010).  Adjustment was achieved by performing a 
linear regression of PWV with mean arterial pressure as the determinant.  
Unstandardised residuals derived from this regression were then added to the mean 
PWV to calculate adjusted PWV (PWVadj). 
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2.2.2 Pulse Wave Analysis 
The technique of pulse wave analysis (PWA) enables assessment of the central 
aortic pressure waveform and determination of central aortic BP and the 
augmentation index (AIx; Figure 2-7).  Pulse wave analysis was performed non-
invasively with the high-fidelity micromanometer and the SphygmoCor system.  The 
micromanometer was used to flatten, but not occlude, the radial artery using gentle 
pressure (Figure 2-8).  Data were collected directly into a portable computer and after 
11 seconds of data capture, an averaged peripheral waveform with corresponding 
central aortic waveform, central aortic pressures and AIx were generated using a 
validated transfer function (Figure 2-9) (Chen et al., 1997).  Although measurement 
at the carotid artery is preferred as this provides a true central pressure waveform, 
measurement at the radial artery is technically less challenging as the artery is well 
supported by surrounding bony structures.  The determination of central aortic 
pressures from a transfer function has been validated using invasive techniques 
(Pauca et al., 2001), although it should be noted that the use of brachial BP as a 
proxy for radial or carotid BP is a potential source of error.  This method is 
reproducible in both healthy subjects and in patients with renal impairment (Savage 
et al., 2002; Wilkinson et al., 1998). 
 
The central pressure waveform begins at the start of systole with arrival of the foot of 
the pulse wave and peaks at systolic pressure (P1).  The inflection point (P2) 
represents the arrival of reflected waves from the periphery.  The dicrotic notch, 
which occurs synchronously with closure of the aortic valve, represents the end of 
systole.  The AIx is defined as the difference between the two systolic peaks of the 
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arterial pressure waveform (P1 and P2; Figure 2-7) expressed as a percentage of the 
pulse pressure.  Results for AIx were also adjusted to a heart rate of 75 beats/minute 
(AIx75) (Wilkinson et al., 2000).  Central AIx increases with age and systolic blood 
pressure (Baksi et al., 2009) and is an independent predictor of all-cause and 
cardiovascular mortality in patients with ESKD (London et al., 2001; Safar et al., 
2002). 
 
 
 
Figure 2-7.  The central proximal aortic pressure waveform generated from pulse wave analysis. 
Systolic pressure is represented by the peak of the pulse wave (P1).  The inflection point (P2) 
represents the arrival of reflected waves from the periphery.  The pressure difference between P1 and 
P2 is the augmentation pressure.  This is expressed as a percentage of pulse pressure to derive the 
augmentation index. 
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Figure 2-8.  Using applanation tonometry to perform pulse wave analysis on the radial artery. 
 
 
 
 
Figure 2-9.  Output from pulse wave analysis. 
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2.3 Assessment of Blood Pressure 
 
Office brachial BP was measured with a validated oscillometric sphygmomanometer 
(Dinamap Procare 200, GE Healthcare, Hatfield, United Kingdom) following 15 
minutes of supine rest as per the latest British Hypertension Society and European 
Society of Hypertension guidelines (O'Brien et al., 2003).  Measurements were made 
in triplicate in the non-dominant arm and the first two measurements were discarded. 
 
Twenty-four hour ambulatory BP was recorded using a validated ambulatory BP 
monitor (Meditech ABPM-04, PMS Instruments, Maidenhead, United Kingdom) with 
recordings performed every 30 minutes during the day (07:00 to 23:00) and every 
hour at night (23:00 to 07:00).  Day-time, night-time and 24-hour averages were 
calculated for systolic BP, diastolic BP, pulse pressure, mean arterial pressure and 
heart rate. 
 
2.4 Echocardiography 
 
A comprehensive transthoracic echocardiogram (Vivid 7, GE Vingmed Ultrasound, 
Horten, Norway; Figure 2-10) was performed with the subject in the left lateral 
decubitus position by a single experienced blinded echocardiographer using second 
harmonic imaging and an M3S multi-frequency transducer (Figure 2-11).  Analysis 
was performed offline by a single blinded observer using an EchoPAC workstation 
(version 108.1.4, GE Vingmed Ultrasound, Horten, Norway).  All parameters were 
measured in triplicate and averaged as per the latest recommendations from the 
 62 
American Society of Echocardiography (Lang et al., 2005).  Ventricular dimensions, 
wall thickness, chamber volumes and stroke volume were determined using standard 
methods.  Left ventricular mass was determined by the 2-dimensional area-length 
formula and indexed to body surface area.  Resting LV diastolic function was 
determined using standard techniques, including measurement of mitral inflow 
velocities E and A, E/A ratio, E wave deceleration, mitral inflow velocity propagation, 
isovolumic relaxation time and pulmonary vein systolic and diastolic flow (Nagueh et 
al., 2009).  Peak systolic (s’), early diastolic (e’) and late diastolic (a’) mitral annular 
velocities were measured at end expiration at the septal, lateral, inferior and anterior 
LV walls with real time pulsed wave tissue Doppler (Alam et al., 1999), allowing 
calculation of mean e’ and E/e’ for further assessment of diastolic function. 
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Figure 2-10.  Vivid 7 echocardiography machine. 
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Figure 2-11.  Transthoracic echocardiography in progress. 
 
2.4.1 Strain and Strain Rate Imaging 
Images for 2-dimensional LV strain and strain rate imaging were acquired in cineloop 
format in triplicate using gray scale harmonic imaging from the apical 4-, 2- and 3-
chamber views at end-expiration at frame rates >70/second for offline analysis using 
commercially available software (Speqle Tracking, GE Healthcare, United Kingdom).  
The endocardial border was manually traced at end-systole and the software then 
generated a region of interest to overlie the myocardium.  The thickness of this 
region of interest was altered according to the thickness of the myocardium.  This 
enabled frame-to-frame tracking of ultrasonic speckles that changed position 
according to underlying myocardial tissue motion throughout the cardiac cycle.  
Tracking of the myocardium was assessed by both the software and the observer; if 
tracking was unsatisfactory in any myocardial segment the region of interest was 
 65 
manually adjusted up to a maximum of three times to enable adequate tracking.  If 
tracking of any segments remained suboptimal, such segments were excluded from 
analyses.  Any views in which more than three segments failed to track were 
excluded from analyses.  Peak longitudinal systolic (s’) and early diastolic (e’) 
velocities (Figure 2-12), peak longitudinal systolic, end systolic and post systolic 
strain (if present; Figure 2-13) and peak longitudinal systolic (s’) and early diastolic 
(e’) strain rate (Figure 2-14) were measured and recorded for each myocardial 
segment (where available) in triplicate and averaged.  Values were recorded for all 
three segments (basal, mid and apical) that comprised the six walls of the left 
ventricle (anterolateral, inferoseptum, anterior, inferior, anteroseptum and 
inferolateral).  Global peak longitudinal systolic strain was defined as the mean peak 
longitudinal systolic strain of all 18 myocardial segments. 
 
 
 
Figure 2-12.  Segmental left ventricular longitudinal velocities determined using speckle tracking. 
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Figure 2-13.  Segmental left ventricular longitudinal strain determined using speckle tracking. 
 
 
 
Figure 2-14.  Segmental left ventricular longitudinal strain rate determined using speckle tracking. 
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2.4.2 Left Ventricular Rotation and Twist 
The same techniques described in section 2.4.1 were adopted for acquisition and 
analysis of images for the assessment of LV rotation and twist.  Parasternal short 
axis views were acquired at basal, equatorial and apical levels and stored for offline 
analysis.  Peak rotation, time to peak rotation and systolic and diastolic rotation rates 
were recorded at the base and apex (Figure 2-15) for each myocardial segment.  
Instantaneous twist curves were automatically generated by the software through 
subtraction of the basal rotation curve from the apical rotation curve (Figure 2-16); 
peak twist and time to peak twist were recorded.  Similarly instantaneous rotation 
rate curves were generated through subtraction of the basal rotation rate curve from 
the apical rotation rate curve; peak twist rate, untwist rates and timings were 
recorded.  Basal and apical pairs were analysed in triplicate and averaged. 
 
 
 
Figure 2-15.  Apical rotation assessed using speckle tracking. 
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Figure 2-16.  Left ventricular twist assessed using speckle tracking. 
 
2.5 Dual Energy X-ray Absorptiometry Scanning 
 
Dual energy x-ray absorptiometry scanning (Hologic QDR Series 4500 with 
Discovery Software version 11.02:03, Hologic Europe, Zaventem, Belgium) was used 
to assess BMD of the lumbar spine (L1–L4) and both proximal femurs (femoral neck, 
Ward’s region, trochanteric region).  An experienced bone densitometry clinical 
scientist blinded to clinical data reported all scans.  T-scores that refer to the young 
adult reference mean calculated from the manufacturer’s database (based on the 
NHANES population) were determined (Looker et al., 1998).  Osteopenia and 
osteoporosis were defined according to the World Health Organisation definitions 
(normal bone T-score >-1, osteopenia T-score -1 to -2.5 and osteoporosis T-score <-
2.5).  The BMD of each subject was standardised by calculating the difference 
between the observed and predicted values (sourced from the manufacturer’s 
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reference database based on the NHANES population) divided by the square root of 
the estimated variance.  This derived standard score, or Z-score, is a measure of the 
deviation from the expected population mean, adjusted for the covariance on a scale 
with zero mean and unit standard deviation, so that 95% of the normal population will 
have a Z-score between -2 and 2.  The coefficient of variation for the determination of 
BMD is 1.1%. 
 
2.6 Lateral Lumbar Spine Radiography 
 
The presence and extent of abdominal aortic calcification were assessed using a 
lateral lumbar spine radiograph and validated semi-quantitative scoring method as 
previously described (Figure 2-17) (Kauppila et al., 1997).  This semi-quantitative 
technique shows good correlation with electron beam computed tomography 
assessment (Bellasi et al., 2006).  The abdominal aorta adjacent to the L1–L4 
vertebra was divided into four sections using the midpoint of each intervertebral 
space as a boundary.  The anterior and posterior aortic walls of each section were 
scored out of 3 according to the extent of calcification present: if less than 1/3 of the 
wall was calcified, a score of 1 would be given; if more than 1/3 but less than 2/3 of 
the wall was calcified, a score of 2 would be given; if more than 2/3 of the wall was 
calcified, a score of 3 was given.  The maximum score possible for the entire 
abdominal aorta was 24.  All radiographs were analysed and scored by two 
independent observers.  Any discordance in the presence or absence of calcification 
between the two observers resulted in re-assessment of that radiograph and 
evaluation by a radiologist to reach a final consensus. 
 70 
 
 
 
Figure 2-17.  Lateral lumbar spine radiography demonstrating calcification of the anterior and posterior 
walls of the abdominal aorta. 
 
2.7 Biochemical Assays 
 
2.7.1 Assessment of Renal Function 
Renal function was assessed in the following studies through measurement of eGFR 
using the 4-variable MDRD equation with serum creatinine recalibrated to be 
traceable to an isotope-derived mass spectroscopy method (Levey et al., 1999).  
Although a less accurate method of determining “true” GFR compared to radionuclide 
studies, this reflects the method used by the vast majority of population studies that 
demonstrate an increased cardiovascular risk in patients with CKD and does not 
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involve use of ionising radiation.  The MDRD equation has been criticised for 
underestimating true GFR at higher levels of kidney function (Stevens et al., 2007), 
leading to the introduction of the CKD-EPI formula in 2009 (Levey et al., 2009).  As 
recruitment of subjects for these studies began prior to the introduction of this 
formula, the MDRD equation was used. 
 
2.7.2 High Sensitive C-Reactive Protein 
High sensitive CRP (hsCRP) was measured using an in-house enzyme-linked 
immunosorbent assay (ELISA; IBL International GMBH, Hamburg, Germany).  This 
was performed by Dr Nadezhda Wall and myself in the School of Immunity and 
Infection at the University of Birmingham.  10 µl of each serum sample was diluted in 
buffer to a 1:1000 dilution and 100 µl added to a pre-coated 96 well plate.  Five 
standard calibrators were diluted to a 1:100 dilution and also added to the plate in 
order to generate a calibration curve.  Following 30 minutes of incubation at room 
temperature and three wash cycles, 100 µl of conjugated monoclonal anti-human 
CRP antibody was added before another 30 minutes of incubation at room 
temperature.  A second wash was performed before tetramethylbenzidine solution 
was added.  After 10 minutes of incubation at room temperature in a light-protected 
environment the reaction was stopped using 0.5 molar sulphuric acid and the plate 
was read immediately using a microplate reader at an absorbance of 450 nm.  
Optical density was analysed using GraphPad Prism (GraphPad Software, California, 
USA) and samples were plotted against the calibration curve generated from the 
plate standards.  The minimum detectable concentration of the assay was 0.02 µg/ml 
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with an intra-assay coefficient of variation of 4.1–6.9% and inter-assay coefficient of 
variation of 5.8–6.3%. 
 
2.7.3 N-terminal Pro-brain Natriuretic Peptide 
Plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) were 
determined with the assistance of Professor Leong Ng and Paulene Quinn of the 
Pharmacology and Therapeutics Group at the University of Leicester.  Levels of NT-
proBNP were determined using an immunoluminometric assay that has been 
previously described (Hughes et al., 1999).  A rabbit anti-human NT-proBNP 
polyclonal antibody directed against a domain of the C-terminal section of NT-
proBNP and labelled with the chemiluminescent label 4-(2-
succinimidyloxycarbonylethyl)phenyl-10-methylacridinium 9-carboxylate 
fluorosulphonate was used.  Samples were assayed in duplicate and the average of 
two measurements reported.  The lower limit of detection for the assay was 0.3 
pmol/l. 
 
2.7.4 Fibroblast Growth Factor 23 
The phosphatonin FGF-23, its soluble co-receptor klotho, and vitamin D were 
measured alongside serum phosphate, calcium and PTH in order to accurately 
determine calcium-phosphate status.  The roles of FGF-23, klotho and vitamin D in 
phosphate and calcium homeostasis are described in section 1.7.  Fibroblast growth 
factor 23 was measured using a two-site second-generation monoclonal antibody 
ELISA (Kainos Laboratories Inc., Tokyo, Japan) that detects biologically active intact 
FGF-23 (Yamazaki et al., 2002).  50 µl of assay diluent and 50 µl of serum sample 
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were added to each well of a 96 well plate.  50 µl of each of the seven FGF-23 
standards were also added to each plate in order to generate a calibration curve.  
The plate was incubated for 2 hours at room temperature on a plate mixer before four 
wash cycles were performed.  100 µl of murine monoclonal antibody conjugated to 
horseradish peroxidase was then added to each well before further incubation at 
room temperature for 1 hour on the plate mixer.  After a second series of wash cycles 
100 µl of tetramethylbenzidine was added to each well before 30 minutes of 
incubation in a light-protected environment.  100 µl of 0.5 molar sulphuric acid was 
then added to each well to stop the reaction before the plate was read using an 
ELISA plate reader (Medgenix Diagnostics, Belgium) at an absorbance of 450 nm.  
Reporting of absorbance data was performed using SoftMax Pro version 3.1.1. 
software (Molecular Devices Inc, California, USA) and measurements determined 
using the calibration curve plotted from the seven standards.  The range of detection 
of the assay was 10–800 pg/ml.  The FGF-23 assays were performed under the 
supervision of Dr Daniel Zehnder, Associate Clinical Professor, at the University of 
Warwick. 
 
2.7.5 Soluble Klotho 
Soluble serum α-klotho was determined using a solid phase sandwich ELISA 
(Immuno-Biological Laboratories Co., Japan).  100 µl of buffer was added to each 
well of a 96 well plate.  100 µl of each serum sample along with 8 pre-diluted 
standards were added to the wells.  The plate was then incubated at room 
temperature for one hour before washing.  After seven wash cycles 100 µl of 
conjugated anti-human klotho mouse IgG monoclonal antibody was added to each 
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well before a further 30 minutes of incubation at room temperature.  After nine wash 
cycles 100 µl of tetramethylbenzidine was added before another 30 minutes of 
incubation at room temperature in a light-protected environment.  100 µl of 1 molar 
sulphuric acid was then added to each well to stop the reaction before the plate was 
read using the ELISA plate reader at an absorbance of 450 nm.  Reporting of 
absorbance data was performed using SoftMax Pro version 3.1.1. software 
(Molecular Devices Inc, California, USA) and concentrations of soluble klotho were 
then determined using the calibration curve plotted from the standards.  The 
measurement range of the assay was 150–6000 pg/ml with an intra-assay coefficient 
of variation of 2.7–3.5% and inter-assay coefficient of variation of 2.9–11.4%.  Serum 
α-klotho assays were performed under the supervision of Dr Daniel Zehnder, 
Associate Clinical Professor, at the University of Warwick. 
 
2.7.6 Vitamin D 
All vitamin D assays were performed at University College London Hospitals NHS 
Foundation Trust under the supervision of Dr Anne Dawnay, Consultant Biochemist.  
1,25-dihydroxyvitamin D was measured using immunoextraction followed by 
quantification by ELISA (Immunodiagnostic Systems Ltd, Tyne and Wear, UK) using 
a Griffoils Triturus automated ELISA station.  The measurement range of the assay 
was <6–333 pmol/l with an intra-assay coefficient of variation of 9.3–10.7% and an 
inter-assay coefficient of variation of 17.1–19.7%.  25-hydroxyvitamin D2 and 25-
hydroxyvitamin D3 were measured by liquid chromatography-tandem mass 
spectrometry using an ACQUITY UPLC-TQD system (Waters Corporation, Milford, 
Massachusetts, USA) operating in positive electrospray ionisation mode.  Serum 
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samples underwent solid phase extraction using Oasis HLB µElution plates (Waters 
Corporation) and extracts were injected into the chromatography system containing a 
BEH phenyl column (2.1 x 50 mm, 1.7 µm, Waters Corporation) with a water-
methanol gradient supplemented with 0.1% formic acid and 2 mmol/l ammonium 
acetate.  Analytes were measured using multi-residue methods with quantifier and 
qualifier transitions accompanied by respective isotopic internal standards.  
Calibration and quality control were routinely monitored with an inter-assay 
coefficient of variation of <10%. 
 
2.8 Overview of Statistical Methods 
 
All data in this work were analysed using SPSS version 19 (SPSS Inc., Chicago, 
Illinois, USA).  Normality of data distribution for each variable was determined using 
the Kolmogorov-Smirnov test and normality plots.  Normally distributed variables 
were presented as mean ± standard deviation and analysed using parametric tests.  
Any non-normally distributed variables were log-transformed prior to analysis to 
achieve normality and the logs were analysed using parametric tests; such variables 
were quoted as median (interquartile range).  If normality was not achieved with log 
transforming, non-parametric analyses were performed.  Between-group 
comparisons were performed using independent t-tests (two groups) or a one-way 
analysis of variance (more than two groups).  Within-group comparisons across 
different time points were assessed using paired samples t-tests.  Between-group 
comparisons across different time points (week 0 and week 40) were performed 
using a repeated measures analysis of variance, with the time point (week 0 or week 
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40) as the within-subjects factor and the group (placebo, sevelamer) as the between-
subjects factor, thus testing the difference in change over time between the two 
groups.  Linear regression analysis was performed to determine the relationship 
between continuous variables; parametric variables were assessed using Pearson’s 
correlation and any non-parametric variables assessed using Spearman’s.  Co-
linearity between explanatory variables was assessed by examining the variance 
inflation factor, with a variance inflation factor >10 indicating relevant co-linearity.  
Categorical variables were presented as frequency (percentage) and analysed using 
the Pearson χ2 test.  A Type I error rate below 5% (P<0.05) was considered 
statistically significant. 
 
2.9 Approvals and Authorisations 
 
West Midlands Research Ethics Committee granted ethical approval for the human 
research studies conducted in this thesis (ref. 08/H1208/37).  The Medicines and 
Healthcare products Regulatory Agency provided authorisation for the unlicensed 
use of sevelamer carbonate in patients with normal serum phosphate and stage 3 
CKD (EudraCT number 2008-003727-23).  University Hospitals Birmingham NHS 
Foundation Trust acted as sponsor for the study (ref. RRK3563).  Written, informed 
consent was obtained from each participant.  All studies were conducted in 
accordance with the Declaration of Helsinki and the principles of Good Clinical 
Practice. 
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3 RELATIONSHIP BETWEEN SERUM PHOSPHATE AND DECLINE 
IN RENAL FUNCTION 
 
3.1 Introduction 
 
3.1.1 Background 
Patients with CKD have high levels of cardiovascular morbidity and mortality that 
cannot be fully explained by traditional cardiovascular risk factors.  One “alternative” 
risk factor for future cardiovascular morbidity and mortality is the rate of deterioration 
in renal function; some studies suggest this is a better predictor of future 
cardiovascular risk than baseline renal function (Matsushita et al., 2009; Shlipak et 
al., 2009).  Markers of decline in renal function may therefore prove to be reliable 
determinants of future cardiovascular risk in this population. 
 
Serum phosphate has been identified as a predictor of progression of renal 
dysfunction in “advanced” (stage 4 and 5) CKD (Voormolen et al., 2007), in 
hypertensive renal disease in African-Americans (Norris et al., 2006) and, more 
recently, in transplant recipients (Connolly et al., 2009; Moore et al., 2010). 
 
3.1.2 Objective 
The aim of this study was to investigate the relationship between serum phosphate 
levels and markers of arterial stiffness on the progression of renal dysfunction in a 
well-characterised cohort of patients with early-stage CKD. 
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3.2 Subjects and Methods 
 
3.2.1 Participants 
This was a single-centre cohort study of participants that were recruited to take part 
in studies examining the effectiveness of treatments aimed at lowering 
cardiovascular risk in patients with CKD (Edwards et al., 2009).  Subjects were 
recruited from specialist renal clinics at the Queen Elizabeth Hospital Birmingham, 
United Kingdom from May 2004 to October 2007.  Inclusion criteria were CKD as 
defined by Kidney Dialysis Outcomes Quality Initiative (K/DOQI) (K/DOQI clinical 
practice guidelines for chronic kidney disease: evaluation, classification, and 
stratification, 2002) not yet on dialysis, stable renal function within the last 3 months 
(<5 ml/min/1.73m2 change) and no change in medication in the preceding 3 months.  
Patients with atrial fibrillation, known LV dysfunction (ejection fraction <55%) or with 
signs and symptoms of congestive heart failure were excluded.  Patients on 
calcineurin inhibitors were excluded because of the known direct haemodynamic 
effects of these agents.  Patients on phosphate binders and vitamin D analogues 
were also excluded.  South Birmingham Research Ethics Committee provided 
approval for this study. 
 
3.2.2 Outcome Measures 
Follow-up data were prospectively collected.  At outpatient review venous blood was 
routinely collected and analysed for phosphate, calcium, PTH and other 
haematological and biochemical parameters.  Serum calcium levels were corrected 
for albumin level.  All serum creatinine values were measured during normal clinical 
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practice and recorded for the duration of follow up.  Estimated glomerular filtration 
rate was determined by the 4-variable MDRD formula with serum creatinine 
recalibrated to be traceable to an isotope derived mass spectroscopy method (Levey 
et al., 1999).  Progression of renal dysfunction was defined as the slope of eGFR 
plotted against time.  Time was defined as time between data collection until death, 
start of renal replacement therapy or study termination.  A combined endpoint of start 
of dialysis (excluding temporary dialysis) or ≥25% decline in eGFR since study entry 
was used.  The study database was closed in September 2008.  Follow-up data were 
censored at the start of renal replacement therapy or death. 
 
Brachial BP was measured as described in section 2.3.  Aortic PWV and PWA were 
used as indices of arterial stiffness and were measured using the methods described 
in section 2.2. 
 
3.2.3 Statistical Analysis 
All data were analysed as described in section 2.8.  Aortic PWV was adjusted for 
mean arterial pressure as described in section 2.2.1.  Linear and logistic regression 
analysis was used to assess the relationship between decline in renal function and 
parameters under investigation.  In multivariate analyses variables associated with 
decline in kidney function as defined by K/DOQI were used, including baseline 
eGFR, haemoglobin and systolic BP (K/DOQI clinical practice guidelines for chronic 
kidney disease: evaluation, classification, and stratification, 2002).  Analysis was also 
corrected for age, gender and proteinuria (Hunsicker et al., 1997; Jungers et al., 
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1995; K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification, 2002). 
 
3.3 Results 
 
3.3.1 Participants 
A total of 257 patients were recruited.  Thirty-two patients were excluded due to 
incomplete data collection leaving 225 subjects used in analyses.  Demographic, 
biochemical and co-morbidity characteristics of these patients are listed in Table 3-1.  
Renal diagnoses and medication at recruitment are listed in Table 3-2.  Patients were 
on average on 2.0 ± 1.2 antihypertensive agents.  Median follow-up was 924 days 
(interquartile range 637–1176) and the median number of eGFR determinations per 
patient was 10 (7–14).  Eleven (5%) patients died during follow-up. 
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Variable n=225 
Age (years) 59 ± 13 
Male gender (%) 135 (60) 
eGFR (ml/min/1.73m2) 43 ± 19 
eGFR decline (ml/min/1.73m2/month) 0.11 ± 0.54 
Brachial systolic BP (mmHg) 138 ± 20 
Brachial diastolic BP (mmHg) 80 ± 11 
Aortic systolic BP (mmHg) 127 ± 18 
Aortic diastolic BP (mmHg) 81 ± 12 
AIx75 25 ± 10 
Pulse wave velocity (m/s) 9.0 ± 2.6 
Pulse wave velocityadj (m/s) 9.0 ± 2.5 
Body mass index (kg/m2) 28.2 ± 5.2 
Diabetes mellitus (%) 27 (12) 
Cardiovascular disease (%) 41 (18) 
Current or ex-smokers (%) 97 (43) 
Phosphate (mmol/l) 1.22 ± 0.27 
Calcium (mmol/l) 2.34 ± 0.14 
Parathyroid hormone (pg/ml)* 51 (32–84) 
Haemoglobin (g/dl) 13.1 ± 1.7 
Urinary albumin: creatinine ratio (mg/mmol) 5.4 (0.8–31.5) 
 
Table 3-1.  Baseline characteristics of the study population. 
*Available in 200 patients.  Data are mean ± standard deviation, frequency (percentage) or median 
(interquartile range).  eGFR, estimated glomerular filtration rate; BP, blood pressure; AIx75, 
augmentation index adjusted for a heart rate of 75 beats per minute. 
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Primary kidney disease (%)  
Multi-system disease 34 
Glomerulonephritis 20 
Renal vascular disease/nephrosclerosis 9 
Polycystic kidney disease 6 
Diabetic nephropathy 3 
Other 16 
Unknown 12 
Medication (%)  
ACEI or ARB 79 
β-blocker 27 
Calcium channel blocker 32 
Diuretic 43 
α-blocker 16 
Statin 48 
Aspirin 23 
Warfarin 6 
 
Table 3-2.  Renal diagnoses of the study population and medication at recruitment. 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
 
3.3.2 Baseline 
The mean baseline eGFR was 43 ± 19 ml/min/1.73m2 (Table 3-1).  The stage of CKD 
was divided as follows: stage 2 16%, stage 3 59%, stage 4 20% and stage 5 5%.  
The mean serum phosphate concentration was 1.22 ± 0.27 mmol/l.  Phosphate 
within the target range as defined by the 2009 Kidney Disease: Improving Global 
Outcomes Initiative (KDIGO) guidelines (KDIGO clinical practice guideline for the 
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diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral 
and Bone Disorder (CKD-MBD), 2009) (0.8–1.2 mmol/l) was present in 121 (54%); 
hyperphosphataemia was present in 102 (45%) and hypophosphataemia in 2 (1%) 
patients.  No patients were on a low protein diet. 
 
Serum phosphate levels were significantly inversely associated with baseline eGFR 
(r=-0.19, P=0.005).  After correction for baseline eGFR, serum phosphate was 
associated with PTH (β=0.28, P<0.0001), higher albuminuria (β=0.14, P=0.04), lower 
haemoglobin (β=0.18, P=0.008), lower calcium (β=0.14, P=0.048) and female gender 
(β=0.19, P=0.005). 
 
3.3.3 Decline in Renal Function 
The mean decline in renal function was 0.11 ± 0.54 ml/min/1.73m2/month.  Serum 
phosphate was significantly associated with decline in renal function (Figure 3-1, 
Table 3-3): a 1 mmol/l increase in serum phosphate was associated with a 0.34 
ml/min/1.73m2/month steeper slope of renal function decline (P=0.01).  After 
adjusting for risk factors known to accelerate progression of renal dysfunction 
(baseline eGFR, haemoglobin, systolic BP, age, gender and proteinuria), serum 
phosphate remained independently associated with the rate of decline (P=0.02; 
Table 3-3).  Omission of haemoglobin from the model or inclusion of renal diagnosis 
or medication made no appreciable difference to the result.  Further adjustment for 
albumin did not influence the rate of decline in renal function at 0.343 (0.064–0.623) 
ml/min/1.73m2/month.  When dichotomized on cut-off points defined in the KDIGO 
guidelines (KDIGO clinical practice guideline for the diagnosis, evaluation, 
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prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder 
(CKD-MBD), 2009), patients with a plasma phosphate concentration above 1.2 
mmol/l had a 0.147 (0.000–0.304; P=0.05) ml/min/1.73m2/month steeper decline than 
patients with levels below this cut-off point. 
 
Decline Crude β P Adjusted β P 
Phosphate (mmol/l) 0.340 (0.0810–0.599) 0.010 0.340 (0.057–0.624)* 0.019 
Brachial SBP (mmHg) 0.005 (0.001–0.008) 0.011 0.005 (0.000–0.009)† 0.020 
AIx75 0.000 (-0.007–0.007) 0.913 0.000 (-0.008–0.008)‡ 0.928 
PWV (m/s) 0.004 (-0.027–0.034) 0.802 -0.015 (-0.054–0.024)‡ 0.444 
PWVadj (m/s) -0.008 (-0.039–0.024) 0.625 -0.016 (-0.055–0.022)‡ 0.398 
 
Table 3-3.  Association of baseline phosphate, brachial and aortic blood pressure, augmentation index 
and pulse wave velocity with decline in renal function. 
*Adjusted for age, gender, baseline eGFR, systolic blood pressure, proteinuria, haemoglobin and 
serum calcium; †adjusted for age, gender, baseline eGFR, proteinuria, haemoglobin, serum calcium 
and serum phosphate; ‡adjusted for age, gender, baseline eGFR, systolic blood pressure, proteinuria, 
haemoglobin, serum calcium and serum phosphate.  The β describes the magnitude of decline in 
renal function in ml/min/1.73m2/month for every unit increase in the variable shown (for example, a 1 
mmol/l increase in serum phosphate is associated with a 0.34 ml/min/1.73m2/month decline in renal 
function).  A negative β is equivalent to an improvement in renal function.  SBP, systolic blood 
pressure; AIx75, augmentation index adjusted for a heart rate of 75 beats per minute; PWV, pulse 
wave velocity; PWVadj, pulse wave velocity adjusted for mean arterial pressure; eGFR, estimated 
glomerular filtration rate. 
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Figure 3-1.  Association between serum phosphate concentration and decline in renal function. 
The line indicates the regression line (with 95% confidence intervals) for the relationship between 
decline in renal function and serum phosphate level.  R=-0.170, β=-0.34 (P=0.01) 
 
Serum calcium was not significantly associated with kidney function decline over the 
follow-up period (P=0.2).  In the subgroup of 200 patients with PTH results, higher 
PTH was associated with a slightly greater decline in renal function (0.002 [0.001–
0.002] ml/min/1.73m2/month; P<0.0001). 
 
Brachial and aortic systolic BP were associated with decline in renal function; each 1 
mmHg higher systolic BP was associated with a 0.005 and 0.006 
ml/min/1.73m2/month steeper slope of renal function decline respectively (P=0.01 
and P=0.004).  After adjustment for risk factors known to accelerate renal decline, 
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higher brachial and aortic systolic BP remained independently associated with more 
rapid rates of decline (0.005 [0.000–0.009] and 0.006 [0.002–0.01] 
ml/min/1.73m2/month [P=0.020 and 0.008] respectively; Table 3).  Neither PWV nor 
AIx75 were associated with the rate of renal function decline whether unadjusted or 
adjusted for known risk factors (Table 3); these results were not influenced by either 
adjusting for brachial mean arterial pressure or aortic systolic or mean arterial 
pressure. 
 
3.3.4 Combined Renal Endpoint 
Comparison of characteristics of participants who did and did not reach the combined 
endpoint of commencement of dialysis or ≥25% decline in eGFR is shown in Table 
3-4.  Consistent with the results of eGFR slope, there was a significant difference in 
serum phosphate and brachial and aortic BP but no differences in AIx75 or PWV 
between the two groups.  Serum phosphate was independently associated with the 
combined endpoint (β=0.211, P=0.03) after adjustment for age, gender, baseline 
eGFR, systolic BP, proteinuria, haemoglobin and serum calcium.  Neither AIx (β=0.5, 
P=0.1), PWV (β=-0.02, P=0.2) nor PWVadj (β=0.02, P=0.1) were associated with the 
combined endpoint after adjustment. 
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Variable <25% decline in GFR 
(n=184) 
≥25% decline in GFR or 
start of RRT (n=41) 
P 
Age (years) 59 ± 13 56 ± 13 0.2 
Male (%) 115 (60) 26 (59) 1.0 
Diabetic (%) 21 (11) 7 (16) 0.4 
Number of antihypertensives  1.9 ± 1.2 2.4 ± 1.3 0.02 
eGFR (ml/min/1.73m2) 45 ± 18 33 ± 22 <0.001 
ACR (mg/mmol) 4.0 (0.8–28.8) 17.8 (0.2–130.2) 0.1 
Parathyroid hormone (pg/ml)* 45 (31–62) 95 (53–152) <0.001 
Calcium (mmol/l) 2.33 ± 0.14 2.35 ± 0.15 0.6 
Phosphate (mmol/l) 1.19 ± 0.24 1.32 ± 0.36 0.04 
Total cholesterol (mmol/l) 4.8 ± 1.1 4.8 ± 1.4 0.7 
Haemoglobin (g/dl) 13.3 ± 1.7 12.2 ± 1.8 <0.001 
Brachial systolic BP (mmHg) 135 ± 18 149 ± 25 0.001 
Brachial diastolic BP (mmHg) 78 ± 10 86 ± 14 0.002 
Aortic systolic BP (mmHg) 124 ± 16 138 ± 23 <0.001 
Aortic diastolic BP (mmHg) 80 ± 10 88 ± 14 0.001 
Heart rate (beats/min) 68 ± 14 70 ± 11 0.4 
AIx75 (%) 24 ± 11 27 ± 9 0.2 
Pulse wave velocity (m/s) 9.0 ± 2.5 9.0 ± 2.9 0.9 
Pulse wave velocityadj (m/s) 9.1 ± 2.5 8.5 ± 2.7 0.2 
 
Table 3-4.  Comparison of patients reaching the combined renal end point (start of renal replacement 
therapy or ≥25% decline in renal function). 
*Available in 200 patients.  Data are mean ± standard deviation, frequency (percentage) or median 
(interquartile range).  GFR, glomerular filtration rate; RRT, renal replacement therapy; eGFR, 
estimated glomerular filtration rate; ACR, urinary albumin: creatinine ratio; BP, blood pressure; AIx75, 
augmentation index corrected for a heart rate of 75 beats per minute. 
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3.4 Discussion 
 
In this observational study of 225 patients with predominantly early CKD it was 
demonstrated that baseline serum phosphate predicts progression of renal 
dysfunction over a median follow-up of 2.5 years.  This association persisted 
following adjustment for factors known to accelerate renal function decline including 
age, proteinuria and systolic BP.  Brachial and aortic systolic BP also independently 
predicted a decline in renal function, although no association was found with 
measures of arterial stiffness.  These findings were supported by the presence of a 
significantly higher phosphate concentration in those patients reaching the combined 
renal end-point of dialysis or ≥25% decline in eGFR compared to those that did not. 
 
3.4.1 Serum Phosphate as a Predictor of Declining Renal Function 
In a rat model of renal failure, hyperphosphataemia resulting from a high-phosphate 
diet was associated with progression of renal dysfunction (Neves et al., 2004).  
Serum phosphate has since been shown to predict decline in renal function in 
humans with more advanced (stage 4 and 5) CKD than in our cohort (Voormolen et 
al., 2007).  In our study of patients with predominantly early CKD an equivalent 
change in slope of renal function per equivalent increase in serum phosphate 
concentration was observed when compared to the Voormolen study of patients with 
advanced CKD (0.11 ml/min/1.73m2/month vs. 0.15 ml/min/1.73m2/month decline per 
1 mg/dl increase in serum phosphate; a 1 mg/dl change in serum phosphate is 
equivalent to a 0.32 mmol/l change).  Similarly in a community study of African-
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Americans with hypertensive renal disease and eGFR ranging from 20–65 
ml/min/1.73m2 serum phosphate was independently associated with an increased 
risk of decline in eGFR (by 50% or 25 ml/min/1.73m2) or progression to ESKD (Norris 
et al., 2006).  Serum phosphate was also an independent predictor of CKD 
progression in a cohort study of 985 males with stages 1–5 CKD (Schwarz et al., 
2006).  A 1 mg/dl increase in serum phosphate was associated with an adjusted 
hazard ratio of 1.29 of the composite endpoint of ESKD or doubling of serum 
creatinine, although only the highest quartile of serum phosphate showed a 
significant hazard ratio for the composite endpoint; this quartile comprised subjects 
with predominantly stage 4 CKD.  Our results confirm that phosphate predicts rate of 
decline in renal function across a broad range of patients with widely varying severity 
and aetiology of CKD.  Furthermore, the higher phosphate concentration observed 
amongst patients reaching the combined renal end-point of dialysis or ≥25% decline 
in eGFR is consistent with the findings of the CRIB longitudinal cohort study of 382 
patients with CKD, in which serum phosphate was an independent predictor of 
progression to ESKD in Cox regression analyses (Landray et al., 2010).  In a post 
hoc analysis of 331 participants of the Ramipril Efficacy In Nephropathy (REIN) 
study, the cumulative incidence of ESKD or doubling of serum creatinine increased 
across increasing phosphate quartiles, and each 1 mg/dl (0.32 mmol/l) increase in 
serum phosphate was associated with an 84% increase in the risk of ESKD (Zoccali 
et al., 2011).  Another recent study has shown similar results, with phosphate levels 
>4 mg/dl (>1.28 mmol/l) increasing the risk of ESKD by a factor of 1.9 compared to 
levels <4 mg/dl in 13372 participants of NHANES III (O'Seaghdha et al., 2011).  The 
same group reported a 2.1-fold increased risk of incident CKD amongst 2269 
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subjects from the Framingham Heart Study in those with serum phosphate >4 mg/dl 
(>1.28 mmol/l) compared to those with a serum phosphate of 2.5–3.5 mg/dl (0.8–
1.12 mmol/l). 
 
The mechanism underlying the association between serum phosphate and 
progression of renal dysfunction is unknown.  The Western diet is typically rich in bio-
available phosphate, resulting in high renal phosphate load (Ferro et al., 2009).  A 
study of variable dietary phosphate content in uraemic rat models in the 1980s 
provided interesting insights into potential mechanisms of kidney damage (Haut et 
al., 1980).  Higher dietary phosphate was associated with greater urinary phosphate 
excretion and greater calcium and phosphate deposition in the renal tubules and 
interstitium of subtotally nephrectomised rats.  Interstitial oedema and fibrosis, 
together with tubular atrophy and dilatation, were present histologically.  The 
nephrotoxicity of phosphate appeared to increase as renal functional mass 
decreased.  It has been hypothesised that high intracellular phosphate promotes 
precipitation of calcium-phosphate product within renal tubules, or that phosphate 
itself acts as a direct tubular toxin (Loghman-Adham, 1993).  Dietary restriction of 
phosphate in animal models has been shown to reduce progression of kidney 
disease (Ibels et al., 1978), and use of the non-calcium-based phosphate binder 
sevelamer hydrochloride reduces renal calcium content and appears to protect 
against further deterioration in renal function (Cozzolino et al., 2003; Nagano et al., 
2003).  In the post hoc analysis of participants from the Ramipril Efficacy in 
Nephropathy (REIN) study, in which subjects were randomly allocated to ACEI 
therapy or placebo, higher serum phosphate levels appeared to blunt the reno-
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protective effects of ACEI, which may represent an alternative mechanism of 
acceleration of kidney dysfunction (Zoccali et al., 2011). 
 
There are limited data linking higher FGF-23 levels with a greater decline in renal 
function.  In a longitudinal study that followed up 177 patients with non-diabetic CKD 
over a median of 53 months, FGF-23 independently predicted decline in renal 
function after adjustment for age, gender, proteinuria and serum phosphate, calcium 
and PTH (Fliser et al., 2007).  In a post hoc analysis of 1099 participants of the 
Homocysteine in Kidney and End Stage Renal Disease study, higher FGF-23 levels 
were independently associated with initiation of dialysis therapy (Kendrick et al., 
2011).  It is possible that the decline in renal function observed with higher serum 
phosphate levels is mediated by FGF-23, which is elevated in CKD as a 
compensatory response to hyperphosphataemia.  Further studies are required to 
assess this relationship to determine whether this is causal or merely an association 
(Larsson et al., 2003). 
 
Serum phosphate has been established as a predictor of cardiovascular mortality in 
the general population and in CKD, including renal transplant and dialysis patients 
(Block et al., 2004; Connolly et al., 2009; Kestenbaum et al., 2005; Tonelli et al., 
2005).  We have speculated that much of this cardiovascular risk might be attributed 
to direct effects of phosphate on the vasculature and myocardium (Ferro et al., 
2009), but considering the strong relationships between renal function and rate of 
decline in renal function and cardiovascular risk, it is also possible that phosphate 
might exert its effects on cardiovascular risk indirectly via the kidney. 
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3.4.2 Markers of Arterial Stiffness and Renal Function Decline 
Brachial and aortic systolic BP both independently predicted progression of kidney 
disease in our cohort, despite brachial BP being controlled to national targets (mean 
138/80 mmHg).  This has been well established in previous observational studies 
(K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification, 2002).  We were unable to demonstrate a 
relationship between markers of arterial stiffness and decline in renal function.  
These findings are in keeping with a prospective longitudinal analysis of the 
Framingham Offspring Study which did not find an association between baseline 
aortic PWV and incident CKD or microalbuminuria (Upadhyay et al., 2009).  Three 
small studies have found an association.  Taal et al measured radial-dorsalis pedis 
PWV in 35 patients with stage 4 and 5 CKD and found PWV and AIx predicted 
progression to ESKD (Taal et al., 2007).  Studying a cohort of patients with advanced 
CKD and the unorthodox use of radial-dorsalis pedis PWV rather than the gold 
standard carotid-femoral PWV may explain this difference.  In a Japanese study of 
only 41 subjects with non-diabetic CKD AIx predicted a greater decline in renal 
function (Takenaka et al., 2005), although a subsequent study by this group of 42 
patients failed to replicate this finding (Takenaka et al., 2009).  A third study of 133 
patients with stage III-IV CKD showed PWV predicted decline in renal function (Ford 
et al., 2010).  Although this study examined a similar patient cohort, a number of 
differences may collectively account for their contrasting findings: firstly, they used 
the Complior device, which generates higher aortic PWV measurements compared to 
the SphygmoCor (Rajzer et al., 2008); secondly, this group had poorer renal function 
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with a mean eGFR of 32 compared to 43 ml/min/1.73m2 in our cohort; thirdly, 
although their subjects were treated to a target BP of 130/80 mmHg their actual 
achieved mean BP was 155/83 mmHg compared with 138/80 mmHg in our study, 
with a considerably higher pulse pressure potentially accounting for their higher 
reported PWV; fourthly, despite similar usage in the number of antihypertensives, our 
cohort had much greater use of agents targeting the renin-angiotensin-aldosterone 
axis which potentially have a greater influence on reducing arterial stiffness, 
particularly in CKD (Chue et al., 2010); fifthly, their patients were on average 11 
years older than those in our study, and age is known to be a significant determinant 
of arterial stiffness (McEniery et al., 2005); finally, they had a higher proportion of 
diabetics compared to our study (23% vs. 12%).  Our study is larger than these three 
studies combined and has a much longer follow-up period.  The differences between 
all of these studies including our own, however, highlight the fact that very little is 
known about the complex and presumably two-way interactions between arterial 
stiffness and kidney disease.  Research is hindered by the multiplicity of factors that 
influence this relationship in CKD patients including age, BP and medication (Chue et 
al., 2010; Moody et al., 2011).  The recent formation of collaborative networks such 
as EURECAM (Covic et al., 2009a) and UREKA (Tomlinson et al., 2010) will 
hopefully facilitate the recruitment of patients into much larger studies in order to 
address these important questions. 
 
Our results raise the possibility that therapeutic lowering of phosphate levels might 
be an effective method of reducing the rate of decline of renal function.  Similarly, our 
data support the control of systolic BP as a means of reducing progression of kidney 
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dysfunction, although we have found no indication that lower arterial stiffness is 
associated with improved renal outcomes in this population. 
 
3.4.3 Study Limitations 
There are limitations to this study.  Although prospective, it is observational and 
cross-sectional in design and therefore subject to potential residual confounding from 
missing variables.  Only baseline measurements of arterial stiffness were acquired 
and thus the relationship between changes in arterial stiffness and kidney disease 
was not examined longitudinally.  All subjects recruited into this study were under 
regular nephrology review and most had primary renal disease, potentially limiting 
applicability to patients with CKD treated solely in the community.  Phosphate, 
however, is associated with cardiovascular morbidity and mortality in the general 
population as well as in CKD.  Data on serum vitamin D or FGF-23 concentrations 
were not collected, which may have provided greater insight into potential aetiological 
mechanisms. 
 
3.4.4 Conclusion 
Serum phosphate is an independent predictor of decline in renal function in early 
stage chronic kidney disease.  Further work is required to determine the underlying 
mechanisms through which phosphate influences kidney function decline, and 
randomised controlled trials are warranted to investigate the benefits of phosphate 
lowering in the preservation of kidney function. 
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4 RELATIONSHIP BETWEEN LEFT VENTRICULAR MASS AND 
PHOSPHATE IN PATIENTS WITH CHRONIC KIDNEY DISEASE 
 
4.1 Introduction 
 
4.1.1 Background 
The mechanism through which phosphate influences cardiovascular risk is currently 
unknown.  It has been postulated that phosphate might affect cardiac structure and 
function indirectly through promotion of vascular calcification and an increase in 
arterial stiffness, but direct effects on the myocardium, such as cardiac fibrosis and 
ventricular hypertrophy, have also been demonstrated.  In a rat model of CKD, rats 
fed a high phosphate diet developed more cardiac fibrosis compared to those fed a 
low phosphate diet (Amann et al., 2003).  Increased left ventricular mass has also 
been demonstrated in a similar experimental rat model of CKD (Neves et al., 2004).  
Left ventricular hypertrophy is an established predictor of cardiovascular and all-
cause mortality in several patient populations including CKD (Shlipak et al., 2005).  
There is also emerging evidence that LV mass assessed as a continuous variable, 
rather than using the dichotomy of LVH being present or absent, has prognostic 
value in predicting cardiovascular disease (Schillaci et al., 2000).  Furthermore, 
reductions in LV mass have been associated with reduced mortality in a variety of 
groups at high cardiovascular risk (Devereux et al., 2004). 
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4.1.2 Objective 
The majority of cardiovascular deaths in late stage CKD are attributable to structural 
heart disease, such as LVH, which acts as a substrate for the development of CHF 
and SCD.  The relationship between serum phosphate, arterial stiffness and LV mass 
in patients with CKD is unclear.  The aim of this study was to investigate these 
relationships to determine whether serum phosphate was associated with increased 
LV mass and arterial stiffness in early CKD. 
 
4.2 Methods 
 
4.2.1 Study Design, Setting and Participants 
The patients studied in this cross-sectional cohort study were recruited prospectively 
from renal clinics at the Queen Elizabeth Hospital Birmingham, United Kingdom for 
the previously published trial of spironolactone in CKD (Edwards et al., 2009) and for 
the randomised controlled trial of sevelamer described in section 5.  Patients were 
included if aged 18–80 years, with stage 2 (GFR 60–89 ml/min/1.73m2 and evidence 
of kidney damage for ≥3 months), stage 3 (GFR 30–59 ml/min/1.73m2) or stage 4 
CKD (GFR 15–29 ml/min/1.73m2) (K/DOQI clinical practice guidelines for chronic 
kidney disease: evaluation, classification, and stratification, 2002) and no change in 
medication in the preceding three months.  Patients with diabetes mellitus, 
uncontrolled BP (mean daytime ambulatory BP >130/85 mmHg), atrial fibrillation, 
known LV dysfunction, valvular disease and signs and symptoms of congestive heart 
failure were excluded.  Patients receiving treatment with a phosphate binder or 
vitamin D analogue were also excluded. 
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All subjects underwent baseline investigations including measurement of height and 
weight and collection of serum and plasma.  Glomerular filtration rate was estimated 
by the 4-variable MDRD formula with serum creatinine recalibrated to be traceable to 
an isotope derived mass spectroscopy method (Levey et al., 1999).  Serum calcium 
levels were corrected for serum albumin.  Albuminuria was measured using spot 
albumin: creatinine ratio (ACR).  Office BP and 24-hour ambulatory BP were 
measured in accordance with the methods described in section 2.3.  Arterial stiffness 
was assessed through measurement of PWV as described in section 2.2.1.  
Cardiovascular magnetic resonance imaging was used to determine LV volumes, 
function and mass according to the methods described in section 2.1.1. 
 
4.2.2 Statistical Analysis 
Statistical analysis was performed as described in section 2.8.  Reproducibility of LV 
mass index was determined as described in section 2.1.3.   
 
4.3 Results 
 
4.3.1 Demographics 
Of 3349 patients screened, a total of 736 patients met the study entry criteria.  Of 
these, 528 patients declined the study and therefore 208 subjects were recruited.  
Renal diagnoses and prescribed medication of the entire cohort are shown in Table 
4-1.  Patients were on a mean of 1.8 ± 1.2 antihypertensive agents with 89% of 
patients either on an ACEI or ARB.  No patients were taking erythropoietin-
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stimulating agents.  Fifty-seven per cent were male, 86% Caucasian, 10% South 
Asian and 4% Afro-Caribbean with a mean age of 54 ± 13 years.  Seventeen per 
cent were current smokers.  The biochemical and haematological characteristics of 
the cohort are shown in Table 4-2.  The mean eGFR was 50 ± 15 ml/min/1.73m2 with 
a mean phosphate of 1.11 ± 0.21 mmol/l.  Frequency of CKD stage was as follows: 
stage 2 22%, stage 3a 39%, stage 3b 34% and stage 4 6%.  Fifty-nine per cent of 
patients had renal disease confirmed by biopsy, with a further 23% diagnosed using 
ultrasonography. 
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Primary kidney disease (%)  
Glomerulonephritis 29 
Renal vascular disease/nephrosclerosis 17 
Multi-system disease 13 
Reflux nephropathy/nephrolithiasis/obstruction 10 
Polycystic kidney disease 9 
Other 18 
Unknown 4 
Medication (%)  
ACEI or ARB 89 
β-blocker 18 
Calcium channel blocker 28 
Diuretic 31 
α-blocker 12 
Statin 40 
Aspirin 17 
Warfarin 0.5 
 
Table 4-1.  Renal diagnoses and medication of study population. 
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker. 
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  Phosphate quartiles  
 All 
(n=208) 
1 
(n=53) 
2 
(n=55) 
3 
(n=48) 
4 
(n=52) 
P value 
Phosphate (mmol/l) 1.11 ± 0.21 0.86 ± 0.08 1.04 ± 0.03 1.16 ± 0.04 1.39 ± 0.13 <0.001 
Age (years) 54 ± 13 56 ± 13 54 ± 15 51 ± 12 55 ± 12 0.4 
Male (%) 57 70 60 58 41 0.03* 
Number of antihypertensives 1.8 ± 1.2 1.4 ± 1.2 2.0 ± 1.0 1.9 ± 1.2 2.0 ± 1.0 0.03 
eGFR (ml/min/1.73m2) 50 ± 15 50 ± 11 50 ± 17 46 ± 16 53 ± 17 0.2 
ACR (mg/mmol) 8 (1–47) 8 (1–40) 3 (1–53) 7 (2–43) 34 (28–44) 0.3 
Body mass index (kg/m2) 28 ± 5 28 ± 4 28 ± 5 28 ± 6 28 ± 4 1.0 
Haemoglobin (g/dl) 13.3 ± 1.6 13.6 ± 1.4 13.4 ± 1.7 13.4 ± 1.4 12.9 ± 1.6 0.09 
Cholesterol (mmol/l) 4.89 ± 1.17 4.93 ± 1.15 4.79 ± 0.99 4.78 ± 0.94 5.07 ± 1.49 0.5 
HDL (mmol/l) 1.53 ± 0.52 1.49 ± 0.45 1.50 ± 0.59 1.45 ± 0.47 1.68 ± 0.55 0.1 
Calcium (mmol/l) 2.25 ± 0.14 2.22 ± 0.11 2.25 ± 0.11 2.24 ± 0.12 2.28 ± 0.20 0.3 
PTH (pg/ml) 46 (32–66) 57 (31–74) 52 (37–66) 45 (34–69) 34 (28–44) 0.08 
 
Table 4-2.  Demographic, haematological and biochemical characteristics of the entire cohort and 
according to quartiles of increasing serum phosphate. 
*Analysed using χ2.  Data are mean ± standard deviation, percentages or median (interquartile range).  
Analysed with one-way analysis of variance.  eGFR, estimated glomerular filtration rate; ACR, urinary 
albumin: creatinine ratio; HDL, high-density lipoprotein cholesterol; PTH, parathyroid hormone. 
 
Imaging, BP and PWV parameters are shown in Table 4-3 and Table 4-4.  Left 
ventricular mass index was higher in men than women (62.5 vs. 49.9 g/m2; 
P<0.0001).  Five patients (2%) had LVH, of which three were male.  Mean PWV was 
8.6 ± 2.1 m/s with no differences between males and females. 
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    Phosphate quartiles  
 All 
(n=208) 
1 
(n=53) 
2 
(n=55) 
3 
(n=48) 
4 
(n=52) 
P value 
Phosphate (mmol/l) 1.11 ± 0.12 0.86 ± 0.08 1.04 ± 0.03 1.16 ± 0.04 1.39 ± 0.13 <0.001 
LV mass index (g/m2) 57 ± 15 54 ± 13 55 ± 13 58 ± 17 61 ± 16 0.04 
Absolute LV mass (g) 110 ± 35 102 ± 27 107 ± 31 114 ± 42 118 ± 36 0.1 
LVH (%) 2 0 0 2 8 0.03* 
LVEF (%) 72 ± 8 73 ± 7 73 ± 9 72 ± 8 70 ± 9 0.3 
LVEDVI (ml/m2) 59 ± 12 59 ± 11 59 ± 12 59 ± 12 60 ± 14 0.9 
LVSVI (ml/m2) 43 ± 10 44 ± 10 44 ± 10 42 ± 7 43 ± 12 0.9 
 
Table 4-3.  Cardiac magnetic resonance parameters for the entire cohort and according to quartiles of 
increasing serum phosphate. 
*Analysed using χ2.  Data are mean ± standard deviation or percentages.  Analysed with one-way 
analysis of variance.  LV, left ventricular; LVH, left ventricular hypertrophy; LVEF, left ventricular 
ejection fraction; LVEDVI, left ventricular end diastolic volume index; LVSVI, left ventricular stroke 
volume index. 
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    Phosphate quartiles  
 All 
(n=208) 
1 
(n=53) 
2 
(n=55) 
3 
(n=48) 
4 
(n=52) 
P value 
Phosphate (mmol/l) 1.11 ± 0.12 0.86 ± 0.08 1.04 ± 0.03 1.16 ± 0.04 1.39 ± 0.13 <0.001 
Office blood pressure (mmHg)      
 Systolic 129 ± 17 128 ± 19 128 ± 18 131 ± 17 129 ± 19 0.9 
 Diastolic 75 ± 11 76 ± 10 75 ± 11 76 ± 11 73 ± 12 0.6 
24-hour blood pressure (mmHg)      
     Systolic 122 ± 11 121 ± 13 123 ± 9 122 ± 14 121 ± 11 0.8 
 Diastolic 73 ± 8 71 ± 8 73 ± 9 73 ± 7 73 ± 8 0.7 
Day-time average blood pressure (mmHg)     
     Systolic 125 ± 11 125 ± 13 125 ± 10 126 ± 13 126 ± 9 0.9 
 Diastolic 76 ± 9 75 ± 9 76 ± 11 77 ± 8 76 ± 8 0.9 
Night-time average blood pressure (mmHg)     
       Systolic 114 ± 14 11 ± 14 117 ± 15 116 ± 16 112 ± 13 0.4 
 Diastolic 66 ± 10 65 ± 10 67 ± 12 67 ± 12 66 ± 9 0.7 
PWV (m/s) 8.6 ± 2.1 8.6 ± 2.2 9.2 ± 2.2 8.4 ± 2.0 8.2 ± 1.8 0.1 
 
Table 4-4.  Blood pressure and pulse wave velocity for the entire cohort and according to quartiles of 
increasing serum phosphate. 
Data are mean ± standard deviation.  Analysed with one-way analysis of variance.  PWV, pulse wave 
velocity. 
 
4.3.2 Relationships With Serum Phosphate 
Sixty-two (30%) patients had a serum phosphate higher than the recommended 
treatment threshold of 1.2 mmol/l as defined in the KDIGO guidelines (KDIGO clinical 
practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic 
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Kidney Disease-Mineral and Bone Disorder (CKD-MBD), 2009).  Patients with serum 
phosphate >1.2 mmol/l had a greater LV mass index than those with serum 
phosphate <1.2 mmol/l (61 vs. 55 g/m2; P=0.03) with no differences in eGFR (52 ± 
16 vs. 49 ± 15 ml/min/1.73m2; P=0.3), age (54 ± 12 vs. 54 ± 13 years; P=0.8), or 
office BP (systolic 130 ± 18 vs. 129 ± 17 mmHg; P=0.6) and 24-hour ambulatory BP 
(systolic day-time average 122 ± 12 vs. 121 ± 11 mmHg; P=0.4).  This association 
was also present when gender-specific LV mass index was assessed with serum 
phosphate (men 70 vs. 60 g/m2; P=0.001, women 53 vs. 48 g/m2; P=0.03) with no 
differences in eGFR, body mass index, age, PWV or office and 24-hour ambulatory 
BP between phosphate groups. 
 
When the cohort was divided into quartiles according to serum phosphate 
concentrations, LV mass index increased across phosphate quartiles (P=0.04; Table 
4-3).  There were no differences in age, office or 24-hour ambulatory BP, PWV, 
eGFR, calcium, PTH, haemoglobin, albuminuria or cholesterol across the quartiles 
(Table 4-2).  The relationship between serum phosphate quartiles and LV mass index 
persisted when analysed separately for men (P=0.002, Figure 4-1) and women 
(P=0.04, Figure 4-2).  There was no observed difference in absolute LV mass across 
quartiles (P=0.1), but more women were in the higher serum phosphate quartiles 
than in the lower quartiles (Table 4-2; P=0.03).  When men and women were 
analysed separately, absolute LV mass increased across phosphate quartiles 
(P=0.002 and P=0.04 respectively). 
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Figure 4-1.  Left ventricular mass index in men (n=119) according to serum phosphate quartile. 
One-way analysis of variance, P=0.002. 
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Figure 4-2.  Left ventricular mass index in women (n=89) according to serum phosphate quartile. 
One-way analysis of variance, P=0.04. 
 
4.3.3 Correlations with Left Ventricular Mass 
Log-ACR (r=0.184; P=0.009), haemoglobin (r=0.162; P=0.02), serum phosphate, 
(r=0.173; P=0.01; Figure 4-3) and office systolic BP (r=0.323; P<0.0001), diastolic BP 
(r=0.260; P<0.0001) and pulse pressures (r=0.191; P=0.008) all correlated with LV 
mass index.  There was no correlation between PWV and LV mass index (P=0.2).  
Age, eGFR, calcium, log-PTH, total cholesterol and HDL-cholesterol did not correlate 
with LV mass index. 
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Figure 4-3.  Scatterplot of serum phosphate versus left ventricular mass index labelled by gender. 
Pearson’s correlation: whole cohort r=0.17, P=0.01, n=208; men r=0.34, P<0.0001, n=119; women 
r=0.23, P=0.03, n=89. 
 
4.3.4 Determinants of Left Ventricular Mass 
All variables that significantly correlated with LV mass index (including gender) were 
entered into an “enter” linear regression model using LV mass index as a continuous 
variable and office systolic BP used as the most highly correlated measure for BP 
(Table 4-5).  Log-ACR and haemoglobin were not significantly associated with LV 
mass index in this model.  The model explained 30% of the variation in LV mass 
index (P<0.0005).  The importance of serum phosphate and systolic BP in explaining 
the variance in LV mass index was confirmed, with serum phosphate accounting for 
5% and systolic BP 6% of the variance.  Substitution of central BP for peripheral BP 
 107 
in the model made no appreciable difference to the results.  When analysis was 
repeated with absolute LV mass as the outcome variable and BMI as an additional 
covariate, the model remained significant with 37% of the variation in absolute LV 
mass being explained (P<0.0005).  Serum phosphate, systolic BP and gender were 
the only significant independent predictors of absolute LV mass, with serum 
phosphate and systolic BP accounting for 5% and 4% of the variance respectively. 
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 B 95% CI β P 
Male gender -12.45 -16.49–-8.41 -0.41 <0.0005 
Phosphate (mmol/l) 16.66 7.51–25.81 0.23 <0.0005 
Office systolic blood pressure (mmHg) 0.21 0.11–0.32 0.25 <0.0005 
Log albumin: creatinine ratio 1.41 -0.37–3.18 0.10 0.12 
Haemoglobin (g/dl) 0.41 -0.86–1.68 0.04 0.53 
 
Table 4-5.  Enter linear regression.  Predictors of left ventricular mass index. 
Predicted variable: left ventricular mass index in g/m2 (r2 for model 0.303).  Independent variables 
used in model: gender (male 0 female 1), serum phosphate, office systolic blood pressure, log 
albumin: creatinine ratio and haemoglobin.  B, unstandardised coefficient; β, standardised coefficient; 
95% CI, 95% confidence interval. 
 
4.4 Discussion 
 
In this study it was shown that serum phosphate is associated with LV mass in both 
men and women with early CKD.  The association is maintained after adjusting for 
multiple confounders and is independent of BP, age and renal function.  A 
relationship between serum phosphate and arterial stiffness was not demonstrated.  
In this cohort of patients with well-controlled BP, the variance in LV mass explained 
by serum phosphate is of a very similar magnitude to that explained by systolic BP.  
These findings raise the possibility that lowering serum phosphate might be a novel 
way of reducing LV mass and thus provide alternative means of improving 
cardiovascular outcome in this group of patients. 
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Although the higher cardiovascular risk conferred by the presence of LVH as a 
categorical variable is well accepted, it is increasingly recognised that there is no 
biological dichotomy; LV mass is a continuous variable with a graded relationship 
with cardiovascular risk (Devereux et al., 2004; Schillaci et al., 2000).  The reasons 
for this association are unclear; LV mass may merely reflect the cumulative burden of 
exposure to high BP, or may directly influence cardiovascular risk through factors 
such as increased myocardial oxygen consumption, reduced coronary flow reserve 
and ventricular scarring and fibrosis causing an increased risk of arrhythmia (Schillaci 
et al., 2000).  In patients with CKD, increased LV mass is just one manifestation of a 
“uraemic cardiomyopathy”.  In favour of a causative relationship with cardiovascular 
risk is the finding that in patients with hypertension and LVH, a reduction in LV mass 
during antihypertensive therapy is associated with improved cardiovascular outcome 
in addition to the benefit gained from lower BP (Devereux et al., 2004).  Furthermore, 
reduction of BP within the normal range is associated with further reductions in LV 
mass (Edwards et al., 2009; Simpson et al., 2010).  There may be limits to how low 
BP can be reduced without increasing cardiovascular events and mortality, however, 
and although chronic pressure overload is generally accepted as a major determinant 
of LVH, the contribution of other biological variables is now acknowledged (Cuspidi, 
2010). 
 
Two studies have demonstrated a similar association between serum phosphate and 
LV mass in ESKD patients (Patel et al., 2009; Strozecki et al., 2001).  Strozecki et al 
used echocardiography to demonstrate a correlation between serum phosphate and 
LV mass in 22 normotensive haemodialysis patients (Strozecki et al., 2001).  These 
 110 
results were verified in a more recent study of 246 haemodialysis patients in which 
serum calcium-phosphate product was a major determinant of LV mass measured 
using CMR (Patel et al., 2009).  Our study extends these findings to the early CKD 
population, indicating that phosphate may have an influence on cardiovascular 
structure in the early stages of CKD when the majority of patients have a serum 
phosphate level that lies below the recommended treatment threshold according to 
KDIGO guidelines (KDIGO clinical practice guideline for the diagnosis, evaluation, 
prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder 
(CKD-MBD), 2009).  Improved control of hyperphosphataemia through use of a daily 
dialysis regimen has been shown to be independently associated with a reduction in 
LV mass over 12 months compared to conventional haemodialysis in ESKD patients 
(Ayus et al., 2005).  Whether similar reductions in serum phosphate are associated 
with decreased LV mass in pre-dialysis CKD patients requires further investigation. 
 
Associations have been demonstrated between serum phosphate and LVH in the 
non-CKD population.  In a cohort study of 4055 subjects with normal renal function 
(mean eGFR 119ml/min/1.73m2) and normal serum phosphate (mean 3.7 mg/dl; 1.2 
mmol/l), serum phosphate levels were associated with the presence of LVH (Foley et 
al., 2009a).  This finding was confirmed in a later study evaluating the association 
between serum phosphate and incident heart failure, which demonstrated an 
association between serum phosphate and LV mass at baseline in a cohort of 3300 
subjects with normal cardiac and renal function (Dhingra et al., 2010).  In an 
observational study of 978 patients with stable coronary artery disease and normal 
renal function, serum phosphate was associated with LV mass in males but not in 
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females (Saab et al., 2010).  In our cohort the strength of association between 
phosphate and LV mass was weaker in females compared to males.  It is possible 
that hormonal factors may explain this difference in strength of association, but this is 
an area that requires further study.   
 
Phosphate may play a causative role in the development of LVH and myocardial 
fibrosis through a number of possible actions.  The most widely accepted mechanism 
is by an increase in arterial stiffness and therefore LV afterload.  In vitro experiments 
have shown that high levels of intracellular phosphate actively promote osteogenic 
transformation of VSMC, resulting in vascular calcification (Giachelli, 2003).  
Deposition of calcium-phosphate mineral in the vasculature is highly prevalent in 
dialysis patients, and the extent of calcification correlates with severity of arterial 
stiffness and is a predictor of all cause and cardiovascular mortality in ESKD (London 
et al., 2003).  An association between vascular calcification, arterial stiffness and LV 
mass has been demonstrated in small numbers of ESKD patients (Nitta et al., 2004; 
Yildiz et al., 2005), and in larger studies of non-CKD populations serum phosphate 
has been associated with surrogate measures of arterial stiffness (Ix et al., 2009; 
Kendrick et al., 2010).  Our cohort of early CKD patients with a mean age of 54 ± 13 
years had well-controlled BP and only marginally elevated PWV (mean 8.6 ± 2.1 
m/s), which may account for the absence of any demonstrable relationship between 
PWV and serum phosphate or LV mass.  Our study thus provides no support for this 
hypothesis but being observational in nature does not exclude such a mechanism.  
Alternatively, animal studies suggest that phosphate might exert direct actions on the 
myocardium, inducing fibrosis and LVH, although the mechanism by which this 
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occurs requires further study (Amann et al., 2003; Neves et al., 2004).  Given 
concerns regarding the use of gadolinium-based contrast agents in patients with 
renal dysfunction, this was not studied in our population. 
 
An alternative explanation for the relationship between serum phosphate and LV 
mass is the existence of a common factor present in CKD that influences both of 
these variables.  Hyperphosphataemia is associated with increased levels of FGF-23, 
increased PTH and decreased vitamin D levels.  The phosphaturic hormone FGF-23 
regulates calcium-phosphate metabolism and was associated with LV mass 
independently of serum phosphate levels in a study of 220 pre-dialysis CKD patients 
(Gutierrez et al., 2009).  The authors did not demonstrate a relationship between 
serum phosphate and LV mass in their cohort.  Approximately half of their cohort was 
diabetic, however, and comprised a large proportion of Afro-Caribbean subjects.  
They also included patients with coronary artery disease and congestive heart failure.  
Furthermore, 15% of subjects with the lowest eGFR were receiving phosphate 
binders and 25% were on activated vitamin D.  All of these factors could have 
significantly affected the relationship between serum phosphate and LV mass in their 
cohort.  Levels of FGF-23 and serum phosphate are intricately linked (Gutierrez et 
al., 2005), and activation of FGF receptors has been shown to induce myocyte 
hypertrophy in vitro (Corda et al., 1997).  There is evidence from in vitro and animal 
models that FGF-23 directly induces LVH (Faul et al., 2011), but it remains unclear 
whether FGF-23 increases arterial stiffness in CKD.  The effects of FGF-23 are 
mediated by the renal co-receptor klotho, expression of which is reduced in early 
CKD.  It has been suggested that klotho is the initiator of renal mineral bone disorder 
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and abnormal phosphate handling in CKD, although its relationships with arterial 
stiffness and LV mass are currently unknown (Kuro-o, 2011).  Parathyroid hormone 
has been implicated in the development of cardiac fibrosis in animal models (Amann 
et al., 1994), and a small study of normotensive haemodialysis patients has 
demonstrated an association between PTH and echocardiographically-derived LV 
mass (Strozecki et al., 2001).  A larger study of haemodialysis patients using CMR-
derived LV mass was unable to replicate this finding (Patel et al., 2009).  We were 
also unable to demonstrate an association.  Vitamin D receptor gene polymorphisms 
have been linked to LVH in ESKD patients (Testa et al., 2010) and treatment with 
vitamin D analogues is associated with reductions in LV mass in animal models 
(Bodyak et al., 2007) and regression of LVH in haemodialysis patients (Park et al., 
1999).  It remains unclear whether these observations are due to direct 
cardiovascular effects of vitamin D or whether other mediators are involved. 
 
Phosphate plays a key role in multiple aspects of myocyte metabolism including 
regulation of cardiac energetics (Beadle and Frenneaux, 2010).  There is some 
evidence that reduced phosphate is associated with impaired myocardial 
performance (O'Connor et al., 1977), and abnormal cardiac energetics have been 
demonstrated in patients with increased LV mass and may play a role in the 
progression of structural heart disease and development of heart failure (Smith et al., 
2006).  Impaired cardiac energetics have also been demonstrated in animal models 
of CKD (Raine et al., 1993).  The relationship between cardiac energetics and a high 
phosphate state is unknown but represents an area worthy of future study. 
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There are limitations to this study.  All subjects recruited were under regular review 
by nephrologists and most had primary renal disease, potentially limiting the 
applicability of our results to patients with CKD treated solely in the community.  Data 
was not collected on serum vitamin D or FGF-23 concentrations, which would have 
provided greater insight into potential aetiological mechanisms.  Unlike these tests, 
however, serum phosphate is an easily measured variable that is widely available 
and regularly used in routine clinical practice.  The use of gadolinium-enhanced CMR 
may have provided useful insights into the effects of phosphate on myocardial 
fibrosis.  This study was observational and cross-sectional in design and thus subject 
to potential confounding from missing variables, therefore we are able only to 
describe associations and not infer causality.  Nevertheless, this is the first study to 
report a clear association between serum phosphate and LV mass, a prognostically 
important cardiovascular variable, in patients with early stage CKD.  Further 
longitudinal and interventional studies are required to determine whether the 
association between phosphate and LV mass is causative and whether lowering 
phosphate exposure is effective at reducing LV mass and therefore cardiovascular 
risk in this group of patients. 
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5 EFFECTS OF PHOSPHATE BINDING WITH SEVELAMER 
CARBONATE IN PATIENTS WITH STAGE 3 CHRONIC KIDNEY 
DISEASE 
 
5.1 Introduction 
 
5.1.1 Background 
The association between serum phosphate and increased arterial stiffness (Ix et al., 
2009) as well as increased LV mass (Chue et al., 2012; Dhingra et al., 2010; Foley et 
al., 2009a) suggests a potential mechanism by which phosphate might cause 
cardiovascular disease, although the cellular processes remain unclear.  The ability 
of the kidneys to excrete phosphate is reduced at GFRs below 60 ml/min/1.73m2.  
Serum phosphate, however, remains within the normal range until the GFR falls 
below 30 ml/min/1.73m2 due to increased production of the phosphatonins PTH and 
FGF-23, which promote urinary phosphate excretion (Craver et al., 2007; Isakova et 
al., 2011b).  Recent data have linked FGF-23 to increases in LV mass and 
development of LVH (Faul et al., 2011). 
 
It is likely that non-atheromatous pathogenic processes such as increased arterial 
stiffness and structural cardiac abnormalities predominate and are responsible for the 
excess cardiovascular morbidity and mortality in CKD (Chue et al., 2010).  Heart 
failure and arrhythmias are the commonest cause of cardiovascular death, and the 
current paradigm is that these events are a consequence of LV disease, 
predominantly LVH and fibrosis (Tonelli et al., 2006).  It is increasingly recognised 
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that LV mass, assessed as a continuous variable, has a graded relationship with 
cardiovascular risk (Schillaci et al., 2000).  Given that over 70% of incident dialysis 
patients have established LVH (Foley et al., 1995), an understanding of the early 
pathophysiology of increased LV mass and LVH is essential for the targeting of 
therapeutic strategies to attenuate cardiovascular disease in CKD. 
 
5.1.2 Hypothesis 
We hypothesised that lowering gastrointestinal phosphate absorption through use of 
the non-calcium based phosphate binder, sevelamer carbonate, would reduce serum 
levels of phosphatonins such as FGF-23, thereby reducing LV mass and arterial 
stiffness as well as improving LV systolic and diastolic function in patients with early 
stage CKD. 
 
5.2 Methods 
 
5.2.1 Study Design 
The study was a single-centre, prospective, randomised, double-blind, placebo-
controlled trial (Chue et al., 2011b).  The non-calcium-based phosphate binder 
sevelamer carbonate was chosen due to its lack of calcium content and proven 
efficacy in the treatment of hyperphosphataemia in advanced CKD (Bleyer et al., 
1999).  The study was in two phases: all subjects were administered 1600 mg of 
sevelamer carbonate with meals during a four-week open-label run-in phase; 
subjects that tolerated sevelamer then underwent 1:1 randomisation to continue a 
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further 36 weeks of treatment with either sevelamer or placebo with meals (Figure 
5-1) during the second part of the study, the blinded treatment phase. 
 
5.2.2 Setting and Participants 
Subjects were recruited from renal outpatient clinics at the Queen Elizabeth Hospital 
Birmingham, United Kingdom from 2009 to 2011 with the following inclusion criteria: 
age 18–80 years with stage 3 CKD (eGFR between 30–59 ml/min/1.73m2), total 
cholesterol <5.5 mmol/l and office BP controlled to <140/90 mmHg for ≥12 months 
prior to enrolment.  Inclusion and exclusion criteria for the study are detailed in Table 
5-1.  Treatment with vitamin D analogues and other phosphate binders was not 
permitted during study enrolment.  Regular medications unrelated to mineral 
metabolism that were taken at study entry were continued; no changes were made to 
regular medications during the study period. 
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Inclusion Criteria 
Age 18–80 years 
Chronic kidney disease stage 3 (estimated glomerular filtration rate 30–59 ml/min/1.73m2) 
Office blood pressure controlled to <140/90 mmHg for ≥12 months before entry 
Total cholesterol <5.5 mmol/l 
Exclusion Criteria 
Existing or previous treatment within the past year with a phosphate binder or vitamin D analogue 
Hyperphosphataemia (serum phosphate >1.8 mmol/l) 
Hypophosphataemia (serum phosphate <0.8 mmol/l) 
Uncontrolled secondary hyperparathyroidism (parathyroid hormone >80 pg/ml) 
Diabetes mellitus 
Pregnancy 
Women of child-bearing age not on contraception 
Bowel obstruction 
Dysphagia or other swallowing disorder 
Severe gastrointestinal motility disorders including severe constipation 
Previous major gastrointestinal tract surgery  
	  
Table 5-1.  Inclusion and exclusion criteria. 
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Figure 5-1.  Study flow diagram. 
PWA, pulse wave analysis; PWV, pulse wave velocity; CMR, cardiovascular magnetic resonance; 
DEXA, dual energy x-ray absorptiometry. 
 
5.2.3 Baseline Visit 
Subjects were assessed at baseline (week 0), at the end of the four-week open-label 
run-in phase (week 4) and at the end of the study (week 40).  The following were 
performed at the baseline visit following an overnight fast: i) questionnaire detailing 
past medical history, drug history and tobacco and alcohol consumption; ii) clinical 
examination of all systems; iii) measurement of height (in centimetres), weight (in 
kilograms), hips and waist (both in centimetres); iv) 12-lead ECG; v) office brachial 
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BP and heart rate measurement as described in section 2.3; vi) applanation 
tonometry for assessment of PWA and aortic pulse wave velocity PWV as in section 
2.2; vii) dual energy x-ray absorptiometry scanning for assessment of lumbar spine 
and femoral bone density as described in section 2.5; viii), collection of serum and 
plasma for biochemical and haematological analysis; ix) spot urine collection for 
ACR; x) 24-hour urine collection for phosphate excretion; xi) lateral lumbar spine 
radiography to assess presence and extent of aortic calcification at baseline as 
previously described (Kauppila et al., 1997); xii) transthoracic echocardiography to 
assess ventricular dimensions, systolic function and diastolic function together with 
myocardial deformation (strain), ventricular rotation and twist as detailed in section 
2.4; xiii) CMR to determine LV mass, volumes and function together with aortic 
distensibility as described previously in section 2.1; and xiv) 24-hour ambulatory BP 
monitoring as detailed in section 2.3.  Eligible female subjects of childbearing age 
underwent urine pregnancy testing prior to entry into the study.  Reproducibility for 
the primary endpoint of LV mass was assessed using the methods described in 
section 2.1.3.  No dietary changes were enforced during the study and no dietary 
counselling was provided. 
 
5.2.4 Open-Label Run-In Phase 
Following baseline studies all subjects were prescribed 1600mg (two 800mg tablets) 
of sevelamer carbonate with meals for 4 weeks during an open-label run-in phase to 
assess tolerability, short-term efficacy, compliance and side effect profile.  This was 
reduced to 800mg with meals only if persistent adverse effects or 
hypophosphataemia occurred.  Subjects were seen at week 2 to monitor for adverse 
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effects that may be related to treatment, to assess compliance and for monitoring of 
serum phosphate and renal function.  In the event that serum phosphate fell below 
0.8 mmol/l, the dose of sevelamer was halved to 800 mg with meals (Table 5-2) and 
levels rechecked two weeks later to ensure serum phosphate was ≥0.8 mmol/l.  If 
serum phosphate remained below this level after 6 weeks and/or a dose reduction 
subjects were withdrawn from the study after a final set of measurements. 
 
 Serum Phosphate (mmol/l) Action 
<0.8 Reduce dose to 800 mg tds and continue to week 4 
Week 2 
≥0.8 Continue to week 4 
<0.8 Reduce dose to 800 mg tds and continue to week 6 
If already on 800 mg tds withdraw from study after week 4 visit Week 4 
≥0.8 Randomise 
<0.8 Final measurements and withdraw from study 
Week 6 
≥0.8 Randomise 
	  
Table 5-2.  Management of serum phosphate levels during run-in phase. 
 
5.2.5 Randomisation and Treatment Phase 
At the end of the open-label run-in phase subjects attended for a second study visit 
and the following were repeated following an overnight fast: i) office brachial BP and 
heart rate; ii) applanation tonometry to determine aortic pulse wave velocity; iii) 
applanation tonometry to derive central pressure waveforms from pulse wave 
analysis; iv) collection of serum and plasma for haematological and biochemical 
analysis; v) collection of a spot urine sample to determine ACR; and vi) 24-hour urine 
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collection for determination of phosphate excretion.  Samples were collected at the 
same time of day as on the baseline visit. 
 
Participants were then randomised by computer assignment to continue 1600 mg (or 
half-dose) sevelamer with meals or receive an identical placebo for the remaining 36 
weeks.  During this blinded treatment phase subjects underwent monitoring of renal 
function and serum calcium, phosphate and PTH every four weeks (Figure 5-1).  
Serum phosphate levels were managed according to a pre-defined protocol during 
the treatment period (Table 5-3).  Adherence to study medication was also assessed 
at every patient contact (every four weeks) using pill counts of returned medication, 
taking into consideration the typical number of meals per day.  The number of pills 
taken was determined by subtracting the number of pills returned from the number of 
pills dispensed; compliance was then calculated as a percentage of prescribed pills 
taken.  The occurrence of any adverse effects was assessed and documented at 
each patient visit. 
 
Participants were regularly encouraged to take tablets with meals as prescribed; 
recommendations to improve compliance were given when deemed appropriate.  
These suggestions included: i) use of a small container of study medication in the 
event of meals taken outside the home; ii) a drug diary; iii) involvement of relatives to 
assist with medication reminders; iv) use of pill counts; and v) patient education to 
ensure understanding of the study and its aims.  All measurements performed at the 
initial main study visit (except for the plain lateral abdominal radiograph) were 
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repeated at a final visit 40 weeks after baseline studies, marking the end of subject 
participation in the study. 
 
 
 Serum Phosphate (mmol/l) Action 
<0.8 Recheck serum phosphate within 1 week 
At visit 
≥0.8 Continue routine 4-weekly checks 
<0.8 Reduce treatment/placebo dose to 800 mg tds 
and recheck in 2 weeks Within 1 week of visit 
≥0.8 Continue routine 4-weekly checks 
<0.8 Final measurements and withdraw from study 
2 weeks after visit 
≥0.8 Continue routine 4-weekly checks 
	  
Table 5-3.  Management of serum phosphate levels during treatment phase. 
 
5.2.6 Subject Withdrawal 
Withdrawal criteria are listed in Table 5-4.  The average serum phosphate level of 
patients with stage 3 CKD enrolled in a previous study by the investigators was 1.2 ± 
0.2 mmol/l (Edwards et al., 2009).  It was therefore felt unlikely that significant 
numbers of participants would need to be withdrawn because of 
hypophosphataemia.  The majority of patients with stage 3 CKD do not require 
phosphate-binding medication for overt hyperphosphataemia and the prevention of 
metabolic bone disease.  If any subjects in the placebo group developed serum 
phosphate >1.8 mmol/l, they would have been withdrawn from the study and non-trial 
therapy with appropriate phosphate binders would have been administered.  Subjects 
would also have been withdrawn if they developed persistent hypophosphataemia, 
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defined as serum phosphate <0.8 mmol/l on two sequential blood tests, or persistent 
adverse effects related to treatment, despite halving of therapy to 800 mg three times 
daily.  Subjects withdrawn after randomisation were included in final intention-to-treat 
analyses where data were available. 
 
Pregnancy 
Hypophosphataemia (serum phosphate <0.8 mmol/l despite dose reduction of treatment/placebo) 
Hyperphosphataemia (serum phosphate >1.8 mmol/l in subjects receiving placebo) 
Occurrence of any serious adverse event, intercurrent illness or laboratory abnormality which, in 
the opinion of the investigators, warrants the subject’s permanent withdrawal from the study 
Poor compliance with study medication 
Poor attendance at study visits 
Subject inability to tolerate study medication due to side effect profile 
Subject decision to withdraw 
Deteriorating renal function 
Subject lost to follow-up (loss of contact before final study visit) 
	  
Table 5-4.  Withdrawal criteria. 
 
5.2.7 Biochemical Analyses 
Serum and plasma were stored at -80oC for later analysis for FGF-23, soluble klotho 
and vitamin D.  Methods for these assays are detailed in section 2.7.  Twenty-four-
hour urine collections were used to determine urinary phosphate excretion (mmol/24 
hours), urinary phosphate concentration (mmol/l) and fractional excretion of 
phosphate, calculated by the equation: 
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Fractional excretion of phosphate allows correction for incomplete urine collections 
over 24 hours and standardises urinary phosphate excretion according to degree of 
renal impairment (Isakova et al., 2011b). 
 
5.2.8 Outcomes and Follow-up 
The primary endpoint for the study was change in LV mass from baseline assessed 
using CMR after 40 weeks of treatment.  Left ventricular mass is a powerful predictor 
of cardiovascular and all-cause mortality in the general population (Levy et al., 1990; 
Schillaci et al., 2000) and in CKD (Silberberg et al., 1989).  A therapeutic reduction in 
LV mass has been shown to effectively reduce cardiovascular morbidity and mortality 
(Devereux et al., 2004; Wachtell et al., 2007).  Secondary endpoints included change 
in aortic distensibility measured by CMR, change in arterial stiffness as assessed 
using PWV and PWA, change in LV function as assessed by tissue Doppler imaging, 
strain and strain rate analysis and torsion, change in serum FGF-23 and change in 
bone density on DEXA scanning. 
 
5.2.9 Monitoring and Safety Assessments 
All adverse events, including serious adverse events (SAEs), were recorded and 
followed up for the duration of the study or until resolution.  Assessment of adverse 
events was performed by the study investigators.  All SAEs were graded and 
reported to the sponsor.  Any suspected unexpected serious adverse reactions were 
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reported to the sponsor, ethics committee and Medicines and Healthcare products 
Regulatory Agency. 
 
5.2.10 Power Calculation 
Sample size calculations were based on the primary endpoint of change in LV mass 
after 40 weeks of treatment.  A previous study by our group evaluating the 
cardiovascular effects of spironolactone in patients with early chronic kidney disease 
revealed a 14 ± 12 gram drop in LV mass from baseline following 40 weeks of 
therapy (Edwards et al., 2009).  Using data from this previous study and a more 
conservative estimate of effect size, it was calculated that 55 subjects in each arm 
would provide >90% power of detecting an 8 gram difference in the change in LV 
mass from baseline to 40 weeks using a two-tailed t-test at the 5% significance level, 
assuming a standard deviation of the change in LV mass from baseline of 12 grams.  
Recruiting 60 subjects to each group would allow a 10% withdrawal or dropout rate. 
 
5.2.11 Statistical Analyses 
Statistical analyses were performed as described in the methods section 2.8.  
Differences between groups after 40 weeks of treatment were assessed using 
repeated measures analysis of variance.  Analysis was by intention-to-treat. 
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5.3 Results 
 
5.3.1 Recruitment 
Recruitment for the study began in February 2009 and was completed in January 
2011.  During this period a total of 1297 patients with non-diabetic CKD were 
screened in the outpatient renal clinics at University Hospital Birmingham NHS 
Foundation Trust (Figure 5-2).  695 were not eligible for the study, leaving 602 
potential subjects.  494 of these were approached and formally invited to take part in 
the study; the remaining 108 failed to attend their clinic appointments or were 
missed.  Of those approached, 120 agreed to participate, 197 declined and 177 did 
not return the reply slip included with the study information. 
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Figure 5-2.  Study recruitment, follow-up and withdrawal. 
 
5.3.2 Baseline Results 
Demographic data for the 120 subjects recruited into the study are detailed in Table 
5-5.  The mean age was 55 ± 14 years with 54% male.  The prevalence of 
hypertension was high at 73% and 11% of subjects had a history of established 
cardiovascular disease.  Aortic calcification was present in 48% of subjects at 
baseline with calcification scores ranging from 1 to 18 (median score of 4 for those 
with calcification).  Compared to baseline data of participants of the Calcification 
Outcome in Renal Disease (CORD) study, an epidemiological study that aimed to 
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identify risk factors for vascular calcification and arterial stiffness (Honkanen et al., 
2008), our cohort comprised subjects who were younger (mean age 55 vs. 61 years), 
had fewer males (54 vs. 61%) and had a lower prevalence of previous cardiovascular 
disease (11 vs. 44%). 
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Demographic  
Age (years) 55 ± 14 
Males 65 (54) 
Hypertension 88 (73) 
Ethnicity:  
 Caucasian 105 (88) 
 Afro-Caribbean 4 (3) 
 Asian Indian 7 (6) 
 Asian Pakistani 4 (3) 
Previous cardiovascular disease: 13 (11) 
 Transient ischaemic attack 6 (5) 
 Stroke 3 (3) 
 Coronary artery disease 6 (5) 
 Peripheral vascular disease 2 (2) 
Current smoker 21 (18) 
Previously smoked 44 (37) 
Pack years* 15 (4–25) 
Height (cm) 169 ± 10 
Weight (kg) 83 ± 16 
Body mass index (kg/m2) 29.0 ± 5.5 
Body surface area (m2) 1.9 ± 0.2 
Hips (cm) 105 ± 12 
Waist (cm) 98 ± 13 
Hip: waist ratio 1.1 ± 0.1 
 
Table 5-5.  Baseline demographic data. 
*n= 65 for those with a history of smoking.  Data are mean ± standard deviation, frequency 
(percentage) or median (interquartile range). 
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Causes of kidney disease are detailed in Table 5-6.  The cause of renal disease was 
diagnosed by biopsy in 53% and ultrasound in 34% (predominantly adult polycystic 
kidney disease and reflux nephropathy).  Medications are detailed in Table 5-7.  Most 
patients were receiving either an ACEI or ARB as per national guidelines. 
 
Diagnosis  
Hypertensive nephropathy 16 (13) 
IgA nephropathy 13 (11) 
Reflux nephropathy 13 (11) 
Adult polycystic kidney disease 12 (10) 
Systemic vasculitis 9 (8) 
Focal segmental glomerulosclerosis 8 (7) 
Nephrectomy for neoplasm 5 (4) 
Other glomerulonephritis 11 (9) 
Renovascular disease 4 (3) 
Nephrolithiasis 3 (3) 
Obstructive nephropathy 3 (3) 
Cystic renal disease 2 (2) 
Other 18 (15) 
Unknown 3 (3) 
 
Table 5-6.  Renal diagnoses. 
Data are frequency (percentage). 
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Medication  
ACEI 64 (53) 
ARB 32 (27) 
ACEI or ARB 92 (77) 
Aspirin 23 (19) 
Warfarin 1 (1) 
Statin 53 (44) 
Fibrate 3 (3) 
Ezetimibe 3 (3) 
β-blocker 20 (17) 
Calcium-channel blocker 33 (28) 
Diuretic 32 (27) 
α-blocker 17 (14) 
Aldosterone antagonist 2 (2) 
Nitrate 1 (1) 
Calcium supplement 8 (7) 
Bisphosphonate 9 (8) 
Immunosuppressant 23 (19) 
Erythropoietin 1 (1) 
Number of antihypertensives 1.7 ± 1.2 
 
Table 5-7.  Medication at study entry. 
Data are frequency (percentage) or mean ± standard deviation.  ACEI, angiotensin converting enzyme 
inhibitor; ARB, angiotensin receptor blocker. 
 
Biochemical and haematological data are summarized in Table 5-8 to Table 5-10.  
Mean GFR was 50 ± 13 ml/min/1.73m2.  Mean serum phosphate, calcium, PTH, 
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klotho and vitamin D levels were within the normal laboratory reference range.  
Serum FGF-23 levels and urinary fractional excretion of phosphate were both above 
the upper limit of normal from published reference ranges (Isakova et al., 2011b; 
Yamazaki et al., 2002). 
 
Biochemical and haematological parameter  
Haemoglobin (g/dl) 13.3 ± 1.5 
Sodium (mmol/l) 142 ± 3 
Potassium (mmol/l) 4.4 ± 0.4 
Urea (mmol/l) 8.9 ± 3.2 
Creatinine (µmol/l) 123 ± 33 
Estimated glomerular filtration rate (ml/min/1.73m2) 50 ± 13 
Albumin (g/l) 44 ± 4 
Bilirubin (µmol/l) 9 ± 4 
Total protein (g/l) 70 ± 6 
Aspartate aminotransferase (U/l) 23 ± 9 
Total cholesterol (mmol/l) 4.92 ± 1.22 
High density lipoprotein cholesterol (mmol/l) 1.45 ± 0.51 
Low density lipoprotein cholesterol (mmol/l) 2.74 ± 0.92 
Triglycerides (mmol/l) 1.2 (0.8–2.0) 
Glucose (mmol/l) 5.1 ± 1.0 
Bicarbonate (mmol/l) 26.7 ± 2.8 
Uric acid (µmol/l) 414 ± 111 
hsCRP (µg/ml) 2.17 (1.09–6.35) 
 
Table 5-8.  Baseline biochemical and haematological data: serum and plasma. 
Data are mean ± standard deviation or median (interquartile range).  hsCRP, high sensitive C-reactive 
protein. 
 134 
Phosphate and calcium metabolism  
Alkaline phosphatase (U/l) 182 ± 56 
Phosphate (mmol/l) 1.03 ± 0.16 
Corrected calcium (mmol/l) 2.21 ± 0.09 
Calcium phosphate product 2.3 ± 0.4 
Parathyroid hormone (ng/l) 52 (38–71) 
Fibroblast growth factor 23 (pg/ml) 68 (50–85) 
Soluble klotho (pg/ml) 943 ± 396 
1,25-dihydroxyvitamin D (pmol/l) 76 ± 31 
25-hydroxyvitamin D (pmol/l) 56 ± 30 
 
Table 5-9.  Baseline markers of calcium and phosphate metabolism. 
Data are mean ± standard deviation or median (interquartile range). 
 
Urine  
Albumin: creatinine ratio (mg/mmol) 6.3 (0.8–48.3) 
24-hour urine volume (ml) 2015 ± 805 
24-hour phosphate excretion (mmol) 22.3 ± 8.2 
24-hour urinary phosphate concentration (mmol/l) 11.7 ± 5.0 
Fractional excretion of phosphate (%) 20.8 (12.7–32.3) 
 
Table 5-10.  Baseline biochemical data: urine. 
Data are mean ± standard deviation or median (interquartile range). 
 
Blood pressures and arterial stiffness indices are shown in Table 5-11 and Table 
5-12.  Despite a high prevalence of hypertension (73%), BP was well controlled with 
an office mean of 128/71 mmHg and 24-hour ambulatory mean of 124/71 mmHg. 
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Office brachial blood pressure  
Systolic (mmHg) 128 ± 17 
Diastolic (mmHg) 71 ± 11 
Pulse pressure (mmHg) 57 ± 17 
Mean arterial pressure (mmHg) 91 ± 11 
Heart rate (beats/minute) 63 ± 10 
Central aortic blood pressure  
Systolic (mmHg) 117 ± 17 
Diastolic (mmHg) 72 ± 11 
Pulse pressure (mmHg) 45 ± 16 
Mean arterial pressure (mmHg) 91 ± 12 
Arterial stiffness indices  
AIx 26.1 ± 11.9 
AIx75 19.9 ± 11.8 
Pulse wave velocity (m/s) 8.9 (7.3–11.2) 
Pulse wave velocityadj (m/s)* 9.1 (7.7–10.6) 
 
Table 5-11.  Baseline haemodynamic and arterial stiffness data. 
*Adjusted for mean arterial pressure.  Data are mean ± standard deviation or median (interquartile 
range).  AIx, augmentation index; AIx75, augmentation index adjusted to heart rate of 75bpm. 
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24 hour blood pressure data  
Day-time:  
 Systolic (mmHg) 128 ± 12 
 Diastolic (mmHg) 75 ± 10 
 Pulse pressure (mmHg) 53 ± 11 
 Mean arterial (mmHg) 93 ± 9 
 Heart rate (beats/minute) 75 ± 11 
Night-time*:  
 Systolic (mmHg) 116 ± 16 
 Diastolic (mmHg) 64 ± 10 
 Pulse pressure (mmHg) 51 ± 12 
 Mean arterial (mmHg) 82 ± 11 
 Heart rate (beats/minute) 66 ± 11 
24-hour average:  
 Systolic (mmHg) 124 ± 12 
 Diastolic (mmHg) 71 ± 9 
 Pulse pressure (mmHg) 53 ± 11 
 Mean arterial (mmHg) 89 ± 9 
 Heart rate (beats/minute) 72 ± 10 
Nocturnal dipper* 58 (50) 
 
Table 5-12.  Baseline 24-hour ambulatory blood pressure data. 
*Data available for 116 subjects.  Data are mean ± standard deviation or frequency (percentage). 
 
Baseline 2-dimensional echocardiographic parameters are shown in Table 5-13 and 
Table 5-14.  Mean LV dimensions and ejection fraction were within normal limits.  
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Strain, strain rate, rotation and twist data obtained with speckle tracking analysis are 
displayed in Table 5-15. 
 
Left ventricular chamber measurement  
Interventricular septum diastole (cm) 0.9 ± 0.2 
Left ventricular internal dimension diastole (cm) 4.9 ± 0.7 
Left ventricular internal dimension systole (cm) 3.0 ± 0.6 
Left ventricular posterior wall diastole (cm) 0.9 ± 0.2 
Fractional shortening (%) 39 ± 10 
Left ventricular ejection fraction (%) 62 ± 6 
Left ventricular end diastolic volume index (ml/m2) 49 ± 11 
Left atrial volume index (ml/m2) 28 ± 8 
Left ventricular mass index (g/m2) 92 ± 34 
 
Table 5-13.  Baseline echocardiographic data: left ventricular chamber quantification. 
Data are mean ± standard deviation. 
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Left ventricular functional parameter  
Transmitral E (m/s) 0.68 ± 0.13 
Transmitral A (m/s) 0.71 ± 0.18 
Transmitral E/A 0.9 (0.8–1.1) 
E wave deceleration time (ms) 223 ± 54 
Velocity propagation (cm/s) 57 (46–75) 
Transmitral E/velocity propagation 1.13 ± 0.48 
E/mean e’ 7.6 (6.5–9.4) 
Isovolumic relaxation time (ms) 110 ± 27 
Pulmonary vein S:D 1.21 ± 0.34 
a duration – A duration (ms) -39 ± 24 
Left ventricular Tei index 0.32 ± 0.07 
Anterolateral s’ (m/s) 8.9 ± 2.4 
Anterolateral e’ (m/s) 10.3 ± 3.8 
Inferoseptal s’ (m/s) 9.1 ± 2.1 
Inferoseptal e’ (m/s) 7.8 ± 2.7 
Mean s’ (m/s) 9.0 ± 1.9 
Mean e’ (m/s) 9.1 ± 3.0 
Calibrated integrated backscatter (dB) -15.7 ± 6.4 
Right ventricular measurements  
Right ventricular internal dimension (cm) 3.1 ± 0.7 
Right ventricular Tei index 0.48 ± 0.27 
TAPSE (mm) 26 ± 5 
 
Table 5-14.  Baseline echocardiographic data: left ventricular function and right ventricular 
measurements. 
Data are mean ± standard deviation or median (interquartile range).  TAPSE, tricuspid annular plane 
systolic excursion. 
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Left ventricular rotation  
Basal peak rotation (o)* -9.8 ± 2.7 
Time to peak basal rotation (ms)* 342 ± 44 
Apical peak rotation (o)† 12.0 ± 4.1 
Time to peak apical rotation (ms)† 359 ± 57 
Left ventricular twist‡  
Peak twist (o) 19.7 ± 4.9 
Time to peak twist (ms) 350 ± 47 
Peak systolic twist rate (o) 124 ± 28 
Time to peak systolic twist rate (ms) 182 ± 52 
Peak early diastolic untwist rate (o) -134 ± 41 
Time to peak early diastolic untwist (ms) 447 ± 50 
Longitudinal strain§  
Global longitudinal peak systolic strain (%) -19.3 ± 2.6 
Global longitudinal end systolic strain (%) -19.1 ± 2.6 
Global longitudinal peak systolic strain rate (s-1) -1.35 ± 0.22 
Global longitudinal early diastolic strain rate (s-1) 1.58 ± 0.32 
 
Table 5-15.  Baseline echocardiographic data: strain, rotation and twist. 
*Data available in 59 pts; †data available in 84 patients; ‡data available in 53 patients; §data available 
in 112 patients.  Data are mean ± standard deviation. 
 
Cardiovascular magnetic resonance imaging was unable to be performed in 13 
subjects (11%) due to claustrophobia.  Baseline ventricular measurements are 
shown for the 107 subjects that underwent CMR in Table 5-16.  Mean LV mass, LV 
systolic and diastolic function and LV volumes were within normal limits; only one 
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patient had LVH.  Aortic distensibility data derived from CMR are shown in Table 
5-17. 
 
Left ventricle  
Ejection fraction (%) 74 ± 7 
End diastolic volume index (ml/m2) 60 ± 16 
End systolic volume index (ml/m2) 16 ± 7 
Stroke volume index (ml/m2) 44 ± 9 
Cardiac index (l/min/m2) 3.0 ± 0.8 
Mass (g) 101 ± 30 
Mass index (g/m2) 52 ± 13 
Left ventricular hypertrophy 1 (1) 
Right ventricle  
Ejection fraction (%) 73 ± 7 
End diastolic volume index (ml/m2) 59 ± 14 
End systolic volume index (ml/m2) 16 ± 7 
Stroke volume index (ml/m2) 42 ± 9 
Cardiac index (l/min/m2) 2.9 ± 0.8 
 
Table 5-16.  Baseline cardiac magnetic resonance imaging data: left and right ventricle. 
Data available for 107 subjects.  Data are mean ± standard deviation or frequency (percentage). 
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Aortic distensibility  
Ascending aortic distensibility (x10-3 mmHg-1) 2.7 ± 2.0 
Ascending aortic distensibilityadj (x10-3 mmHg-1)* 2.6 ± 2.0 
Proximal descending aortic distensibility (x10-3 mmHg-1) 3.3 ± 1.6 
Proximal descending aortic distensibilityadj (x10-3 mmHg-1)* 3.2 ± 1.5 
Distal descending aortic distensibility (x10-3 mmHg-1) 4.2 ± 2.1 
Distal descending aortic distensibilityadj (x10-3 mmHg-1)* 4.1 ± 2.0 
Ascending: proximal descending ratio 0.76 ± 0.30 
Ascending: distal descending ratio 0.61 ± 0.31 
Proximal descending: distal descending ratio 0.82 ± 0.28 
 
Table 5-17.  Baseline cardiac magnetic resonance imaging data: aortic distensibility. 
Data available for 107 subjects.  *Adjusted for mean arterial pressure.  Data are mean ± standard 
deviation. 
 
Bone density data for the lumbar spine and both hips are shown in Table 5-18.  28% 
of subjects had evidence of osteopenia at one or more sites; one patient had overt 
osteoporosis. 
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Bone density  
Left hip:  
 Bone mineral density (g/cm2) 1.00 ± 0.14 
 T-score 0.03 ± 1.00 
 Z-score 0.61 ± 1.08 
Right hip:  
 Bone mineral density (g/cm2) 0.99 ± 0.14 
 T-score 0.00 ± 0.95 
 Z-score 0.57 ± 1.05 
Both hips:  
 Bone mineral density (g/cm2) 1.00 ± 0.14 
 T-score 0.01 ± 0.98 
 Z-score 0.59 ± 1.06 
Lumbar spine:  
 Bone mineral density (g/cm2) 1.09 ± 0.17 
 T-score 0.16 ± 1.53 
 Z-score 0.94 ± 1.67 
Osteopenia 34 (28) 
Osteoporosis 1 (1) 
 
Table 5-18.  Baseline bone mineral density data. 
Data are mean ± standard deviation or frequency (percentage).  
 
5.3.3 Open-Label Run-In Phase 
Data are available for 112 subjects at week 0 and week 4.  Biochemical and 
haematological data are displayed in Table 5-19 and Table 5-20.  Following four 
weeks of open-label treatment with sevelamer carbonate significant reductions in 
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serum cholesterol (4.91 ± 1.20 vs. 4.46 ± 1.13 mmol/l, P<0.01), low density 
lipoprotein cholesterol (2.74 ± 0.84 vs. 2.26 ± 0.85 mmol/l, P<0.01), serum urate (415 
± 111 vs. 396 ± 97 µmol/l, P<0.01), hsCRP (2.17 [1.09–6.35] vs. 1.74 [0.79–5.12] 
µg/ml, P<0.01) and urinary ACR (5.7 [0.8–42.7] vs. 4.2 [1.9–46.7] mg/mmol, P<0.01) 
were seen.  There was also a small but statistically significant increase in serum 
phosphate (1.02 ± 0.17 vs. 1.05 ± 0.16 mmol/l, P<0.05).  Levels of both 1,25-
dihydroxyvitamin D and 25-hydroxyvitamin D decreased significantly after 4 weeks of 
treatment, but this was not accompanied by any significant changes in FGF-23, 
klotho or measures of 24-hour urinary phosphate excretion (Table 5-20).  Small but 
significant changes were also noted with haemoglobin, serum albumin, total protein, 
aspartate aminotransferase, alkaline phosphatase and triglycerides. 
 
Haemodynamic data and indices of arterial stiffness are shown in Table 5-21.  There 
was a small but significant decrease in brachial systolic BP (128 ± 16 vs. 125 ± 16 
mmHg, P<0.05), brachial pulse pressure (57 ± 17 vs. 54 ± 16 mmHg, P<0.01) and 
central pulse pressure (45 ± 16 vs. 43 ± 15 mmHg, P<0.01), but no observed 
differences in central systolic BP or any indices of arterial stiffness. 
 
Eleven subjects were withdrawn during the four-week open-label run-in phase (five 
withdrew consent, two were unable to tolerate the study drug, one had persistent 
hypophosphataemia and three subjects did not comply with study instructions) 
leaving 109 subjects to be randomised to receive sevelamer (n=55) or placebo 
(n=54; Figure 5-2). 
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 Week 0 Week 4 
Haematological:   
 Haemoglobin (g/dl) 13.3 ± 1.5 13.0 ± 1.6* 
 White cell count (x109/l) 6.7 ± 1.9 6.5 ± 1.8 
 Platelets (x109/l) 240 ± 59 236 ± 59 
Biochemical:   
 Urea (mmol/l) 8.9 ± 3.2 9.0 ± 3.5 
 Creatinine (µmol/l) 124 ± 33 126 ± 34 
 Estimated glomerular filtration rate (ml/min/1.73m2) 50 ± 13 49 ± 13 
 Albumin (g/l) 44 ± 4 43 ± 4† 
 Total protein (g/l) 70 ± 6 68 ± 6* 
 Bilirubin (µmol/l) 9.2 ± 4.2 9.4 ± 5.3 
 Aspartate aminotransferase (U/l) 23 ± 10 26 ± 13‡ 
 Bicarbonate (mmol/l) 26.7 ± 2.9 27.0 ± 2.8 
 Total cholesterol (mmol/l) 4.91 ± 1.20 4.46 ± 1.13* 
 High density lipoprotein cholesterol (mmol/l) 1.45 ± 0.53 1.44 ± 0.52 
 Low density lipoprotein cholesterol (mmol/l) 2.74 ± 0.84 2.26 ± 0.85* 
 Triglycerides (mmol/l) 1.1 (0.8–1.9) 1.3 (0.9–1.9)‡ 
 Glucose (mmol/l) 5.1 ± 1.0 5.0 ± 1.1 
 Urate (µmol/l) 415 ± 111 396 ± 97* 
 hsCRP (µg/ml) 2.17 (1.09–6.35) 1.74 (0.79–5.12)† 
 
Table 5-19.  Biochemical and haematological data from the 4-week open-label run-in phase. 
*P<0.001; †P<0.005; ‡P<0.05.  Data are mean ± standard deviation or median (interquartile range).  
Analysed with paired t-tests, n=112.  hsCRP, high sensitive C-reactive protein. 
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 Week 0 Week 4 
Serum and plasma markers of phosphate metabolism:   
 Alkaline phosphatase (U/l) 181 ± 56 194 ± 69* 
 Phosphate (mmol/l) 1.02 ± 0.17 1.05 ± 0.16† 
 Corrected calcium (mmol/l) 2.21 ± 0.10 2.21 ± 0.08 
 Parathyroid hormone (ng/l) 53 (38–71) 55 (44–71) 
 Fibroblast growth factor 23 (pg/ml) 69 (51–85) 68 (53–86) 
 Soluble klotho (pg/ml) 936 ± 403 945 ± 359 
 1,25-dihydroxyvitamin D (pmol/l) 76 ± 31 68 ± 25* 
 25-hydroxyvitamin D (nmol/l) 55 ± 29 52 ± 28‡ 
Urine:   
 Albumin: creatinine ratio (mg/mmol) 5.7 (0.8–42.7) 4.2 (1.9–46.7)‡ 
 24-hour urine volume (ml)§ 2021 ± 778 2073 ± 903 
 24-hour phosphate excretion (mmol)§ 22.7 ± 7.8 21.4 ± 10.2 
 Phosphate concentration (mmol/l)§ 11.7 ± 4.7 11.0 ± 5.9 
 Fractional excretion of phosphate§ 21.2 (13.1–32.8) 20.6 (13.8–33.2) 
 
Table 5-20.  Markers of phosphate metabolism and urinary data from the 4-week open-label run-in 
phase. 
*P<0.001; †P<0.05; ‡P<0.005; §data available for 101 subjects.  Data are mean ± standard deviation 
or median (interquartile range).  Analysed with paired t-tests, n=112.
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  Week 0 Week 4 
Haemodynamics:   
 Brachial systolic BP (mmHg) 128 ± 16 125 ± 16* 
 Brachial diastolic BP (mmHg) 71 ± 11 71 ± 10 
 Brachial pulse pressure (mmHg) 57 ± 17 54 ± 16† 
 Brachial mean arterial pressure (mmHg) 90 ± 11 90 ± 11 
 Central systolic BP (mmHg) 117 ± 16 115 ± 16 
 Central diastolic BP (mmHg) 72 ± 11 72 ± 10 
 Central pulse pressure (mmHg) 45 ± 16 43 ± 15† 
 Central mean arterial pressure (mmHg) 91 ± 11 90 ± 11 
 Heart rate (beats/minute) 63 ± 10 64 ± 11* 
Arterial stiffness indices:   
 AIx 25.8 ± 12.0 25.1 ± 11.6 
 AIx75 19.7 ± 11.9 19.8 ± 10.8 
 Pulse wave velocity (m/s) 9.0 (7.4–11.2) 8.7 (7.4–10.6) 
 Pulse wave velocityadj (m/s)‡ 9.1 (7.7–10.6) 8.6 (7.4–10.3) 
 
Table 5-21.  Haemodynamics and indices of arterial stiffness at baseline and week 4. 
*P<0.05; †P<0.01; ‡adjusted for mean arterial pressure.  Data are mean ± standard deviation or 
median (interquartile range).  Analysed with paired t-tests, n=112.  BP, blood pressure; AIx, 
augmentation index; AIx75, augmentation index adjusted to heart rate of 75bpm. 
 
5.3.4 Follow-up 
Participants were well matched at baseline (Table 5-22 to Table 5-24).  There were 
significantly more individuals with hypertension in the placebo group (83% vs. 60%, 
P<0.05) and consequently a greater mean number of antihypertensive agents (1.9 ± 
1.2 vs. 1.4 ± 1.2, P<0.05) prescribed per patient.  Aortic calcification was present in 
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35% of subjects in the placebo group and 55% in the sevelamer group (P=0.06).  Of 
those randomised, twelve patients (11%) did not complete follow-up to 40 weeks 
(seven in placebo group, five in sevelamer group, P=0.6; Figure 5-2).  Six patients 
declined continued participation in the study due to difficulties with tablet frequency 
and a wish to discontinue study visits, four experienced persistent 
hypophosphataemia despite dose reduction of study drug and two became intolerant 
of medication.  No patients died. 
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 Placebo 
n=54 
Sevelamer 
n=55 
Age (years) 55 ± 14 55 ± 13 
Male gender 28 (52) 32 (58) 
Hypertension 45 (83) 33 (60)* 
Hypercholesterolaemia 28 (52) 25 (46) 
Ethnicity:   
 Caucasian 48 (89) 47 (86) 
 Afro-Caribbean 0 (0) 4 (7) 
 Asian Indian 3 (6) 3 (6) 
 Asian Pakistani 3 (6) 1 (2) 
Previous cardiovascular disease 5 (9) 6 (11) 
Smoking status:   
 Current smoker 8 (15) 8 (15) 
 Previous smoker 17 (32) 24 (44) 
Alcohol drinker 29 (54) 36 (66) 
Body mass index (kg/m2) 29.7 ± 6.7 28.6 ± 4.3 
Hip: waist ratio 1.08 ± 0.10 1.08 ± 0.09 
Aortic calcification present 19 (35) 30 (55) 
 
Table 5-22.  Baseline demographics of placebo and treatment group. 
*P<0.05.  Data are mean ± SD or frequency (%).  Analysed using independent samples t-test or χ2. 
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 Placebo 
n=54 
Sevelamer 
n=55 
Hypertensive nephropathy 10 (19) 3 (6)* 
IgA nephropathy 3 (6) 7 (13) 
Reflux nephropathy 4 (7) 7 (13) 
Adult polycystic kidney disease 8 (15) 4 (7) 
Systemic vasculitis 5 (9) 4 (7) 
Lupus nephritis 0 (0) 3 (6) 
Focal segmental glomerulosclerosis 4 (7) 3 (6) 
Nephrectomy for neoplasm 2 (4) 3 (6) 
Other glomerulonephritis 2 (4) 3 (6) 
Other 15 (28) 16 (29) 
Unknown 1 (2) 2 (4) 
 
Table 5-23.  Renal diagnoses of placebo and treatment group. 
*P<0.05.  Data are frequency (percentage) and analysed using χ2. 
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 Placebo 
n=54 
Sevelamer 
n=55 
Angiotensin converting enzyme inhibitor 32 (59) 25 (46) 
Angiotensin receptor blocker 16 (30) 13 (24) 
Aspirin 9 (17) 10 (18) 
Aldosterone antagonist 1 (2) 1 (2) 
Beta blocker 12 (22) 6 (11) 
Calcium channel blocker 15 (28) 14 (26) 
Diuretic 19 (35) 10 (18) 
Statin 26 (48) 24 (44) 
Other lipid lowering therapy 3 (6) 3 (6) 
Prednisolone 8 (15) 9 (16) 
Immunosuppressant 11 (20) 11 (20) 
Number of antihypertensives 1.9 ± 1.2 1.4 ± 1.2* 
 
Table 5-24.  Baseline medication use in placebo and treatment group. 
*P<0.05.  Data are frequency (percentage) or mean ± standard deviation.  Analysed using 
independent samples t-test or χ2. 
 
5.3.5 Treatment Effects 
Data for effects of treatment compared to placebo over 40 weeks are shown in Table 
5-25 to Table 5-34.  After 40 weeks of treatment with sevelamer carbonate there was 
a significant decrease in total cholesterol when compared to placebo (P<0.05) but 
LDL and HDL did not change significantly (Table 5-25).  There were no significant 
changes in any other biochemical parameters measured, in particular phosphate, 
calcium, PTH, FGF-23, klotho, vitamin D or urinary phosphate excretion (Table 5-26).  
 151 
There were no significant changes in the primary endpoint of LV mass (Figure 5-3 
and Table 5-27) or LV mass indexed to body surface area.  There were no changes 
in any indices of LV systolic or diastolic function (Table 5-27 and Table 5-30), strain 
or twist (Table 5-31).  There were no observed differences in peripheral office, central 
or ambulatory BP, or in any indices of arterial stiffness (Table 5-32, Table 5-28 and 
Table 5-33).  Bone density remained unaltered in both groups (Table 5-34).  When 
patients with aortic calcification were excluded from analyses no significant 
differences were observed in LV mass (P=0.2), AIx (P=0.6) or PWV (P=0.6) at 40 
weeks.  Further subgroup analyses that only included patients with the greatest falls 
in LDL and FGF-23 also showed no significant difference in the above endpoints. 
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  Placebo 
n=50 
Sevelamer 
n=54 
  Week 0 Week 40 Week 0 Week 40 
Haemoglobin (g/dl) 13.0 ± 1.5 13.1 ± 1.7 13.5 ± 1.4 13.4 ± 1.4 
Creatinine (µmol/l) 124 ± 33 125 ± 33 126 ± 35 130 ± 41 
eGFR (ml/min/1.73m2) 49 ± 13 50 ± 14 49 ± 13 48 ± 14 
Albumin (g/l) 43 ± 3 43 ± 3 44 ± 4 43 ± 4 
Alkaline phosphatase (U/l) 190 ± 55 186 ± 53 173 ± 58 189 ± 68* 
Total cholesterol (mmol/l) 4.69 ± 1.06 4.54 ± 1.00 5.03 ± 1.34 4.38 ± 1.23† 
HDL cholesterol (mmol/l) 1.40 ± 0.49 1.41 ± 0.58 1.45 ± 0.43 1.39 ± 0.56 
LDL cholesterol (mmol/l) 2.71 ± 0.94 2.58 ± 1.10 2.75 ± 0.91 2.37 ± 1.00 
Triglycerides (mmol/l) 1.1 (0.8–1.7) 1.1 (0.8–1.5) 1.3 (0.9–2.2) 1.4 (1.0–1.9) 
Glucose (mmol/l) 5.2 ± 1.1 5.1 ± 1.8 5.1 ± 0.9 4.9 ± 0.8 
Bicarbonate (mmol/l) 26.4 ± 2.8 27.2 ± 3.4 27.0 ± 2.7 27.2 ± 6.2 
Urate (µmol/l) 410 ± 105 414 ± 102 414 ± 106 411 ± 103 
hsCRP (µg/ml) 3.37 (1.09–6.42) 2.64 (1.06–8.35) 1.96 (0.96–1.89) 1.42 (0.77–2.94) 
 
Table 5-25.  Biochemical data at week 0 and week 40 for placebo and treatment groups. 
*P<0.005; †P<0.05.  Data are mean ± standard deviation or median (interquartile range).  Data 
analysed with repeated measures analysis of variance with time point (week 0, week 40) as the within-
subjects factor and group (placebo, sevelamer) as the between-subjects factor, testing the difference 
in change over time between groups.  eGFR, estimated glomerular filtration rate; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; hsCRP, high sensitive C-reactive protein. 
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  Placebo 
n=50 
Sevelamer 
n=54 
  Week 0 Week 40 Week 0 Week 40 
Markers of phosphate metabolism:     
 Phosphate (mmol/l) 1.05 ± 0.17 1.07 ± 0.17 1.02 ± 0.16 1.02 ± 0.23 
 Corrected calcium (mmol/l) 2.20 ± 0.10 2.19 ± 0.08 2.22 ± 0.09 2.21 ± 0.08 
 Calcium phosphate product 2.38 ± 0.43 2.35 ± 0.40 2.34 ± 0.38 2.25 ± 0.52 
 Parathyroid hormone (ng/l) 54 (37–73) 51 (39–72) 52 (39–70) 52 (35–75) 
 FGF-23 (pg/ml) 68 (51–88) 64 (52–84) 71 (53–83) 66 (49–91) 
 Klotho (pg/ml) 869 ± 279 873 ± 320 1001 ± 500 980 ± 533 
 1,25-dihydroxyvitamin D (pmol/l) 75 ± 33 68 ± 28 74 ± 27 71 ± 27 
 25-hydroxyvitamin D (nmol/l) 56 ± 31 55 ± 31 57 ± 28 59 ± 33 
Urine:     
 ACR (mg/mmol) 3.0 (0.7–31.4) 2.6 (0.7–21.1) 8.9 (0.9–63.7) 7.5 (0.8–63.7) 
 24-hour phosphate excretion (mmol) 21.1 ± 7.2 21.9 ± 8.6 24.2 ± 7.6 21.9 ± 7.4 
 UPi (mmol/l) 11.7 ± 4.2 11.3 ± 4.8 12.1 ± 5.2 10.8 ± 4.4 
 FEPi (%) 21 (13–28) 20 (10–24) 22 (13–34) 18 (13–30) 
 
Table 5-26.  Biochemical data for markers of phosphate metabolism and urinary data at week 0 and 
week 40 for placebo and treatment groups. 
Data are mean ± standard deviation or median (interquartile range).  Data analysed with repeated 
measures analysis of variance with time point (week 0, week 40) as the within-subjects factor and 
group (placebo, sevelamer) as the between-subjects factor, testing the difference in change over time 
between groups.  FGF-23, fibroblast growth factor 23; ACR, albumin: creatinine ratio; UPi, urinary 
phosphate concentration; FEPi, urinary fractional excretion of phosphate. 
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Figure 5-3.  Mean change in left ventricular mass between placebo group and treatment group. 
P=0.58, independent samples t-test of difference in change between groups over 40 weeks. 
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 Placebo 
n=45 
Sevelamer 
n=45 
 Week 0 Week 40 Week 0 Week 40 
Ejection fraction (%) 76 ± 7 76 ± 6 73 ± 6 72 ± 13 
End diastolic volume index (ml/m2) 59 ± 11 57 ± 11 62 ± 20 61 ± 16 
End systolic volume index (ml/m2) 15 ± 6 14 ± 6 17 ± 7 16 ± 7 
Stroke volume index (ml/m2) 44 ± 8 43 ± 8 44 ± 10 44 ± 13 
Cardiac index (l/min/m2) 3.0 ± 0.7 2.9 ± 0.7 3.1 ± 0.9 2.9 ± 0.9 
Mass (g) 99 ± 31 99 ± 30 102 ± 29 101 ± 27 
Mass index (g/m2) 51 ± 13 51 ± 12 52 ± 13 52 ± 13 
 
Table 5-27.  Left ventricular cardiovascular magnetic resonance imaging data at week 0 and week 40 
for placebo and sevelamer groups.  
Data are mean ± standard deviation.  Data analysed using repeated measures analysis of variance 
with time point (week 0, week 40) as the within-subjects factor and group (placebo, sevelamer) as the 
between-subjects factor, testing the difference in change over time between groups. 
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 Placebo 
n=45 
Sevelamer 
n=45 
 Week 0 Week 40 Week 0 Week 40 
Ascending 2.34 ± 1.79 2.40 ± 1.49 2.54 ± 1.64 2.70 ± 1.88 
Ascendingadj† 2.27 ± 1.73 2.29 ± 1.25 2.52 ± 1.62 2.81 ± 1.72 
Proximal descending 3.07 ± 1.51 3.13 ± 1.43 3.22 ± 1.45 3.42 ± 1.55 
Proximal descendingadj† 2.96 ± 1.39 3.01 ± 1.05 3.22 ± 1.42 3.55 ± 1.36 
Distal descending 3.94 ± 2.00 3.94 ± 1.79 4.44 ± 2.27 4.37 ± 2.08 
Distal descendingadj† 3.82 ± 1.82 3.77 ± 1.42 4.41 ± 2.29 4.50 ± 1.79 
Ascending: proximal descending 0.71 ± 0.29 0.73 ± 0.27 0.76 ± 0.31 0.76 ± 0.29 
Ascending: distal descending 0.54 ± 0.24 0.58 ± 0.23 0.60 ± 0.27 0.60 ± 0.23 
Proximal descending: distal descending 0.82 ± 0.27 0.83 ± 0.23 0.82 ± 0.29 0.82 ± 0.21 
 
Table 5-28.  Aortic distensibility cardiovascular magnetic resonance imaging data at week 0 and week 
40.  
*Adjusted for mean arterial pressure.  Data are mean ± standard deviation and analysed using 
repeated measures analysis of variance with time point (week 0, week 40) as the within-subjects 
factor and group (placebo, sevelamer) as the between-subjects factor, testing the difference in change 
over time between groups. 
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 Placebo 
n=50 
Sevelamer 
n=54 
 Week 0 Week 40 Week 0 Week 40 
LVIDd (cm) 5.0 ± 0.6 4.9 ± 0.6 4.8 ± 0.6 4.8 ± 0.5 
LVIDs (cm) 3.1 ± 0.6 2.9 ± 0.6 2.9 ± 0.6 2.9 ± 0.5 
Fractional shortening (%) 39.1 ± 7.6 40.0 ± 7.2 39.0 ± 7.3 39.0 ± 6.7 
LVEF (%) 62 ± 5 62 ± 4 62 ± 6 61 ± 4 
LVEDVI (ml/m2) 48.6 ± 9.6 45.6 ± 9.9 48.6 ± 12.1 45.3 ± 10.7 
LAVI (ml/m2) 28.9 ± 8.2 26.4 ± 7.3 27.3 ± 8.1 25.7 ± 8.1 
RVID (cm) 3.2 ± 0.5 3.2 ± 0.5 3.1 ± 0.7 3.1 ± 0.5 
 
Table 5-29.  Echocardiographic chamber dimension data at week 0 and week 40 for placebo and 
treatment groups. 
Data are mean ± standard deviation and analysed using repeated measures analysis of variance with 
time point (week 0, week 40) as the within-subjects factor and group (placebo, sevelamer) as the 
between-subjects factor, testing the difference in change over time between groups.  LVIDd, left 
ventricular internal dimension in diastole; LVIDs, left ventricular internal dimension in systole; LVEF, 
left ventricular ejection fraction; LVEDVI, left ventricular end diastolic volume index; LAVI, left atrial 
volume index; RVID, right ventricular internal dimension in diastole. 
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 Placebo 
n=50 
Sevelamer 
n=54 
 Week 0 Week 40 Week 0 Week 40 
Transmitral E/A 0.96 (0.81–1.13) 0.99 (0.81–1.17) 0.93 (0.77–1.06) 0.97 (0.73–1.16) 
Transmitral DT (ms) 227 ± 57 219 ± 44 216 ± 50 202 ± 40 
VP (cm/s) 62 (45–74) 57 (48–69) 57 (47–79) 53 (46–64) 
Transmitral E/VP 1.19 ± 0.44 1.23 ± 0.37 1.10 ± 0.45 1.17 ± 0.38 
Mean e’ (m/s) 9.3 ± 3.4 9.1 ± 2.8 8.6 ± 2.7 8.8 ± 2.6 
E/mean e’ 7.3 (6.6–9.3) 7.4 (6.5–9.3) 7.8 (6.5–9.4) 7.2 (6.2–9.4) 
IVRT (ms) 108 ± 23 113 ± 26 108 ± 31 119 ± 19 
Pulmonary vein S:D 1.2 ± 0.4 1.3 ± 0.3 1.2 ± 0.3 1.3 ± 0.3 
a duration – A duration (ms) -35.8 ± 22.7 -30.0 ± 24.1 -39.3 ± 21.3 -31.9 ± 27.4 
Left ventricular Tei index 0.32 ± 0.07 0.35 ± 0.06 0.32 ± 0.08 0.37 ± 0.07 
Anterolateral s’ (m/s) 9.3 ± 2.5 9.5 ± 2.3 8.4 ± 2.3 9.2 ± 2.3 
Inferoseptal s’ (m/s) 9.1 ± 1.7 9.0 ± 1.8 8.9 ± 1.9 9.0 ± 1.7 
cIB (dB) -15.1 ± 6.5 -15.6 ± 4.7 -16.2 ± 6.1 -17.8 ± 7.5 
RV Tei index 0.47 ± 0.25 0.61 ± 0.26 0.52 ± 0.31 0.59 ± 0.26 
TAPSE (mm) 26 ± 5 25 ± 5 27 ± 5 26 ± 5 
 
Table 5-30.  Echocardiographic functional data at week 0 and week 40 for placebo and treatment 
groups. 
Data are median (interquartile range) or mean ± standard deviation.  Analysed using repeated 
measures analysis of variance with time point (week 0, week 40) as the within-subjects factor and 
group (placebo, sevelamer) as the between-subjects factor, testing the difference in change over time 
between groups.  DT, deceleration time; VP, velocity propagation; IVRT, isovolumic relaxation time; 
cIB, calibrated integrated backscatter; RV, right ventricular; TAPSE, tricuspid annular plane systolic 
excursion. 
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 Placebo 
n=50 
Sevelamer 
n=54 
 Week 0 Week 40 Week 0 Week 40 
Global peak longitudinal systolic strain (%) -19.9 ± 2.6 -20.8 ± 2.0 -19.2 ± 2.6 -19.5 ± 2.8 
Global peak strain rate (s-1) -1.37 ± 0.22 -1.36 ± 0.18 -1.36 ± 0.23 -1.32 ± 0.23 
Global early diastolic strain rate (s-1) 1.58 ± 0.30 1.60 ± 0.32 1.57 ± 0.32 1.53 ± 0.31 
Peak systolic twist (º) 19.4 ± 3.6 17.0 ± 5.8 18.9 ± 5.1 19.6 ± 5.3 
Peak systolic torsion (º/cm) 2.72 ± 0.61 2.57 ± 0.84 2.75 ± 0.76 2.47 ± 0.65 
Peak apical rotation (º) 12.2 ± 4.5 11.6 ± 4.6 11.8 ± 3.7 12.0 ± 4.6 
Peak twist rate (º/s) 124 ± 23 115 ± 40 120 ± 30 118 ± 40 
Peak early diastolic untwist rate (º/s) -129 ± 28 -115 ± 43 -129 ± 46 -135 ± 37 
 
Table 5-31.  Echocardiographic strain and twist data at week 0 and week 40 for placebo and treatment 
groups. 
Data are mean ± standard deviation.  Analysed using repeated measures analysis of variance with 
time point (week 0, week 40) as the within-subjects factor and group (placebo, sevelamer) as the 
between-subjects factor, testing the difference in change over time between groups. 
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  Placebo 
n=50 
Sevelamer 
n=54 
  Week 0 Week 40 Week 0 Week 40 
Brachial office blood pressure (mmHg):     
 Systolic 126 ± 17 124 ± 21 129 ± 15 124 ± 15 
 Diastolic 70 ± 11 67 ± 10 73 ± 10 71 ± 10 
 Pulse pressure 56 ± 17 57 ± 19 56 ± 15 53 ± 13 
 Mean arterial pressure 89 ± 12 87 ± 13 92 ± 10 89 ± 11 
Central aortic blood pressure (mmHg):     
 Systolic 115 ± 18 113 ± 21 119 ± 15 114 ± 16 
 Diastolic 71 ± 11 68 ± 11 74 ± 10 72 ± 10 
 Pulse pressure 44 ± 17 46 ± 19 45 ± 14 42 ± 13* 
 Mean arterial pressure 90 ± 12 87 ± 13 92 ± 10 89 ± 11 
Arterial stiffness indices:     
 AIx 24.6 ± 11.5 26.7 ± 13.7 27.8 ± 11.6 27.4 ± 12.1 
 AIx75 18.9 ± 12.0 20.1 ± 13.2 21.4 ± 10.9 20.8 ± 12.2 
 Pulse wave velocity (m/s) 9.3 (7.6–11.2) 8.8 (7.9–10.6) 8.5 (7.3–10.7) 8.6 (7.5–10.7) 
 Pulse wave velocityadj (m/s)† 9.2 (8.1–10.6) 8.9 (8.1–10.6) 8.6 (7.1–10.7) 8.7 (7.7–10.7) 
 
Table 5-32.  Haemodynamic data and arterial stiffness indices at week 0 and week 40. 
*P<0.05; †adjusted for mean arterial pressure.  Data are mean ± standard deviation or median 
(interquartile range).  Data analysed with repeated measures analysis of variance with time point 
(week 0, week 40) as the within-subjects factor and group (placebo, sevelamer) as the between-
subjects factor, testing the difference in change over time between groups.  AIx, augmentation index; 
AIx75, augmentation index adjusted to heart rate of 75 bpm. 
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  Placebo 
n=50 
Sevelamer 
n=54 
  Week 0 Week 40 Week 0 Week 40 
Day-time:     
 Systolic (mmHg) 128 ± 15 126 ± 15 128 ± 10 127 ± 13 
 Diastolic (mmHg) 74 ± 10 72 ± 11 76 ± 9 75 ± 10 
 Pulse pressure (mmHg) 54 ± 11 54 ± 11 52 ± 11 52 ± 11 
 Mean arterial pressure (mmHg) 92 ± 11 90 ± 11 94 ± 8 92 ± 9 
Night-time:     
 Systolic (mmHg) 119 ± 19 115 ± 17 114 ± 12 113 ± 14 
 Diastolic (mmHg) 65 ± 11 63 ± 9 65 ± 10 64 ± 9 
 Pulse pressure (mmHg) 54 ± 14 53 ± 13 49 ± 10 49 ± 10 
 Mean arterial pressure (mmHg) 83 ± 12 80 ± 11 81 ± 10 80 ± 10 
24-hour average:     
 Systolic (mmHg) 125 ± 15 123 ± 16 124 ± 10 122 ± 13 
 Diastolic (mmHg) 71 ± 9 69 ± 10 73 ± 9 71 ± 9 
 Pulse pressure (mmHg) 54 ± 12 54 ± 11 51 ± 10 51 ± 10 
 Mean arterial pressure (mmHg) 89 ± 10 87 ± 11 90 ± 8 88 ± 9 
 Heart rate (beats/minute) 71 ± 11 69 ± 10 71 ± 9 71 ± 10 
Nocturnal dipper (%) 19 (42) 25 (53) 29 (56) 32 (62) 
 
Table 5-33.  24-hour ambulatory blood pressure data at week 0 and week 40. 
Data are mean ± standard deviation or frequency (percentage).  Analysed using repeated measures 
analysis of variance with time point (week 0, week 40) as the within-subjects factor and group 
(placebo, sevelamer) as the between-subjects factor, testing the difference in change over time 
between groups. 
 
 162 
  Placebo 
n=50 
Sevelamer 
n=54 
  Week 0 Week 40 Week 0 Week 40 
Lumbar spine:     
 Bone mineral density (g/cm2) 1.14 ± 0.20 1.14 ± 0.20 1.06 ± 0.16 1.06 ± 0.16 
 T-score 0.61 ± 1.77 0.62 ± 1.75 -0.16 ± 1.34 -0.19 ± 1.36 
 Z-score 1.51 ± 1.89 1.55 ± 1.87 0.60 ± 1.40 0.63 ± 1.40 
Both hips:     
 Bone mineral density (g/cm2) 1.02 ± 0.13 1.03 ± 0.18 1.00 ± 0.14 1.00 ± 0.15 
 T-score 0.24 ± 0.91 0.20 ± 0.93 -0.08 ± 0.94 -0.14 ± 0.96 
 Z-score 0.89 ± 0.99 0.87 ± 1.01 0.50 ± 1.01 0.47 ± 1.01 
 
Table 5-34.  Bone density data at week 0 and week 40 for placebo and treatment groups. 
Data are mean ± standard deviation.  Analysed using repeated measures analysis of variance with 
time point (week 0, week 40) as the within-subjects factor and group (placebo, sevelamer) as the 
between-subjects factor, testing the difference in change over time between groups. 
 
A mean of 79 ± 21% of tablets was taken during the open-label run-in phase.  There 
was no significant difference in compliance between groups during the blinded 
treatment phase (sevelamer group 80 ± 20% vs. placebo group 81 ± 30%, P=0.9).  
Overall, 61 patients (56%) returned <20% of prescribed medication (Figure 5-4).  A 
subgroup analysis that included only these highly compliant subjects revealed 
significant decreases in FGF-23 (-8.9 ± 19.8 vs. 1.0 ± 17.7 pg/ml, P<0.05) and 
urinary phosphate concentration (-2.4 ± 4.3 vs. 0.6 ± 3.6 mmol/l, P<0.01) over 40 
weeks in those receiving sevelamer compared to placebo (Table 5-35) but no 
differences in serum phosphate, PTH, klotho or vitamin D.  There were also no 
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differences in BP, indices of arterial stiffness, LV mass or measures of LV systolic or 
diastolic function (Table 5-36). 
 
 
Figure 5-4.  Compliance displayed as percentage of prescribed pills taken. 
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  Placebo 
n=31 
Sevelamer 
n=30 
  Week 0 Week 40 Week 0 Week 40 
Biochemical:     
 Phosphate (mmol/l) 1.04 ± 0.20 1.06 ± 0.17 1.03 ± 0.15 0.98 ± 0.24 
 FGF-23 (pg/ml) 75 ± 35 76 ± 29 76 ± 31 67 ± 28* 
 Klotho (pg/ml) 888 ± 278 921 ± 355 1060 ± 617 1044 ± 667 
 1,25-dihydroxyvitamin D (pmol/l) 67 ± 27 65 ± 27 73 ± 31 68 ± 28 
 25-hydroxyvitamin D (nmol/l) 60 ± 36 60 ± 34 65 ± 31 62 ± 32 
 UPi (mmol/l) 10.4 ± 3.4 11.0 ± 4.6 12.4 ± 4.6 10.0 ± 3.0† 
 FEPi (%) 21.4 (13.5–34.0) 16.3 (11.8–23.2) 23.8 (15.0–33.8) 17.1 (10.8–29.8) 
 Total cholesterol (mmol/l) 4.7 ± 1.1 4.3 ± 1.3 4.8 ± 1.1 4.2 ± 1.3 
Haemodynamics:     
 Brachial systolic BP (mmHg) 125 ± 17 121 ± 18 126 ± 15 122 ± 13 
 Brachial diastolic BP (mmHg) 69 ± 11 66 ± 11 70 ± 10 67 ± 8 
 Brachial MAP (mmHg) 89 ± 12 85 ± 12 89 ± 11 86 ± 9 
 Heart rate (beats/min) 64 ± 11 63 ± 10 62 ± 9 62 ± 9 
 Central systolic BP (mmHg) 114 ± 17 111 ± 18 116 ± 15 113 ± 14 
 Central diastolic BP (mmHg) 70 ± 11 66 ± 11 71 ± 10 68 ± 8 
 Central MAP (mmHg) 89 ± 12 85 ± 12 89 ± 11 86 ± 9 
 
Table 5-35.  Biochemical and haemodynamic data for patients with ≥80% compliance. 
*P<0.05, †P<0.01.  Data are mean ± standard deviation or median (interquartile range).  Analysed 
using repeated measures analysis of variance with time point (week 0, week 40) as the within-subjects 
factor and group (placebo, sevelamer) as the between-subjects factor, testing the difference in change 
over time between groups.  FGF-23, fibroblast growth factor 23, UPi, urinary phosphate concentration; 
FEPi, urinary fractional excretion of phosphate; BP, blood pressure; MAP, mean arterial pressure. 
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  Placebo 
n=31 
Sevelamer 
n=30 
  Week 0 Week 40 Week 0 Week 40 
Cardiac structure and function:     
 Left ventricular mass (g) 104 ± 33 102 ± 33 94 ± 21 94 ± 19 
 LVEF (%) 75 ± 7 76 ± 7 74 ± 7 75 ± 7 
 Mean TDi s’ (m/s) 9.0 ± 1.2 8.9 ± 1.2 9.1 ± 1.8 9.2 ± 1.7 
 Transmitral E/A 0.98 (0.81–1.13) 0.99 (0.81–1.13) 0.93 (0.79–1.10) 0.94 (0.70–1.19) 
 Mean TDi e’ (m/s) 9.5 ± 3.6 9.4 ± 3.1 8.9 ± 3.0 8.9 ± 3.0 
 E/mean e’ 7.2 (6.2–9.0) 7.5 (6.4–9.4) 8.4 (6.4–9.6) 8.3 (6.1–9.5) 
Arterial stiffness indices:     
 Pulse wave velocity (m/s) 9.0 (7.5–11.7) 8.9 (7.9–10.6) 8.4 (7.2–10.3) 8.8 (7.2–10.8) 
 AIx 24.7 ± 10.5 25.8 ± 12.6 28.0 ± 11.4 28.8 ± 10.5 
 AIx75 19.1 ± 11.4 19.2 ± 12.4 21.8 ± 11.1 22.3 ± 10.1 
Aortic distensibility (x10-3 mmHg-1): 
 Ascending 2.38 ± 1.98 2.38 ± 1.63 2.58 ± 1.83 2.81 ± 2.18 
 Proximal descending 3.10 ± 1.74 3.08 ± 1.44 3.27 ± 1.65 3.57 ± 1.62 
 Distal descending 3.99 ± 2.24 3.95 ± 1.73 4.62 ± 2.68 4.49 ± 2.30 
 
Table 5-36.  Cardiac structure and function data and arterial stiffness data for patients with ≥80% 
compliance. 
Data are mean ± standard deviation or median (interquartile range).  Analysed using repeated 
measures analysis of variance with time point (week 0, week 40) as the within-subjects factor and 
group (placebo, sevelamer) as the between-subjects factor, testing the difference in change over time 
between groups.  LVEF, left ventricular ejection fraction; TDi, tissue Doppler; AIx, augmentation index; 
AIx75, augmentation index adjusted to heart rate of 75 bpm. 
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5.3.6 Comparison with Spironolactone Cohort 
Table 5-37 compares the baseline demographic and biochemical characteristics of 
the patients from the current sevelamer study with those of participants from the 
spironolactone study described previously (Edwards et al., 2009).  There were 
significantly fewer patients with a smoking history in the spironolactone study.  
Furthermore, the spironolactone cohort had lower body mass index and hsCRP at 
baseline, although the mean serum phosphate level was higher.  Table 5-38 shows a 
comparison of baseline haemodynamic data, arterial stiffness indices and left 
ventricular mass data between the study cohorts.  Brachial diastolic BP, brachial 
mean arterial pressure and central diastolic BP were higher in the spironolactone 
cohort, although 24-hour systolic BP was slightly lower.  Patients in the 
spironolactone study had stiffer arteries at baseline, with a higher median PWV (8.9 
(7.3–11.2) vs. 7.9 (7.2–9.3) m/s, P<0.01).  Left ventricular mass was also greater at 
baseline (114 ± 30 vs. 101 ± 30 g, P<0.01). 
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 Sevelamer study 
n=120 
Spironolactone study 
n=117 
Age (years) 55 ± 14 54 ± 12 
Male gender 65 (54) 71 (61) 
Body mass index (kg/m2) 29.0 ± 5.5 27.2 ± 4.2* 
Smoking history 64 (54) 17 (15)† 
Mean eGFR (ml/min/1.73m2) 50 ± 13 50 ± 17 
Phosphate (mmol/l) 1.03 ± 0.16 1.19 ± 0.22† 
Total cholesterol (mmol/l) 4.92 ± 1.22 4.82 ± 1.05 
ACR (mg/mmol) 6.3 (0.8–48.3) 8.2 (1.5–47.9) 
Haemoglobin (g/dl) 13.3 ± 1.5 13.4 ± 1.6 
hsCRP (µg/ml) 2.17 (1.09–6.35) 1.89 (0.57–4.31)* 
Number of antihypertensives 1.7 ± 1.2 2.0 ± 1.0* 
 
Table 5-37.  Comparison of baseline demographic and biochemical characteristics of sevelamer and 
spironolactone study populations. 
*P<0.05; †P<0.0005.  Data are mean ± standard deviation, median (interquartile range) or frequency 
(percentage).  eGFR, estimated glomerular filtration rate; ACR, albumin: creatinine ratio; hsCRP, high 
sensitive C-reactive protein.  Analysed using independent samples t-test or χ2. 
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  Sevelamer study 
n=120 
Spironolactone study 
n=117 
Haemodynamics:   
 Brachial systolic BP (mmHg) 128 ± 17 125 ± 12 
 Brachial diastolic BP (mmHg) 71 ± 11 77 ± 10* 
 Brachial pulse pressure (mmHg) 57 ± 17 54 ± 12 
 Brachial mean arterial pressure (mmHg) 91 ± 12 95 ± 11† 
 Central systolic BP (mmHg) 117 ± 17 121 ± 17 
 Central diastolic BP (mmHg) 72 ± 11 78 ± 10* 
 Central pulse pressure (mmHg) 45 ± 16 43 ± 12 
 Central mean arterial pressure (mmHg) 91 ± 12 92 ± 11 
 24-hour average systolic BP (mmHg) 124 ± 12 121 ± 11‡ 
 24-hour average diastolic BP (mmHg) 71 ± 9 73 ± 8 
 24-hour average pulse pressure (mmHg) 53 ± 11 48 ± 9* 
 24-hour mean arterial pressure (mmHg) 89 ± 9 89 ± 8 
 Nocturnal dipper 58 (50) 54 (47) 
Arterial stiffness and left ventricular mass indices:   
 AIx75 20 ± 12 25 ± 10* 
 PWV (m/s) 7.9 (7.2–9.3) 8.9 (7.3–11.2)† 
 LV mass (g) 101 ± 30 114 ± 30† 
 LV mass index (g/m2) 52 ± 13 60 ± 12* 
 
Table 5-38.  Comparison of baseline haemodynamic indices, arterial stiffness indices and left 
ventricular mass between sevelamer and spironolactone study populations. 
*P<0.0005; †P<0.01; ‡P<0.05.  Data are mean ± standard deviation, median (interquartile range) or 
frequency (percentage).  BP, blood pressure; AIx75, augmentation index adjusted to heart rate of 
75bpm; PWV, pulse wave velocity; LV, left ventricular.  Analysed using independent samples t-test or 
χ2. 
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 Sevelamer study 
n=53 
Spironolactone study 
n=55 
Change in LV mass (g)* -1.0 ± 7.2 -14.0 ± 12.7† 
Change in LV mass index (g/m2) -0.1 ± 4.1 -6.5 ± 5.6† 
Change in PWV (m/s) 0.0 ± 1.1 -0.8 ± 1.0† 
Change in AIx75 -0.7 ± 8.4 -4.9 ± 6.1‡ 
Change in brachial systolic BP (mmHg) -5 ± 15 -5 ± 8 
 
Table 5-39.  Comparison of changes observed in treatment groups between sevelamer and 
spironolactone study populations. 
*Data available for 45 subjects from sevelamer study and 47 subjects from spironolactone study; 
†P<0.0005; ‡P<0.01.  LV, left ventricular; BP, blood pressure; PWV, pulse wave velocity, AIx75, 
augmentation index adjusted to heart rate of 75bpm.  Analysed using independent samples t-test. 
 
Table 5-39 compares the changes observed in the main endpoints after 40 weeks of 
active treatment in each study.  Treatment with spironolactone resulted in significant 
decreases in LV mass, PWV and AIx75 when compared to treatment with sevelamer. 
 
5.3.7 Adverse Effects 
During the open-label run-in phase nine subjects (8%) developed 
hypophosphataemia (phosphate <0.8 mmol/l) necessitating a halving of the dose of 
sevelamer to 800 mg with meals.  One subject was withdrawn during run-in due to 
persistent hypophosphataemia despite dose reduction.  Nine patients (8%) 
experienced dyspepsia, six developed constipation (5%) and two (2%) complained of 
nausea and vomiting.  In eight patients a dose-reduction was required to alleviate 
symptoms.  Two patients were withdrawn due to persistence of adverse effects 
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despite dose reduction (Figure 5-2).  Following randomisation a further seven 
subjects developed hypophosphataemia (three [6%] in the placebo group, four [7%] 
in the treatment group, P=0.7) requiring a dose reduction to 800 mg three times daily 
or equivalent.  Three subjects from the treatment group and one from the placebo 
group were withdrawn from the treatment phase due to persistent 
hypophosphataemia.  Twelve patients were hospitalised during their time in the study 
for unrelated medical conditions (two during run-in, six from the treatment group and 
four from the placebo group). 
 
5.3.8 Subject Withdrawal 
The commonest reason for withdrawal from the study was withdrawal of consent 
(Table 5-40).  Four participants were intolerant to medication, either due to persistent 
adverse effects despite a dose-reduction (three subjects) or finding the tablets too 
large and unpalatable (one participant).  Only 5 subjects were withdrawn due to 
persistent hypophosphataemia. 
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Run-in phase 
Hypophosphataemia 1 
Poor compliance with study 3 
Intolerance to medication 2 
Other 5 
Treatment phase 
Hypophosphataemia 4 
Poor compliance with study 0 
Intolerance to medication 2 
Other 4 
 
Table 5-40.  Subject withdrawal. 
 
5.4 Discussion 
 
In patients with stage 3 non-diabetic CKD, 40 weeks of treatment with sevelamer 
carbonate resulted in no change in LV mass compared with placebo.  Furthermore, 
there were no significant effects on measures of arterial stiffness and wave reflection 
or LV systolic and diastolic function.  Although a small reduction in brachial systolic 
BP was observed after 4 weeks of treatment with sevelamer in the open-label 
uncontrolled phase of the study, this did not persist in the double blind, placebo-
controlled phase.  Despite repeated reminders and suggested methods to maximise 
compliance, adherence to medication was low in both phases of the study with only 
56% of subjects taking ≥80% of their study medication.  Furthermore, several 
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patients withdrew from the study because of difficulty with the frequency and 
tolerability of the study agents. 
 
Chronic kidney disease is the commonest condition associated with deranged 
phosphate homeostasis.  Abnormal phosphate handling, coupled with phosphate-rich 
Western diets, may contribute to the elevated cardiovascular risk observed in this 
patient group (Ferro et al., 2009).  Observational studies have also linked phosphate 
to an increased risk of cardiovascular events (Tonelli et al., 2005) and development 
of symptomatic heart failure in the general population (Dhingra et al., 2010; Dhingra 
et al., 2007), together with a higher prevalence of vascular calcification (Adeney et 
al., 2009; Foley et al., 2009b; Tuttle and Short, 2009).  Cellular mechanisms of 
phosphate cardiovascular toxicity are unclear, but post-prandial increases in serum 
phosphate seen following acute phosphate loading are associated with transient 
endothelial dysfunction (Shuto et al., 2009).  Studies in vitro have demonstrated that 
vascular smooth muscle cells undergo osteogenic transformation in the presence of 
hyperphosphataemia, with upregulation of genes that promote matrix mineralization 
and vascular calcium deposition (Jono et al., 2000).  The presence of vascular 
medial calcification is associated with increased arterial stiffness (Guerin et al., 2000; 
McEniery et al., 2009; Raggi et al., 2007), which appears to be a principal driver of 
abnormalities in cardiac structure and function (Chue et al., 2010).  Relationships 
have been demonstrated between serum phosphate and increased arterial stiffness 
(Ix et al., 2009) as well as increased LV mass (Chue et al., 2012; Dhingra et al., 
2010) and LVH (Foley et al., 2009a), which are all independent predictors of adverse 
cardiovascular outcome and may be responsible for the excess cardiovascular 
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morbidity and mortality observed in CKD (Chue et al., 2010).  Furthermore, evidence 
from haemodialysis patients suggests lowering of serum phosphate may reduce LV 
mass (Achinger and Ayus, 2006).  These observations led to the hypothesis that in 
early stage CKD, when serum phosphate levels are normal, reducing phosphate 
exposure using a non-calcium-based phosphate binder would have beneficial effects 
on both arterial stiffness and LV mass (Ferro et al., 2009). 
 
The absence of improvement in cardiac and vascular parameters after 40 weeks of 
treatment with sevelamer would suggest our primary hypothesis has been refuted.  
Before this concept is discarded, however, a number of issues must be considered.  
Firstly, we chose subjects with stage 3 CKD because at this level of kidney function, 
cardiovascular risk is increased despite normal serum phosphate levels, and serum 
FGF-23 and urinary phosphate excretion are elevated (Isakova et al., 2011b).  This 
was indeed the case, although mean levels of klotho, 1,25-dihydroxyvitamin D and 
PTH levels were normal indicating that most subjects had only mildly impaired renal 
function and therefore only a minimally impaired capacity to excrete a phosphate 
load.  Furthermore, at this level of kidney function it has recently been suggested that 
use of phosphate binders may cause upregulation of the gastrointestinal NPT-2b 
sodium-phosphate co-transporters or enhancement of passive paracellular diffusion 
of phosphate ions (Block et al., 2012); this compensatory response, combined with 
observed reductions in urinary phosphate excretion, may mean that overall 
“phosphate flux” remains unchanged (Berndt et al., 2007).  Given the inaccuracy of 
the MDRD equation in near-normal renal function it is possible that a significant 
number of participants had true GFRs >60 ml/min/1.73m2 (Levey et al., 1999).  
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Despite this, 86% of patients enrolled had histological or radiological evidence of 
kidney disease. 
 
In this study patients with well-controlled BP were selected and almost all had 
baseline LV mass within normal limits.  This was to determine whether intervention 
with a phosphate binder would have beneficial effects on cardiovascular structure 
and function over and above optimal conventional treatment, a concept validated in 
previous research with spironolactone (Edwards et al., 2009).  This could have 
potentially masked any benefits of reducing phosphate absorption.  There is 
increasing evidence highlighting the prognostic value of LV mass as a continuous 
variable, however, even when values lie within normal limits (Schillaci et al., 2000).  
Furthermore, over 70% of incident dialysis patients have established LVH, indicating 
that structural heart disease develops in the earlier stages of CKD (Foley et al., 
1995).  Multiple indices of cardiovascular structure and function were examined, 
which remained unchanged during the controlled phase of the study.  Cardiovascular 
magnetic resonance imaging was also utilised, which is a highly sensitive technique 
for detecting changes in LV mass and which permits a smaller sample size when 
compared to echocardiography (Myerson et al., 2002).  The possibility that the 
cardiovascular effects of sevelamer were too small to detect with a sample size of 60 
in each group cannot be excluded.  The power calculations used in this study were 
based on changes in LV mass observed in a previous trial of the same size, duration 
and design with similar inclusion and exclusion criteria but utilising spironolactone as 
the treatment agent (Edwards et al., 2009).  The calculation of required sample size 
used in the current study was conservative, aiming for >90% power.  Although LV 
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mass data were only available for 45 subjects in each arm of the study, detection of a 
change in LV mass of 8 grams with a standard deviation of the change in LV mass of 
12 grams was possible with 88% power.  The rate of withdrawal from the study was 
higher than the 10% accounted for when calculating sample size but compares 
favourably to other studies of phosphate binders in CKD (Block et al., 2012; Qunibi et 
al., 2011).  Similarly, 40 weeks was chosen for the study duration based on the 
previous spironolactone trial, which demonstrated notable changes in LV mass, 
arterial stiffness and LV function over this time period (Edwards et al., 2009).  
Furthermore, treatment with allopurinol over a 40-week period was also sufficient to 
reduce LV mass and improve endothelial function in patients with CKD (Kao et al., 
2011).  A longer treatment duration with sevelamer may be required to exert 
detectable effects on cardiovascular structure and function, particularly with normal 
BP and LV mass at baseline.  Our findings parallel those of the recently published 
Paricalcitol Capsule Benefits in Renal Failure-Induced Cardiac Morbidity (PRIMO) 
study in which 227 patients with stage 3 and 4 CKD (eGFR 15–59 ml/min/1.73m2) 
failed to show any reductions in LV mass after 48 weeks of treatment with 
paricalcitol, a once daily vitamin D analogue, compared to placebo (Thadhani et al., 
2012).  This was despite a lower mean eGFR at baseline compared to our cohort and 
inclusion of patients with mild to moderate LVH at study entry. 
 
Adherence to both active treatment and placebo was low with 56% of subjects taking 
≥80% of prescribed study medication.  This is likely to be an underestimate of the 
actual tablets taken given the known limitations of pill counts (Lee et al., 2007).  This 
low level of compliance occurred despite regular encouragement and monitoring 
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throughout the study period, and may have reduced the efficacy of treatment; this 
may also account for the modest effects on urinary phosphate excretion, cholesterol 
and urate levels.  Several participants were unable to maintain a regimen of two 
tablets three times a day and this contributed significantly to reasons given by 
patients when withdrawing from the study.  A subgroup analysis of the 61 subjects 
with ≥80% compliance indicated some biochemical changes in those taking 
sevelamer compared to placebo, with significant reductions in serum FGF-23 and 
urinary phosphate excretion.  This is consistent with previous studies of CKD patients 
with normal serum phosphate levels, in which sevelamer reduced urinary phosphate 
excretion and serum FGF-23 without altering serum phosphate (Block et al., 2012; 
Oliveira et al., 2010).  In our compliant patients, no changes in LV mass or arterial 
stiffness were observed between groups.  Such sub-group analyses are likely 
underpowered to detect any differences in these parameters. Effective testing of our 
original hypothesis may thus require the introduction of a well-tolerated, once-daily 
agent that significantly lowers gastrointestinal phosphate absorption and is 
associated with improved compliance.  An analogous situation may have occurred 
with cholesterol lowering; early studies with cholesterol lowering agents failed to 
show significant benefits (Muldoon et al., 1990) and the concept that cholesterol 
lowering was beneficial was not supported until statins were introduced. 
 
Despite excluding patients with diabetes mellitus and including a study population 
with early stage CKD and no history of treatment with calcium-based phosphate 
binders or vitamin D analogues, 48% of subjects had evidence of aortic calcification. 
This is higher than the reported prevalence in non-diabetic stage 3 CKD (Russo et 
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al., 2004).  The use of more sensitive techniques such as computed tomography 
would have increased the proportion of patients with detectable calcification.  It is 
possible that this high prevalence would have made it very difficult, if not impossible, 
to lower arterial stiffness and therefore LV mass in these patients over 40 weeks.  
Treatment with sevelamer over twelve months has been shown to reduce 
progression of arterial calcification in haemodialysis patients but not cause 
regression (Chertow et al., 2002; Kakuta et al., 2011).  In a subgroup analysis that 
only included subjects without aortic calcification there were no differences in arterial 
stiffness or LV mass between groups at 40 weeks, although only 25 patients were 
included in each group. 
 
It remains possible that the association between phosphate and adverse 
cardiovascular outcome is mediated by other pathophysiological processes unrelated 
to arterial stiffness and structural heart disease.  Serum phosphate correlates with 
angiographic severity of coronary artery disease (Narang et al., 1997), and may 
contribute to changes in plaque structure (Ellam and Chico, 2012).  Such changes 
would not have been detected by any of the techniques used in our study.  Finally, it 
is possible that the relationship between poor outcome and serum phosphate is not 
causative but reflects an association observed between worse outcomes and 
declining renal function. Although studies have attempted to mathematically correct 
for renal function, most have done so by adjusting for eGFR.  The accuracy of such 
calculations is reduced at eGFR values close to 60 ml/min/1.73m2 when compared to 
true GFR measurements. 
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5.4.1 Conclusion 
In summary, in patients with stage 3 CKD the use of sevelamer carbonate for 40 
weeks was not associated with any significant changes in LV mass, arterial stiffness, 
or any parameters of LV systolic and diastolic function.  Adherence to the study 
medication was low, however, and more rigorous testing of this hypothesis may be 
achieved with the introduction of a well-tolerated once-daily drug regimen that more 
effectively reduces cardiovascular phosphate exposure. 
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6 SUMMARY AND FUTURE WORK 
 
6.1 Summary of Principal Findings 
 
In this volume of work it was shown that in 225 patients with early stage CKD (mean 
eGFR 43 ± 19 ml/min/1.73m2), serum phosphate was an independent predictor of 
GFR decline, with a 1 mmol/l increase in serum phosphate associated with a 0.34 
ml/min/1.73m2/month steeper slope of renal function decline (P=0.01) (Chue et al., 
2011a).  This finding was supported by the result that serum phosphate was 
significantly higher amongst the subset of patients reaching the combined endpoint of 
commencement of dialysis or ≥25% decline in eGFR, and was independently 
associated with this combined endpoint following adjustment for multiple variables 
known to influence decline in renal function.  These results were in keeping with 
those of an earlier study of patients with more advanced CKD (mean eGFR 13 ± 5.4 
ml/min/1.73m2), and suggest an alternative mechanism through which phosphate 
may increase cardiovascular risk. 
 
In the second cross-sectional study, serum phosphate was shown to be 
independently associated with LV mass in 119 males and 89 females with stage 2–4 
non-diabetic CKD and normal LV mass and well-controlled BP at baseline (Chue et 
al., 2012).  The majority of subjects in this study had serum phosphate levels within 
the normal reference range.  Similar associations between serum phosphate and 
increased LV mass have been demonstrated in ESKD (Strozecki et al., 2001) but 
also in individuals with normal cardiac and renal function (Dhingra et al., 2010; Foley 
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et al., 2009a).  The results of this study add support to the original hypothesis that 
lowering serum phosphate in patients with early CKD could represent a novel way of 
reducing LV mass and thus cardiovascular risk.  The notion that LV mass should be 
considered a continuous variable, rather than according to whether LVH is present or 
absent, was suggested following the demonstration that increasing LV mass has a 
graded relationship with cardiovascular risk (Schillaci et al., 2000).  The question 
raised by this study was whether a reduction in phosphate exposure in early CKD 
would be linked to a reduction in LV mass, which formed the premise for the third 
study described in section 5. 
 
Although an association was not demonstrated between serum phosphate and 
indices of arterial stiffness, or between arterial stiffness and LV mass, the lack of 
such relationships in this observational study does not exclude the possibility that 
phosphate-induced changes in LV mass are mediated by increased arterial stiffness 
and increased afterload.  The use of subjects with normal LV mass, normal serum 
phosphate and only mildly elevated PWV would increase the difficulty of detecting 
such associations.  Previous studies have demonstrated an association between 
serum phosphate and vascular calcification (Foley et al., 2009b; Goodman et al., 
2000) as well as serum phosphate and arterial stiffness (Ix et al., 2009; Kendrick et 
al., 2010; Toussaint et al., 2008).  Several techniques of arterial stiffness 
measurement were therefore adopted in the final study. 
 
The double-blind, randomised, placebo-controlled trial of 120 patients with stage 3 
non-diabetic CKD did not demonstrate a significant reduction in LV mass or arterial 
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stiffness after 40 weeks of treatment with the oral phosphate binder sevelamer 
carbonate when compared to placebo (Chue et al., 2013).  There were also no 
significant changes in indices of systolic or diastolic LV function, aortic distensibility 
or bone density over this period.  Furthermore, there were no detectable changes in 
any biochemical indices of phosphate metabolism, including serum phosphate, 
serum FGF-23, klotho, vitamin D and 24-hour urinary phosphate excretion.  
Compliance with trial medication during the 40-week study period was low, with only 
56% of subjects taking ≥80% of the prescribed study drug.  This level of compliance 
occurred despite repeated reminders to take medication, pill counting, suggested 
methods to improve compliance and monitoring of adverse effects.  A subgroup 
analysis of the 61 patients with ≥80% compliance revealed a significant reduction in 
serum FGF-23 and urinary phosphate excretion in those taking sevelamer compared 
to placebo, suggesting some degree of modification of phosphate handling, although 
no difference in LV mass or arterial stiffness was detected due to the small subgroup 
sample size. 
 
6.2 Future Directions 
 
6.2.1 Drug Efficacy and Acceptability 
There is clear evidence that medication compliance decreases with increasing dose 
frequency (Claxton et al., 2001).  All currently available phosphate binders have a 
multiple daily dosing regimen; the absence of a phosphate binder with a low pill-
burden undoubtedly has adverse effects upon compliance, and in turn efficacy.  
Following initial recruitment and randomisation of the first few patients into the study, 
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sachets providing 2.4 g of sevelamer carbonate in powder form (equivalent to 1600 
mg in tablet form) were introduced.  Although still requiring three-times-daily dosing 
with meals, the administration of a drug in suspension form over a tablet formulation 
has the potential benefit of improved acceptance amongst patients, particularly those 
that find large tablets unpalatable.  An open-label randomised crossover study, 
however, demonstrated equivalent short-term rates of compliance between 
sevelamer hydrochloride tablets and sevelamer carbonate sachets (84% vs. 86%) 
over two 4-week periods; control of hyperphosphataemia was also equivalent (Fan et 
al., 2009).  The lack of a clear improvement in compliance over the traditional tablet 
form highlights the need for a treatment that effectively lowers phosphate, or the 
more sensitive FGF-23, whilst providing a more acceptable dosing regimen.  Until 
such a treatment is introduced, compliance is likely to remain a shortcoming of 
phosphate-lowering therapy. 
 
A novel salivary phosphate-binding chewing gum has been shown to be efficacious 
in reducing serum phosphate when used twice daily in conjunction with an oral 
phosphate binder taken with meals in a small number of patients with ESKD (Savica 
et al., 2009).  It is unknown whether this treatment is effective at lowering serum 
phosphate concentrations when used as sole therapy, and also whether there is 
efficacy in the early CKD population. 
 
A number of studies have examined the phosphate-lowering efficacy of niacin 
(nicotinic acid) and its related compounds, including its metabolite nicotinamide (also 
known as niacinamide) (Cheng et al., 2008; Maccubbin et al., 2010; Muller et al., 
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2007; Sampathkumar et al., 2006; Takahashi et al., 2004).  Nicotinamide reduces 
gastrointestinal phosphate absorption by inhibiting the gastrointestinal sodium-
phosphate co-transporter (Eto et al., 2005).  This alternative mechanism of action 
allows for an extended-release form of the drug, which has the advantage of once-
daily dosing.  Despite promising results of effective phosphate lowering, even in 
patients with early stage CKD (Maccubbin et al., 2010), these compounds are limited 
by their side effect profile, which includes hepatotoxicity, thrombocytopenia and 
flushing, which may limit their regular use (Berns, 2008).  Extended release niacin is 
often given alongside the selective prostaglandin D2 receptor subtype I inhibitor 
laropiprant, which effectively halves the incidence of niacin-induced flushing 
(Maccubbin et al., 2008). 
 
It is possible that novel compounds targeting the FGF-23 pathway, including the non-
specific FGF-23 receptor antagonist PD173074, which has been shown to attenuate 
development of LVH in animal models of CKD (Faul et al., 2011), may be effective in 
improving structural and functional cardiovascular parameters in early stage CKD.  
Although a monoclonal antibody against FGF-23 was shown to improve many 
biochemical parameters of CKD-MBD in a rat model and effectively treat secondary 
hyperparathyroidism, the resulting hyperphosphataemia and vascular calcification 
resulted in excess mortality (Shalhoub et al., 2012).  It is possible that a more 
targeted approach aiming to antagonise the specific FGF-23 receptor responsible for 
the induction of LVH, rather than blanket inhibition of all FGF-23 activity, may prove 
to be more effective in the CKD setting.  Such compounds require further careful 
evaluation to determine whether FGF-23 antagonism is truly beneficial or whether 
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such treatments suppress an important compensatory mechanism designed to 
protect against the harmful effects of hyperphosphataemia. 
 
6.2.2 Study Population 
The population studied in this body of work were predominantly patients with stage 3 
CKD (mean eGFR 50 ml/min/1.73m2) and normal LV mass and BP at baseline.  
Furthermore, these individuals had relatively preserved phosphate handling, and 
despite elevated urinary phosphate excretion and FGF-23 levels at study entry, mean 
levels of klotho, 1,25-dihydroxyvitamin D and PTH were within normal limits.  Despite 
the above, and exclusion of patients with diabetes mellitus, 48% of participants had 
calcification of the abdominal aortic wall, detectable using a relatively insensitive 
imaging modality. 
 
It is possible that repeating a study of sevelamer versus placebo in patients with 
more advanced CKD (for example stage 3b [eGFR 30–44 ml/min/1.73m2] or stage 4 
CKD [eGFR 15–29 ml/min/1.73m2]), and therefore a greater derangement in 
phosphate handling and potentially higher LV mass at baseline, would yield 
significant changes in the endpoints studied.  However, a number of issues relating 
to the study of patients with more advanced kidney disease should be considered.  
Firstly, a greater proportion of these patients will have secondary 
hyperparathyroidism and also hyperphosphataemia, necessitating treatment with 
vitamin D analogues or phosphate binders according to the KDIGO guidelines 
(KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and 
treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), 2009).  
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Use of these therapies introduces a source of confounding, potentially limits the 
number of patients suitable for such a study, and may require cessation of 
recommended therapy.  Secondly, more advanced CKD is likely to be associated 
with a higher prevalence of vascular calcification (Kramer et al., 2005) and 
established aortopathy, which may limit the ability of any treatment to reduce aortic 
stiffness.  Thirdly, a high pill burden and low compliance will still remain as limiting 
factors.  An alternative approach would be to replicate the inclusion criterion of the 
PRIMO study and only include subjects with LVH at baseline (Thadhani et al., 2012).  
Given the low prevalence of LVH in the population currently studied, it is possible that 
many potential subjects will undergo screening transthoracic echocardiography or 
CMR but ultimately be excluded on the basis of normal LV mass.  It should also be 
noted that the PRIMO study did not demonstrate any reduction in LV mass or 
improvement in LV diastolic function after 48 weeks of treatment with the vitamin D 
analogue paricalcitol. 
 
6.2.3 Future Analyses 
In addition to the analyses performed in this body of work, specialised tagging 
sequences have also been acquired during CMR in order to assess LV systolic and 
diastolic function with greater detail and sensitivity.  Dynamic tissue-tagging MRI 
magnetic resonance imaging allows direct non-invasive assessment of regional 
systolic myocardial shortening and has been previously validated (Yeon et al., 2001).  
Spatial modulation of magnetization was used to generate a uniform grid pattern with 
8mm tag separation on the left ventricular myocardium at three short axis sections 
(basal, equatorial and apex) and the horizontal long axis image using a fast field 
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echo multi-shot sequence (temporal resolution 40–50 ms, repetition time 3.9 ms, 
echo time 4.4 ms, voxel size 1.8/1.3/6.0 mm3, flip angle 14º, tag grid angle 45º with 
slice thickness 6 mm and a minimum number of 15 phases per cardiac cycle) with 
prospective ECG gating as previously described (Young et al., 1994).  The 
myocardial grid was followed through systole for deformation caused by ventricular 
contraction.  Analysis will be performed offline (Argus Software, Siemens, Erlangen, 
Germany) by blinded observers for left ventricular longitudinal shortening and apical 
and basal rotation as previously described (Young et al., 1994).  Comparisons 
between healthy controls and CKD patients are planned, along with further analyses 
to determine any changes relating to sevelamer treatment compared to placebo over 
40 weeks. 
 
Further cross-sectional analyses of this patient cohort are also planned, in particular 
examination of serum levels of soluble klotho and their associations with LV mass, 
arterial stiffness and LV systolic and diastolic functional indices for future hypothesis 
generation. 
 
6.2.4 The Next Study 
Taking the above into consideration, the proposed study to further test our 
hypothesis would be a prospective, randomised, double-blind placebo-controlled trial 
to determine the effects of modification of phosphate homeostasis on the primary 
endpoint of LV mass in patients with stage 3b and 4 CKD.  A minimum of 120 
patients with stage 3b or stage 4 CKD with established LVH at baseline would be 
required.  These patients may be recruited from secondary care as in the previously 
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reported study, or alternatively from a primary care setting.  The presence of 
increased LV mass at study initiation, which could be determined through screening 
echocardiography, would improve the likelihood of detecting an improvement in 
structural heart disease related to therapy.  The presence of significantly abnormal 
phosphate homeostasis could be confirmed through measurement of serum FGF-23, 
which is the most sensitive marker of impaired renal phosphate excretion.  An FGF-
23 level of 100 pg/ml or greater (twice the upper limit of the normal range) would 
suggest abnormal phosphate handling.  Proposed inclusion and exclusion criteria are 
listed in Table 6-1.  Cardiac magnetic resonance imaging would again be employed 
to determine the primary endpoint of LV mass, as well as LV volumes and function.  
This would be complemented with transthoracic echocardiography for the 
determination of LV systolic and diastolic function as secondary endpoints.  The non-
invasive assessment of arterial stiffness, namely measurement of carotid-femoral 
PWV and AIx using applanation tonometry and the SphygmoCor system, would 
again be used.  As previous studies of alternative therapies have demonstrated 
changes in LV mass over a 40-week period in patients with CKD, this time frame 
would be considered to be appropriate.  The obvious phosphate-modifying treatment 
of choice, however, is unclear at present.  The use of alternative, non-calcium based 
phosphate binders such as lanthanum would be associated with a similar pill burden 
to sevelamer (and therefore similar issues with compliance) with a comparable 
adverse effect profile.  Agents that modify the FGF-23 axis, such as antibodies and 
antagonists against FGF-23 and its receptor, require further testing in animal models 
to identify an appropriate target for treatment that is not associated with 
hyperphosphataemia and excess mortality.  Such agents will also require testing in 
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humans before trial use and are therefore currently beyond our reach.  This leaves 
the use of an extended-release, once daily niacin-based compound in combination 
with laropiprant to minimise the adverse effect of flushing.  Regular monitoring (4-
weekly at initiation) of liver function, creatine kinase, serum glucose level and 
platelets would be required.  Despite the once-daily dosing regimen, a randomised 
trial assessing the lipid-lowering effect of extended-release niacin compared to 
placebo over a 24-week treatment period was still associated with a 30% withdrawal 
rate before trial completion (Maccubbin et al., 2008).  This would need to be 
considered when performing a power calculation, and such a study may require a 
larger sample size than has been used previously. 
 189 
 
 
Inclusion Criteria 
Age 18–80 years 
Chronic kidney disease stage 3b or 4 (estimated glomerular filtration rate 15–44 ml/min/1.73m2) 
Total cholesterol <5.5 mmol/l 
LVH on echocardiography 
Serum FGF-23 ≥100pg/ml 
Exclusion Criteria 
Existing or previous treatment within the past year with a phosphate binder or vitamin D analogue 
Hyperphosphataemia (serum phosphate >1.8 mmol/l) 
Hypophosphataemia (serum phosphate <0.8 mmol/l) 
Existing or previous treatment within the past 6 months with a niacin-based compound 
Aspartate transaminase or alanine transaminase >1.5x upper limit of normal 
Creatine kinase >2x upper limit of normal 
Thrombocytopenia (platelets <150 x109/l) 
Diabetes mellitus 
Pregnancy 
Women of child-bearing age not on contraception 
 
Table 6-1.  Proposed inclusion and exclusion criteria. 
 
6.2.5 Other Studies in Progress 
The IMPROVE-CKD trial (IMpact of Phosphate Reduction On Vascular Endpoints in 
Chronic Kidney Disease) is a randomised, double-blind, placebo-controlled trial of 
488 patients with stage 3b–4 CKD designed to assess the effect of phosphate 
lowering using lanthanum carbonate on arterial stiffness and vascular calcification 
over 24 months (Australian New Zealand Clinical Trials Registry Number 
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ACTRN12610000650099).  The primary endpoint of this study is arterial stiffness 
measured using PWV, with secondary endpoints including change in aortic 
calcification and bone density assessed using computed tomography scanning, 
change in renal function measured by eGFR, and change in biochemical markers of 
phosphate metabolism.  Although yet to begin recruiting, the results of this study 
would be most compelling: firstly, the changes in arterial stiffness and vascular 
calcification observed as a consequence of phosphate lowering in more advanced 
CKD, and secondly compliance with therapy in subjects required to adhere to a 
three-times-daily dosing regimen over a 24 month period. 
 
An open-label randomised study is comparing the effects of sevelamer carbonate 
against calcium acetate on markers of “vascular health” in 50 patients with stage 3–4 
CKD over a 12 week period (clinicaltrials.gov identifier: NCT 01277497).  In addition 
to the primary endpoint of change in serum FGF-23 levels, the investigators have 
included a number of biochemical markers as secondary endpoints, including 
markers of vascular calcification, endothelial dysfunction and inflammation.  As 
demonstrated in the subset of 61 patients studied in section 5 with ≥80% compliance, 
it is likely that a decrease in FGF-23 levels will be observed in this study, particularly 
the sevelamer arm. 
 
Our group is currently recruiting potential kidney donors to examine the short and 
long-term effects of an acute decrease in GFR (uninephrectomy) on arterial stiffness 
and LV mass.  Kidney donors represent a healthy subset of the general population 
and are carefully screened for co-morbidities including hypertension and 
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cardiovascular disease.  It is hoped that this study will provide insights into the 
cardiovascular effects of decreased renal function in the absence of potential 
confounders, such as the underlying cause of renal disease itself, and the sequelae, 
such as anaemia, chronic inflammation and hypertension (Moody et al., 2011). 
 
Although this body of work did not demonstrate any significant difference in arterial 
stiffness, LV mass or LV systolic or diastolic function in humans with CKD, a similar 
study using a mouse model of CKD is currently underway to investigate the effects of 
sevelamer hydrochloride on arterial stiffness, LV mass and LV diastolic function 
compared to placebo (Maizel et al., 2013).  The authors are planning invasive 
haemodynamic measurements to assess aortic stiffness and are using transthoracic 
echocardiography to measure LV mass and function.  The outcome of such a study, 
which will be performed under controlled conditions and will not be disadvantaged by 
poor adherence to study medication, may lend support to or refute our hypothesis of 
phosphate-lowering being a novel mechanism of improving cardiovascular structure 
and function in CKD. 
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